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ABSTRACT 
Natural products have been the source and inspiration of numerous drugs. However, as 
they need to be isolated from natural sources, they are often obtained in minute 
quantities. Hence, total syntheses of natural products and their analogues give us a 
better chance to look into their biological activities and perform SAR studies for drug 
discovery. 
During my doctoral tenure I have synthesised a number of natural products and also 
some fragments. CPI-2081, a 2:1 mixture of two pentapeptides 1.8 and 1.9, were 
isolated from Streptomyces species NCIM 2081. These peptides are potent inhibitors 
(IC50 36.9 ± 1.8 nM) of the cysteine protease papain and inhibit cancer cell migration. 
However it was not clear which peptide is responsible for the observed biological 
activities. Both peptides have been prepared synthetically in our lab and they are being 
tested. 
Myriastramide C (2.23) is a modified cyclic octapeptide isolated from M. clavosa. The 
complete series of myriastramides A-C represent the first peptide metabolites isolated 
from M. clavosa. They were assumed to be cytotoxic, however myriastramide A was 
found inactive against 10 different human cancer cell lines. Myriastramides B and C 
were isolated in insufficient quantities so similar tests cannot be performed. 
Furthermore, the stereochemistry of the tryptophan residue in myriastramide C was not 
confirmed due to insufficient material isolated. Myriastramide C has been synthesised 
in our laboratory using L-tryptophan, however a mixture of products were obtained due 
to the two proline residues in the peptide. A pure product was purified by our 
collaborator and further NMR and biological studies is underway. 
Goadsporin (3.14) is a linear oligopeptide that was isolated in 2001. Its unique structure 
contains 19 amino acids, six of which are cyclised to form four oxazole and two 
thiazole rings. Goadsporin was found to be active specially in streptomycetes, with the 
ability to promote morphogenesis and secondary metabolism. It can also promote 
antibiotic production. The synthesis of this natural product was challenging, and 
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unfortunately with the limited time of my PhD study, we did not complete the total 
synthesis. However, we have synthesised several fragments of it, and they are going to 
be tested in the future. 
Breitfussin B (4.35) was first isolated in 2007 from the sample of Thuiaria breitfussi 
collected from Bear Island. Its highly unsaturated nature prevented its structure 
elucidation until 2012: Hanssen et al. proposed a structure using a combined atomic 
force microscopy and computational approach. However no biological activity was 
reported. The total synthesis of breitfussin B was completed in our lab, and tested for its 
antimicrobial ability. Further biological studies are underway. 
(All the structures of above natural products are shown in Figure A.) 
 
 
Figure A: Structures of CPI-2081 peptides 1.8 and 1.9, myriastramide C (2.23), goadsporin (3.14) 
and breitfussin B (4.35) 
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Chapter 1: Total Synthesis of CPI-2081 
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1.1 Introduction 
1.1.1 Natural products 
Natural products are compounds produced by a variety of natural sources. They can be 
synthesised by plants, fungi, bacteria and marine organisms.1 Natural products have been 
the most important and successful source for drug discovery.2,3 This is because natural 
products continue to provide us with enormous structural diversity compared to standard 
combinatorial chemistry, and allow us to discover novel drug lead compounds.  
There are two categories of metabolism within an organism. Primary metabolism refers to 
the biosynthesis and breakdown of carbohydrates, proteins and fats that is essential to all 
living organisms. The compounds involved in such pathways are known as “primary 
metabolites”.4 Unlike primary metabolism, the products resulting from secondary 
metabolism are usually unique to the particular organism, and not essential to its growth.4,5 
These “secondary metabolites” are produced when the organism is adapting to its 
environment or resisting its predators. In other words, “secondary metabolites” aid the 
development or survival of the organism.4,6 The natural products that inspire us to discover 
new drugs are compounds from the second category. 
Historically, we have benefitted from natural products for thousands of years. The earliest 
record of natural products can be dated back to the Mesopotamia civilisation (2600 B.C.),2 
and can be also found in ancient Chinese medical literatues,2 however the bioactive 
compounds were not identified. Over the course of history, with the development of 
technology and chemistry, people started to identify and understand the mechanisms behind 
natural products. For example, salicin (1.1, Figure 1.1) was isolated from the willow tree 
Salix alba. The compound acetylsalicyclic acid (1.2), better known as aspirin is derived 
from salicin and it is probably the most well-known drug to date.7 Another important drug, 
morphine (1.3), was firstly reported in 1803, and was the lead to another two famous drugs, 
diacetylmorphine (heroin) and codeine.7 The latter is used as a painkiller.  
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Figure 1.1: Structures of salicin (1.1), acetylsalicyclic acid (1.2) and morphine (1.3) 
 
From a vast variety of natural sources, we have discovered the most famous and important 
drugs for mankind, and they present diverse structures. For example, the most well-known 
breast, lung and ovarian cancer drug paclitaxel (Taxol, 1.4, Figure 1.2) was isolated from 
the bark of the Taxus brevifolia (Pacific Yew tree), and has a complicated structure of 7 
rings and 11 chiral centres. Its unique structure made the total synthesis challenging and 
expensive, but it is necessary as the natural source of Taxol is limited.8 Another important 
example of drug discovery is penicillin, and it is derived from the fungus Penicillium 
notatum which was discovered by Fleming in 1929.9 It is an effective 𝛽-lactam antibiotic, 
killing bacteria by inhibiting the formation of the bacteria cell wall. The first total synthesis 
of penicillin V (1.5) was completed in 1957 by Sheehan.10 Today, many semisynthetic 
derivatives of the natural penicillins are used as antibiotics and have ultimately saved 
countless lives. 
 
 
Figure 1.2: structures of Taxol (1.4) and penicillin V (1.5) 	  
The discovery of natural products did help us to develop better and profitable drugs. 
However only to discover them is far from enough. As natural products are usually isolated 
in tiny quantities and sometimes in a quantity not even enough for biological studies, it is 
very important to synthesise them in the laboratories in order to fully study their 
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bioactivities. Furthermore, synthesis also provides unnatural analogues and routes for 
semisynthesis to enable further SAR studies. 
1.1.2 Cysteine protease and role of proteases in cancer 
Proteases are enzymes that cut peptide bonds in proteins. They are divided into several 
families by their catalytic mechanism: serine proteases, threonine proteases, cysteine 
proteases, aspartate proteases, metalloproteases and glutamic acid proteases. The HIV 
protease belongs to the aspartate protease family. One of our synthetic targets, the peptide 
CPI-2081, is an inhibitor of the cysteine protease papain. Cysteine proteases are defined by 
having a cysteine residue at the active site. Under certain situations, increased activity of 
cysteine proteases can cause a number of diseases,11-13 including cancer.14  
We can find cysteine proteases in all living organisms. These common enzymes exist in 
bacteria (e.g. gingipain in Porhyromonas gingivalis), fungi (e.g. proteinease ysc F in yeast), 
and plants (e.g. papain and chymopapain in Carica papaya). Whereas in mammals, we can 
find two main categories of cysteine protease: lysosomal cathepsins and cytosolic 
calpains.15 The catalytic mechanism of cysteine proteases is well known, this is a five-step 
mechanism, elucidated in Scheme 1.1.  
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Scheme 1.1: Catalytic cycle of cysteine protease. 
 
Cathepsin B is a good example to show the connection of cysteine proteases to cancer.16 It 
was the first cysteine protease that was associated with breast cancer. The increased 
expression and activity of cathepsin B was observed in various cancer tumour cells, 
including breast, lung and gastric cancer cells, and implicated in cancer progression.16 In 
addition, high cathepsin B levels correlates to a lower overall survival in colon cancer 
patients. Due to their association with cancer, cysteine proteases are envisioned as very 
good potential drugs for treating cancers. However, cysteine protease inhibitors that already 
exist are not always potent at low molar concentration, and some of them are toxic. Hence, 
there is a great need to develop effective cysteine proteases inhibitors. Some compounds 
are already found to inhibit tumour metastasis,17 and have potential to be developed for 
tumour chemotherapy.  
Not only cysteine proteases but also many other proteases are associated with cancer 
progression. In the past, people thought that only proteases outside of tumour cells are 
crucial to cancer progression, but recent research results showed that the proteases within 
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the tumour cells are also important. In addition, proteases may also play crucial roles in the 
early stage of cancer progression such as malignancy. Protease inhibitors can reduce 
tumour cell invasion and their metastatic capabilities. They also can either directly inhibit 
tumour progression by inhibition of extracellular matrix proteolysis or indirectly by 
inhibition of activation of proteolytic cascade.16  
1.1.3 Examples of anticancer protease inhibitors 
1.1.3.1 Anticancer activity of cathepsin inhibitor VBY-825  
 
Figure 1.3: Chemical structure of VBY-825 (1.6). 
VBY-825 (1.6, Figure 1.3) is a novel reversible cysteine protease cathepsin inhibitor that 
shows a high antitumour activity reported by Elie B. T. et al.18 In their experiments, 
RIP1-Tag2 (RT2) mice at the age of ten weeks were selected to carry out the test, and 
divided into two groups: one treated with VBY-825 and the other as vehicle control. There 
was no side effect on the mice during the test. After counting the tumours after the trial 
endpoint, 8.7 tumours were found in the pancreas of the control group.18 However, tumour 
number was significantly reduced in the pancreas of mice in the group treated with 
VBY-825, with a value of 5.8 (33% reduced).18 The cumulative tumour volume was also 
reduced by 52%, showing that VBY-825 is a very effective potential anticancer agent.18 
 
 
 
 
1.6
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1.1.3.2 Anticarcinogenic Bowman-Birk protease inhibitor on breast cancer cells 
Another protease inhibitor which has anticancer activity was reported in 2010 by Joanitti G 
A. et al.19 A Bowman-Birk protease inhibitor BTCI (Black-Eyed Pea 
Trypsin/Chymotrypsin Inhibitor, Figure 1.4), which is a polypeptide formed with 56 amino 
acid residues, has cytotoxic effect on MCF-7 breast cancer cells which results in apoptosis 
(Figure 1.5A), the cell viability was reduced by 50% at 200 𝜇M.19 In addition to the 
anti-carcinogenic effect, BTCI also has characteristics that contribute to it being an 
excellent anticancer agent. For example, it does not affect normal breast cells (Figure 1.5B), 
which means that the side effects of BTCI are reduced.19  
 
 
Figure 1.4: Ribbon diagram of the BTCI structure.20 	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Figure 1.5: Effects of BTCI on cell viability.19 (A) several concentrations of BTCI (100-400 µμM) were 
applied to incubated MCF-7 cancer cells, bovine serum albumin (BSA) was applied as control group. (B) 
normal breast cells were incubated with 200 µμM of BTCI. Control group is the untreated cells. 
1.1.3.3 HIV protease inhibitor saquinavir induces apoptosis in ovarian cancer cells 
 
Figure 1.6: Structure of saquinavir (1.7). 
The anticancer effect of the HIV protease inhibitor saquinavir (1.7, Figure 1.6) was 
reported by McLean et al. in 2008.21 They first tested the ability of saquinavir to induce 
ovarian cancer cell death. The result showed a dose-dependent cell killing in cell lines 
A2780, SKOV3 and CAOV3 (Figure 1.7).21 The caspase-dependent apoptotic cell death 
1.7
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was also tested. During apoptosis, DNA-fragmentation is a very important sign. In this test, 
the increased quantity of cells with fragmented DNA (increase of sub-G0 population) 
suggests that saquinavir was inducing cancer cell death.21 
 
 
Figure 1.7: Dose-dependent killing of ovarian cancer cell lines by saquinavir in A2780, SKOV3 and 
CAOV3 cells.21 
1.1.4 CPI-2081 
1.1.4.1 Extraction and isolation of CPI-2081 
The Streptomyces species NCIM 2081 was first cultured under submerged conditions for 
72 h, then the supernatant was lyophilised to an anhydrous powder, which was further 
extracted with n-hexane and CH2Cl2. The solvent was removed under vacuum and the 
product was purified by C18 column equipped with reverse-phase HPLC resin. The 
purified fractions were tested for cell-free protease inhibition, the active fractions were 
selected and pooled and rechromatographed by reverse-phase HPLC. In the end, 9 mg of 
the two natural products (Figure 1.8) were isolated as a 2:1 mixture of compounds 1.8 and 
1.9 from 35 L of the original fermentation broth.22 The structural elucidation was carried 
out by ESI-MS and NMR (500/400 MHz) spectroscopy.22 
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Figure 1.8: Structures of CPI-2081 (1.8 and 1.9).  
1.1.4.2 Papain and cancer cell migration inhibition of CPI-2081 
Papain is regarded as a useful model enzyme to study the inhibition of papain superfamily, 
since it presents many universal features from these proteases.23 The folding pattern of 
papain is comparable to other important cysteine proteases thus making it a very good 
target in drug discovery.23 For example, cathepsin L belongs to the papain family and it is 
reported to be responsible for many different kinds of cancers.24 The amino acid binding 
pattern of cathepsin L is very similar to that in papain. Hence we could use the 
better-studied and readily available protease papain in the design of cathepsin L inhibitors. 
When CPI-2081 was isolated from Streptomyces species NCIM2081, papain was used for 
its activity-guided fractionation.22 Thermodynamic study with CPI-2081 was also carried 
out on the same enzyme. The hydrolytic activity of papain decreased as the concentration 
of CPI-2081 increased and the IC50 value of 36.9  ±  1.8 nM was determined.22  
The ability of CPI-2081 to inhibit cancer cell migration was examined by the scratch 
wound healing assay. The ability to inhibit the wound closure over the time in monolayer 
confluent cells was monitored, and postconfluent MDA-MB-231 (human breast carcinoma), 
B16F10 (murine melanoma) or A-375 (human melanoma) was used in the test. CPI-2081 
successfully inhibited the wound closure in A-375 and MDA-MB-231 compared with 
vehicle control, and can inhibit the wound closure in B16F10 by 20% (Figure 1.9).22 
 
N
H
O H
N
O
S
N
H
O
NH
H
N
O
N
H
O
OH
O
N
H
O H
N
O
S
N
H
O
NH
H
N
O
N
H
O
OH
O
OH
1.8 1.9
	  11	  
  
Figure 1.9: The wound closure after 24 h upon CPI-2081 treatment in MDA-MB-231, A-375 and 
B16F10 cells compared to control.22 
1.1.5 Solid-Phase Peptide Synthesis (SPPS) 
Traditionally, peptides are synthesised by “solution-phase” synthesis, where all materials 
are dissolved in solution and reactions conducted in round-bottomed flasks. However, long 
reaction times and tedious purifications are making many peptides very hard to synthesise. 
Thanks to the pioneering work of Bruce Merrifield published in 1963, which introduced the 
solid-phase peptide synthesis (SPPS), peptide synthesis became quicker and easier.25 The 
purification steps are avoided and the strategy of peptide synthesis has been changed 
dramatically. Moreover, the invention of SPPS also made automated peptide synthesis by 
robotic instrumentation possible (Figure 1.10), both more economical and rapid. 
 
 
Figure 1.10: An automated, computer controlled peptide synthesiser.  
Source: http://www.multisyntech.com/html/syro_ii.html 
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The most important difference between SPPS and traditional solution-phase synthesis is the 
use of resin solid support. After attaching the first amino acid onto the solid support, it is 
immobilised, allowing easy separation of the peptide from any solution. This way, we 
could use large excess of reagents at high concentration to drive coupling reactions to 
complete quicker, then excess of reagents and side-products can be washed off and filtered 
away easily from the insoluble resin. Moreover, all the synthesis can be accomplished using 
the same reaction vessel without the need to transfer the material. 
The principle of SPPS can be elucidated using Scheme 1.2. The N-protected amino acid at 
the C-terminus of the target peptide will be first loaded onto the resin solid support and 
linked by either an ester or amide bond. Then the peptide will be built up in a linear fashion, 
with repeated cycles of deprotection on amino group then coupling of the next amino 
acid.26  
           
Scheme 1.2: Principles of SPPS.26 
In actual synthesis, the base-labile Fmoc (fluorenylmethyloxycarbonyl) group is chosen to 
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protect the terminal amino group and the acid-labile tBu group protects the amino acid side 
chain, the linker between the peptide and the solid support is acid-labile as well.  This 
strategy would allow the protecting groups to be removed by different mechanisms so that 
the use of mild acidic and basic conditions is made possible.26  
There are numerous kinds of matrix polymers (resins) available commercially, and the most 
commonly used resins for SPPS are crosslinked polystyrene (PS) based resins. Two of the 
widely used resins are shown in Figure 1.11. Wang resin (1.10) can be regarded as the 
standard peptide synthesis resin used with Fmoc chemistry. The acid liability allows the 
synthesised peptide to be cleaved with mildly acidic conditions (e.g. 50% v/v 
TFA/CH2Cl2).27 Rink amide resin (1.11) is another popular resin, and it is used for 
ultimately getting the C-terminal amide of the target peptide. It is also removed under 
acidic conditions.28 The resin we chose to use in this project is the Wang resin, as the 
CPI-2081 peptides contain a free carboxylic acid at the C-terminus. 
 
 
Figure 1.11: Structure of Wang resin (1.10) and Rink amide resin (1.11) 
1.1.6 Trp-containing peptide side-reaction in SPPS 
The structure of CPI-2081 components 1.8 and 1.9 differ by the addition of a benzylic 
group on the Trp residue. This type of structural modification is unprecedented in natural 
products. However, when synthesising Trp-containing peptides using Wang resin solid 
support, this benzylation often occurs as a side reaction.29 The byproduct has an additional 
molecular weight of 106 compared with the desired peptide, which corresponds to the MW 
of the linker part of Wang resin (Figure 1.12). Two side products were observed, one with 
mono-substituted tryptophan structure, the other with double-substituted tryptophan 
structure (Figure 1.13).29 
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Figure 1.12: The linker part of Wang resin which has the molecular weight of 106.29 
 
 
Figure 1.13: The modified tryptophan structure after the side reaction.29 
1.1.7 Aims 
We were planning in this project to synthesise compound 1.9 in CPI-2081 in order to test 
its biological activities. Compound 1.8 was synthesised earlier in our group using both 
solution phase and solid phase approaches, and my aim was to continue my M. Sc. project 
in the University of Southampton to complete the synthesis of 1.9. Once we have both 
peptides in hand, their individual biological activities can be tested, as they were only 
studied as a mixture by Singh et al.22 The 4-hydroxybenzyl substituent is a rare 
modification in a natural peptide and its synthesis was considered as the biggest challenge 
in this project. We planned to use solid-phase approach to synthesise peptide 1.9 and 
optimise the incorporation of the 4-hydroxybenzyl substituent. 
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1.2 Results and Discussion 
1.2.1 Strategy 
In order to obtain the alkylated component 1.9 in CPI-2081, the strategy was to synthesise 
it using Wang resin solid support. At the last stage of resin cleavage, we envisioned that 
using low concentration of TFA and addition of p-hydroxybenzyl alcohol would 
simultaneously lead to peptide release and alkylation of tryptophan residue. However, 
under these conditions both mono and doubly alkylated peptides were observed and their 
separation would not be practical. In earlier work by our group, the combination of 
1,2-ethanedithiol/anisole/triisopropylsilane/H2O/indole was used as scavenger to avoid the 
formation of alkylated product 1.9. However in my work, in order to achieve 
tryptophan-alkylated peptide 1.9 only, no scavenger was used. Hence in the cleavage stage, 
we only used TFA (Scheme 1.3), and we obtained a mixture of 1.8 and 1.9 with 2 h of 
reaction time. However the mixture of 1.8 and 1.9 was hard to be separated by HPLC. 
Fortunately, when keeping the cleavage reaction for a prolonged time (72 h), the synthesis 
delivered solely the desired mono-alkylated compound 1.9. 
1.2.2 Synthesis of Ac-Leu-Cys(tBu)-Trp-Ala-Phe-Wang (1.12) 
The synthesis of Ac-Leu-Cys(tBu)-Trp-Ala-Phe-Wang (1.12) was completed according to 
Scheme 1.3, the results shown in this scheme has been achieved during my M. Sc. Project 
in the University of Southampton. Wang resin (1.4 mmol/g loading) was used in the 
beginning of the synthesis. Phenylalanine was loaded onto the resin by the symmetrical 
anhydride method.30 The coupling reagent in all coupling reactions was PyBOP. The 
coupling reactions were confirmed to reach completion within 1.5 h by Kaiser test,30 which 
is carried out by adding 0.2 mL of solution A: prepared from 5% of ninhydrin in ethanol; 
and 0.4 mL of solution B: prepared from a mixture of KCN in pyridine and 80% phenol. A 
solution of 20% piperidine in DMF was used for Fmoc deprotection, the deprotection 
process was completed in 20 min, and the completion of this was also monitored by Kaiser 
test. Because the synthesis was carried out in solid phase, all amino acids and coupling 
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agent were used in a large excess (5 equiv.) to ensure that all reactions had gone to 
completion. 
  
Scheme 1.3: Synthesis of Ac-Leu-Cys(tBu)-Trp-Ala-Phe-Wang (1.12). i. Fmoc-Ala-OH (10 equiv.), DIC 
(5 equiv.), DMAP (10 mol%), DMF (5 mL), 0 ℃, 10 min, then Wang resin, rt, 1 h; ii. piperidine/DMF (1:4, 6 
mL), rt, 20 min; iii. Fmoc-Ala-OH (5 equiv.), PyBOP (5 equiv.), DIPEA (10 equiv.), DMF (3 mL), rt, 1.5 h; 
iv. piperidine/DMF (1:4, 6 mL), rt, 20 min; v. Fmoc-Trp-OH (5 equiv.), PyBOP (5 equiv.), DIPEA (10 
equiv.), DMF (3 mL), rt, 1.5 h; vi. piperidine/DMF (1:4, 6 mL), rt, 20 min; vii. Fmoc-Cys(tBu)-OH (5 equiv.), 
PyBOP (5 equiv.) DIPEA (10 equiv.), DMF (10 mL), rt, 1.5 h; viii. piperidine/DMF (1:4, 6 mL), rt, 20 min; 
ix. Fmoc-Leu-OH (5 equiv.), PyBOP (5 equiv.), DIPEA (10 equiv.), DMF (3 mL), rt, 1.5 h; x. 
piperidine/DMF (1:4, 6 mL), rt, 20 min; xi. Acetic anhydride (5 equiv.), pyridine (5 equiv.), DMF (3 mL), rt, 
1.5 h. 
1.2.3 Wang resin cleavage and tryptophan modification 
The following synthesis of 1.9 was carried out according to Scheme 1.4 and Scheme 1.5. In 
the previous work by our group, high concentration of TFA and scavengers were used to 
get the non-modified product 1.8 only. But in order to get purely the tryptophan-modified 
product 1.9, low concentration of TFA and no scavenger were firstly used, and we also 
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added 4-hydroxybenzyl alcohol to drive the benzylation to occur (Scheme 1.4). A variation 
of concentration of TFA in CH2Cl2 was used here to get the tryptophan-modified product 
only. However, the result always appears to have both 1.9 and doubly modified side 
product 1.18 as observed in MS analysis. The side product has a molecular weight 106 
larger than 1.9. The NMR spectrum is inconclusive without separating the two products and 
they were not separated by HPLC. 
 
 
Scheme 1.4: Wang resin cleavage and the two products achieved. i. TFA/CH2Cl2, p-Hydroxy Benzyl 
alcohol, rt, 0.5 h. 
After getting the previous result, an altered condition in the resin cleavage state was applied 
(Scheme 1.5). Pure TFA was used for cleaving the resin with no scavenger used, and the 
reaction was left for 2 h. This time not only 1.9 was observed, 1.8 was also observed in 
mass spectrum, and the formation of the double alkylated side product was successfully 
avoided. The mixture was taken into purification under HPLC. In the original isolation 
article, the mixture of CPI-2081 appeared as one peak which indicates that they cannot be 
further purified,22 which is the same as we have observed (Figure 1.14). As a result, 1.9 was 
not successfully isolated. 
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Figure 1.14: Analytical HPLC trace of synthetic CPI-2081. The two natural products appear as one 
peak (5:95 to 95:5 MeOH/H2O over 20 min). 
After some consideration, we wondered if the tryptophan modification process actually 
took place after the peptide was cleaved from the resin. Hence, we then did cleavage in 
another way by leaving the resin in pure TFA without scavenger for a prolonged time (72 
h), and fortunately we were successful in avoiding forming compound 1.8. MALDI-TOF 
mass spectrometry showed only the mass of compound 1.9, and this peptide was purified 
by HPLC. The 1H and 13C NMR comparison of the synthetic product and reported natural 
product is given in Table 1.1. With the modified peptide 1.9 at hand together with the 
unmodified peptide 1.8 synthesised previously, we can finally now test them individually in 
papain inhibition and wound healing assay. We would also mix them 2:1 artificially to 
check their activity against the reported value. The biological tests will be carried out by 
another member of our group. 
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Scheme 1.5: Wang resin cleavage using altered conditions. i. TFA, rt, 2 h, mixture of 1.8 and 1.9 was 
obtained; ii. TFA, rt, 72 h, only compound 1.9 formed. 
 
 
Residue Position 𝛿C 𝛿H 
  Natural Synthetic Natural Synthetic 
Leu 
 
 
 
 
 
 
Acetyl 
𝛼 51.65 51.2 4.28 4.32 𝛽 41.27 40.7 4.15 4.09 𝛾 24.61 24.2 2.46 2.43 𝛿 23.48 23.1 0.85 0.89 
22.08 21.7 0.93 0.93 
C=O 172.77 172.8 - - 
NH - - 8.03 8.09 
Ac (Me) 22.96 22.6 1.84 1.84 
Ac(C=O) 169.91 169.9 - - 
Cys 
 
 
 
 
𝛼 53.87 53.4 4.28 4.32 𝛽 30.24 29.1 2.70 2.75 
2.63 2.65 
C=O 170.21 170.4 - - 
NH - - 8.16 8.09 
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tBu Me 31.09 30.7 1.23 1.22 
C 42.44 42.1 - - 
Trp 
 
 
𝛼 54.44 54.1 4.51 4.50 𝛽 27.36 26.9 3.15 3.14 
2.94 2.95 
NH (indole) - - 10.61 10.60 
2 136.99 136.6 - - 
3 106.55 106.1 - - 
3a 128.33 128.4 - - 
4 118.80 118.2 7.50 7.49 
5 118.52 116.0 6.87 6.87 
6 120.50 120.2 6.95 6.95 
7 111.01 111.0 7.20 7.21 
7a 135.99 135.5 - - 
8 31.1 29.8 3.88, 3.93 3.87 (2H) 
9 130.38 130.0 - - 
10 129.69 129.3 6.98 6.98 
11 115.60 115.2 6.66 6.65 
12 156.06 155.6 - - 
13 115.60 115.2 6.66 6.65 
14 129.69 129.3 6.98 6.98 
C=O 170.78 171.8 - - 
NH - - 7.97 7.99 
OH - - 9.18 9.16 
Ala 𝛼 48.61 48.1 4.30 4.32 𝛽 18.83 18.4 1.15 1.15 
C=O 172.07 172.4 - - 
NH - - 7.80 7.78 
Phe 
 
 
𝛼 54.13 53.6 4.36 4.32 𝛽 37.17 
 
36.8 3.03 3.02 
2.90 2.89 
1 138.05 137.4 - - 
2 129.63 129.2 7.23  
 
7.21 (5H) 
3 128.57 128.2 7.25 
4 126.80 126.5 7.23 
5 128.57 128.2 7.25 
6 129.63 129.2 7.22 
NH - - 8.00 8.03 
COOH 173.14 172.8 12.72 12.69 
Table 1.1: 1H and 13C NMR data in ppm for final synthetic product and natural 1.922 in DMSO-d6.  	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The mechanism of the alkylation on the tryptophan residue was not fully studied, but we 
could have a general idea of how it would proceed. From our experimental observation, the 
alkylation happened more thoroughly when we left the reaction for a prolonged time. This 
could indicate that the reaction happened after the peptide had been cleaved from the resin 
(Scheme 1.6). The electron-rich tryptophan can react with the carbocation formed in the 
cleavage stage and link itself with the resin. Further protonation can cleave the resin and 
leave a 4-hydroxy benzyl group on the tryptophan. The initial alkylation could also happen 
on the 3-position, followed by a 1,2-shift mechanism (not shown) to migrate the benzyl 
group to the 2-position. 
 
Scheme 1.6: Possible mechanism of tryptophan alkylation. 
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1.3 Conclusions and Future Work 
The total synthesis of CPI-2081 was accomplished and biological tests of compound 1.9 are 
under way. The most challenging part in this synthesis is the modification on the 
tryptophan residue. It is so unique that nobody ever found a good way to prepare it. Thanks 
to the unique property of Wang resin, we were able to achieve the modification at the resin 
cleavage stage, where the reaction was left for a prolonged time (72 h) and without use of 
scavengers. After getting the pure compound 1.9, both the two natural products contained 
by CPI-2081 will be tested in papain and wound closure assays.	  	  
1.4 Experimental 
1.4.1 General Experimental Methods 
Chemicals and general reagents were purchased from commercial suppliers, and unless 
stated otherwise were used without further purification. Anhydrous solvents were 
purchased and stored under argon atmosphere. Where necessary, solvents and reagents 
were purified according to standard methods. 
All air and/or moisture sensitive reactions were carried out under inert atmosphere of argon 
gas, in oven-dried glassware. The term in vacuo refers to the removal of solvents by the 
means of evaporation at reduced pressure, using a Buchi rotary evaporator. 
Melting points were obtained in open capillary tubes on an Electrothermal Melting Point 
Apparatus and are uncorrected. Optical rotations were recorded on an ADP220 polarimeter, 
in a solvent of MeOH. Infrared spectra were recorded on a PerkinElmer Spectrum 400 
FT-IR/FT-FIR spectrometer. Absorptions were recorded in wave numbers (cm-1). 1H NMR 
and 13C NMR were recorded on Bruker AC400 spectrometers (400 MHz for 1H and 100 
MHz for 13C). Spectral data were reprocessed using ACD Labs software or 
MESTRENOVA and referenced to the residual solvent peak (CDCl3, CD3OD or 
DMSO-d6). Characteristic splitting patterns due to spin spin coupling are expressed as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Chemical 
shifts are given in ppm and coupling constants are measured in Hz.  
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Low-resolution mass spectra were obtained using LC-MS on a Shimadzu LCMS 2010EV 
spectrometer or MALDI-TOF on a Kratos Axima CFR spectrometer. High-resolution mass 
spectra were collected by EPSRC National Mass Spectrometry Facility (Swansea) using a 
Thermofisher LTQ Orbitrap XL mass spectrometer. 
 
1.4.2 Experimental Details for Chapter 1 
1.4.2.1 Attachment of the First Amino Acid to Wang Resin 
Wang resin (500 mg, 0.7 mmol, 1 equiv.) was swelled in DMF (2 mL) for 30 min. To a 
solution of Fmoc-L-phenylalanine (2.71 g, 7 mmol, 10 equiv.) in anhydrous CH2Cl2 (10 mL) 
was added DIC (0.54 mL, 3.5 mmol, 5 equiv.) and the reaction mixture was stirred at 0 ℃ 
for 10 min. A minimal amount of DMF (2 mL) was added to aid dissociation. The activated 
amino acid was concentrated in vacuo and redissolved in DMF (5 mL), then added to the 
swelled Wang resin. DMAP (8.55 mg, 0.07 mmol, 0.1 equiv.) was added to the mixture, 
and the mixture was agitated for 1 h. The loaded resin was washed with DMF (5 mL  ×  3) 
and CH2Cl2 (5 mL  ×  3) and then dried to give the phenylalanine-loaded Wang resin 1.13, 
which was used in the following Fmoc deprotection and peptide coupling steps. 
1.4.2.2 Fmoc Deprotection 
To the amino acid/peptide loaded Wang resin was added a solution of 20% piperidine in 
DMF (3 mL), and the mixture was agitated at rt for 5 min. The resin was filtered and 
washed with DMF (5 mL  ×  3) and CH2Cl2 (5 mL  ×  3), then the deprotection repeated with 
20% piperidine in DMF (3 mL) and agitated for 15 min. The resin was filtered and washed 
with DMF (5 mL  ×  3) and CH2Cl2 (5 mL  ×  3) to give the Wang resin bond peptide with 
free amine. 
1.4.2.3 Peptide Coupling 
To the free Wang resin bonded peptide amine was added amino acid (5 equiv.), PyBOP (5 
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equiv.), DIPEA (10 equiv.) and DMF (3 mL). The mixture was agitated for 1.5 h at rt. The 
resin was filtered and washed with DMF (5 mL  ×  3) and CH2Cl2 (5 mL  ×  3) to give the 
coupled Fmoc Wang resin bond peptide.  
1.4.2.4 Synthesis of Ac-Leu-Cys(tBu)-Trp-Ala-Phe-Wang (1.12) 
To the NH2-Leu-Cys(tBu)-Trp-Ala-Phe-Wang was added pyridine (0.28 mL, 3.5 mmol, 5 
equiv.), acetic anhydride (0.33 mL, 3.5 mmol, 5 equiv.) and DMF (3 mL). The mixture was 
agitated for 20 min at rt. The resin was separated and washed with DMF (5 mL  ×  3) and 
CH2Cl2 (5 mL  ×  3) and dried to give Ac-Leu-Cys(tBu)-Trp-Ala-Phe-Wang (1.12). 
1.4.2.5 Wang resin cleavage towards 1.9 
 
To the Ac-Leu-Cys(tBu)-Trp-Ala-Phe-Wang (1.12) was added TFA (3 mL, large excess). 
The mixture was stirred for 72 h at rt. The solution was filtered off and the resin was 
washed further with TFA (2 mL). TFA was evaporated in vacuo. Cold ether (5 mL) was 
added to the residue and precipitate was formed, filtered and redissolved in MeOH. Solvent 
was removed in vacuo to a give a purple solid. The mixture was purified by HPLC (5:95 to 
95:5 MeOH/H2O over 20 min to afford 1.9 as a light pink solid (25 mg, 4% overall yield); mp: 
130-134 °C; [α]D25 = -10.6 (c 0.09, CH3OH); IR (neat) 3290, 1631, 1538, 1512 cm-1; 1H 
NMR (400 MHz, DMSO-d6) 𝛿: 12.69 (brs, 1H, COOH), 10.60 (s, 1H, NH), 9.16 (brs, 1H, 
OH), 8.09 (d, 2H, J = 7.5 Hz, NH), 8.03 (d, 1H, J = 7 Hz, NH), 7.99 (d, 1H, J = 8 Hz, NH), 
7.78 (d, 1H, J = 7.5 Hz, NH), 7.49 (d, 1H, J = 7.8 Hz, H-11), 7.21 (m, 6H, H-14, H-24, 
H-25, H-26, H-27, H-28), 6.98 (d, 2H, J = 7.8 Hz, H-16 and H-17), 6.95 (m, 1H, H-13), 
6.87 (m, 1H, H-12), 6.65 (d, 2H, J = 8.3 Hz, H-18 and H-19), 4.50 (m, 1H, H-9), 4.32 (m, 
4H, H-2, H-7, H-20, H-22), 3.87 (m, 2H, H-15), 3.14 (dd, 1H, J = 14.7, 6.4 Hz, H-10), 3.02 
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(dd, 1H, J = 13.6, 5.3 Hz, H-23), 2.95 (m, 1H, H-10), 2.89 (m, 1H, H-23), 2.75 (dd, 1H, J = 
13, 5.1 Hz, H-8), 2.65 (dd, 1H, J = 13, 4.3 Hz, H-8), 1.84 (s, 3H, H-1), 1.58 (td, 1H, J = 
13.2, 6.9 Hz, H-4), 1.42 (t, 2H, J = 7 Hz, H-3), 1.22 (s, 9H, tBu), 1.15 (d, 3H, J = 6.8 Hz, 
H-21), 0.86 (d, 3H, J = 6.5 Hz, H-5 or H-6), 0.82 (d, 3H, J = 6.3 Hz, H-5 or H-6) ppm; 13C 
NMR: (100 MHz, CDCl3) 𝛿: 172.8, 172.7, 172.4, 171.8, 170.4, 169.9, 155.6, 137.4, 136.6, 
135.5, 130.0, 129.3 (2C), 129.2 (2C), 128.4, 128.2 (2C), 126.5, 120.2, 118.2, 116.0, 115.2 
(2C), 111.0, 106.1, 54.1, 53.6, 53.4, 51.2, 48.1, 42.1, 40.7, 36.8, 30.7 (3C), 29.8, 29.1, 26.9, 
24.2, 23.1, 22.6, 21.7, 18.4 ppm; ES+ MS m/z 865 ([M+Na]+ 100%); HRMS m/z calculated 
for C45H59N6O8S [M+H]+: 843.4115, found 843.4116. 
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Chapter 2: Synthetic Studies towards 
Myriastramide C 
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2.1 Introduction 
2.1.1 Natural products from marine sponge Myriastra clavosa 
In recent years, marine sponges have become one of the top sources for the discovery of 
bioactive compounds with potential drug applications. From the literature of natural 
product discovery, authors claimed that marine sponges have potential ability to provide 
future drug candidates targeting numerous diseases.31-33 It was proved that natural 
compounds isolated from marine sponges show a wide range of activities including 
antitumour, anti-inflammatory, antibiotic and other bioactivities, and they express these 
activities by inhibiting certain kind of enzyme that are usually involved in the pathogenesis 
of a disease.34  
Not only do marine sponges provide natural compounds that have distinctive activities, but 
they also are champion producers of these compounds. For the last 20 years until 2012, 
over 15,000 marine natural products have been isolated and tested.35 Moreover, these 
natural products are highly diverse in structure, including cyclic peptides, peroxides, 
alkaloids and terpenes.36 In this project, we were interested in natural products isolated 
from the marine sponge Myriastra clavosa (Figure 2.1). 
 
 
Figure 2.1: Photo of Myriastra clavosa.  
Source: http://www.robertosozzani.it/Walea/Varie/spugna01.shtml 
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2.1.1.1 Clavosines A-C 
Clavosines A-C (2.1-2.3, Figure 2.2) was isolated from the extracts of marine sponge 
Myriastra clavosa collected in Palau in 1995.37 Interestingly, 2.1-2.3 tend to 
photochemically isomerise between one another hence pure components require careful 
handling in the dark. These three complex and unsaturated compounds initially showed 
cytotoxicity against human breast (MDA-MB435) and human lung (A549) tumour cell 
lines.37 Clavosine A and B were tested in the National Cancer Institute’s screening panel of 
60 tumour cell lines, and they were found to be very potent.37 They are also found to be 
able to inhibit the catalytic subunit of native protein phosphatase-1 from rabbit skeletal 
muscle, human recombinant PP-1cγ from E. coli, and the catalytic subunit of protein 
phosphatase 2A (PP-2Ac) from bovine heart.37 The activities are all in nanomolar or 
sub-nanomolar range.37 
 
 
Figure 2.2: Structures of clavosines A-C (2.1-2.3). 
2.1.1.2 Clavosolides A and B 
Dimeric macrolides clavosolides A (2.4) and B (2.5) (Figure 2.3) were isolated by Rao and 
Faulkner from the extract of Myriastra clavosa Ridley 1884 in 2001,38 and their structures 
were revised by Barry et al. in 2005.39 Since the potent cytotoxin clavosines A-C isolated 
from the same sponge were already reported by Fu et al.,37 the authors were initially 
hesitant regarding the activity observed with this sponge. However they realised that a set 
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of unusual metabolites was present from the NMR spectrum of the crude extract, and 
clavosolides A and B were isolated. Their unique structures attracted a lot of attention for 
total synthesis,39-44 however they were not found to be cytotoxic. 
 
 
Figure 2.3: Original (left) and revised (right) structures of clavosolides A (2.4) and B (2.5). 
2.1.1.3 Homologous series of polymethoxydienes 
After the isolation of clavosolides A and B, Rao and Faulkner reported another set of 
polymethoxydiene natural products 2.6-2.10 (Figure 2.4).45 They were isolated from the 
methanol extract of Myriastra clavosa collected at depth of 10-15 m near Boracay Island in 
the Philippines. 2.6-2.10 showed moderate cytotoxicity against the HCT-116 human colon 
tumour cell line, with IC50’s of 119, 106, 86, 75, and 92 𝜇M. 
 
 
Figure 2.4: Structure of polymethoxydienes 2.6-2.10. 	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2.1.2 Proline-containing cyclic peptides 
Among bioactive cyclopeptides, many of them have one or multiple proline residues. 
Proline, as well as the proline-X (X stands for any other amino acid) amide bond, has some 
exclusive features that worth introducing. 
2.1.2.1 Special feature of proline-X amide bond 
A) Amide bond 
Amide bond is the fundamental chemical bonding for building proteins from amino acids. 
The reason peptides and proteins are stable is because of the delocalisation of the lone pair 
electrons of the nitrogen atoms onto the carbonyl groups on their amide bonds. Due to this 
fact, the C-N bond has some double-bond character so that the free rotation of the amide 
bond is restricted. Usually, two isomers for the configuration of amide bonds are present: 
cis- and trans- (Figure 2.5). The trans- isomers are much more naturally abundant due to 
less steric clash between the hydrogen atom and the R group on the carbonyl group. 
 
 
Figure 2.5: cis- and trans- isomers of amide bond. The cis- isomer has higher steric hindrance than the 
trans- isomer. 
B) Proline and proline-X amide bond 
Proline, unlike other 𝛼-amino acids, has a distinct cyclic structure (Figure 2.6). The 
nitrogen atom links with two alkyl groups, thus making proline the only amino acid that 
forms tertiary amide. The ring structure of proline also gives proline an exceptional 
structural rigidity compared to other amino acids. Similar to the other amino acids, 
proline-X amide bonds can adopt cis- and trans- conformations (Figure 2.6). However, 
unlike the trans-isomers, which are much more abundant than the cis-isomers in most 
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amide bonds, occurrences of the cis-isomers in proline-X amide bonds are much more 
frequent.46 This is due to the fact that cis- and trans- isomers experience similar internal 
steric repulsion, so that they are energetically similar.  
 
 
Figure 2.6: Cis- and trans- isomers of proline amide bonds. 
It is possible to determine the geometry of proline amide bonds using the 13C NMR method 
reported by Siemion et al.47 The difference in chemical shift between the signal of C𝛽 and 
C𝛾 on the pyrrolidine ring (Δ𝛿𝛽𝛾 =   𝛿𝛽 −   𝛿𝛾) is the key, where a small difference 
(around 4 ppm) indicates trans-isomer and a large difference (around 8 ppm) indicates 
cis-isomer.47 
2.1.2.2 Proline-containing cyclic peptides 
Unlike linear peptides, cyclic peptides are polypeptide chains adopting a macrocycle ring 
structure. They present a wide range of biological activities such as antibacterial, 
immunosuppressive, bactericidal, antitumour, anti-inflammatory, etc. Several natural cyclic 
peptides are now used for pharmaceutical purpose. Although linear peptides can make 
superb drug candidates, cyclic peptides could potentially make better drugs. Firstly, due to 
the conformational rigidity, cyclic peptides present better bioactivities than their linear 
counterparts.48 Secondly, since cyclic peptides have neither the amino nor the acid termini, 
they are more resistant to hydrolysis by exopeptidases.48 Thirdly, some cyclic peptides are 
better at crossing cell membranes.48 
Marine sponges are a common source for the isolation of proline-rich cyclopeptides. In the 
following section, the isolation and synthesis of several proline-containing cyclopeptides 
will be introduced and discussed. 
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A) Segetalin E 
Segetalin E (2.11, Figure 2.7) was isolated from seeds of higher plant Vaccaria segetalis, 
and it was found to inhibit the growth of P-388 cells.50 The structure of segetalin E was 
elucidated by chemical degradation and 2D-NMR methods.49 The total synthesis of 
segetalin E was published by Dahiya and Kaur in 2007,50 and they employed solution phase 
peptide synthesis. The final macrocyclisation was completed by keeping the linear 
precursor with a catalytic amount of TEA/NMM/pyridine at 0 ℃  for seven days.50 
Segetalin E exhibited potent cytotoxicity against DLA and EAC cell lines with IC50 value 
of 3.71 and 9.11 𝜇M respectively, and showed good anthelmintic activity against M. 
konkanensis, P. corethruses and moderate activity against Eudrilus sp. at 2 mg/mL.50 
However, no antifungal activity was found.50 The biological studies have proven that 
segetalin E has the potential to be a potent cytotoxic and anthelmintic drug in the future. 
 
 
Figure 2.7: Structure of segetalin E (2.11). 
B) Cis, cis-ceratospongamide 
In 2000, Tan et al. isolated two conformationally stable cyclic heptapeptides: cis,cis- and 
trans,trans-ceratospongamides (2.12, 2.13, Figure 2.8) from the marine red algae 
Ceratodictyon spongiosum.51  
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Figure 2.8: Structures of cis,cis- and trans,trans-ceratospongamide (2.12 and 2.13). 
These two cyclic peptides both contain two phenylalanine residues, two proline residues, 
one isoleucine residue, one thiazole residue and an oxazoline residue. What makes this set 
of natural products interesting is that although they are structurally identical in connectivity, 
they showed entirely different bioactivities. The trans,trans-isomer presents potent 
inhibition of sPLA2 expression in a cell-based model for anti-inflammation with an ED50 of 
32 nM; however the cis,cis-isomer is inactive.51 This surprising result indicates that the 
conformation of ceratospongamide proline amide bonds is the key to the difference of their 
bioactivities.  
The total synthesis of cis,cis-ceratospongamide was accomplished by Chen et al. in 2003, 
where the trans-oxazoline ring was formed at the end of the synthesis (Scheme 2.1).52 
Interestingly, the cyclodehydration of the 1:1.3 mixture of cis,cis- and cis,trans-2.14 
produced cis,cis-ceratospongamide (2.12) as the sole product in excellent yield (89%). This 
result would indicate that there is an intramolecular interconversion between these two 
conformational isomers cis,cis-2.14 and cis,trans-2.14 at room temperature since the 
product 2.12 was derived only from the cis,cis-2.14.52 
 
N
N
S O
N
HN
ON
O
HN
O
N
H O
O
2.12
N
N
S O
N
HN
ON
O
HN
O
HN
2.13
O
O
	  34	  
 
Scheme 2.1: Final cyclodehydration to form cis,trans-oxazoline.52 i. Deoxo-fluor, CH2Cl2, 89%. 
C) Trunkamide A and mollamides 
Carroll et al. isolated Trunkamide A (2.15, Figure 2.9) from the colonial ascidian 
Lissoclinum sp. collected from the Great Barrier Reef in Australia in 1996.53 Trunkamide A 
was selected by the National Cancer Institute (NCI) for further testing due its specificity 
against UO-31 multidrug resistant renal cell line.53 The initial structure assignment by 
Carroll et al. was found to be incorrect where the stereochemistry of the carbon atom 
adjacent to the thiazoline ring (C45) should be D-configuration.54  
 
 
Figure 2.9: Structure of trunkamide A (2.15). 	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The first total synthesis of trunkamide A and its C45 epimer was completed by McKeever 
and Pattenden in 2001 using solution phase synthesis.55 The synthetic process encountered 
some difficulties, including the failure of the macrocyclisation of 2.16 and concomitant 
epimerisation at C40 and C45 after the macrocyclisation of 2.17 (Scheme 2.2). Shortly after 
the solution phase total synthesis, Caba et al. reported a total synthesis employing the Fmoc 
solid phase strategy and utilising chlorotrityl chloride resin as the solid support.54 The 
macrocyclisation and thiazoline formation steps were carried out after the linear precursor 
was cleaved from the resin. This approach can avoid the use of acid-labile protecting 
groups and enable the use of extremely mild acidic conditions to cleave the resin, as the 
reverse prenyl ether is acid-sensitive.54 
 
Scheme 2.2: Failures in McKeever’s total synthesis of trunkamide A.55 
Another cyclopeptide modified by the reverse prenyl group would be mollamide (2.18, 
Figure 2.10), which was isolated from Indonesian tunicate Didemnum molle in 1994.56 
Mollamide is moderately cytotoxic against several cell lines (i.e. murine leukaemia and 
lung carcinoma). The total synthesis of mollamide was finished in 1999 where solution 
phase synthesis was applied.57 
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Figure 2.10: Structure of mollamide (2.18). 
Fourteen years after the discovery of mollamide, another two cyclic peptides from the same 
family, mollamides B and C (2.19 and 2.20, Figure 2.11) were also isolated from 
Didemnum molle.58 The structures of these two cyclopeptides were established by using a 
combination of 1D, 2D NMR and molecular modelling methods, and they both contain 
reverse prenyl moieties. Mollamide B exhibits moderate antimalarial activity (IC50 around 
2.0 𝜇g/mL) against Plasmodium falciparum and marginal activity against Leishmania 
donovani and HIV-1 in human PBM cells.58 It also showed growth inhibition of several 
cancer cell lines.58 Mollamide C was tested in a disk diffusion assay in vitro and not found 
to be solid tumour-selective.58 There has not been any total synthesis reported in the 
literature. 
 
Figure 2.11: Structures of mollamides B and C (2.19 and 2.20). 
D) Myriastramides A-C 
There have been a lot of investigations of the sponge Myriastra clavosa, and several natural 
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aforementioned clavosines A-C are highly functionalised cytotoxins that inhibit 
serine/threonine protein phosphatases;37 and a homologous series of polymethoxydienes44 
as well as clavosolides A and B;38 showing different cytotoxic activity.  
Myriastramides A-C (2.21-2.23, Figure 2.12) are three new modified cyclic octapeptides 
isolated from extracts of M. clavosa, and they are the first peptide metabolites isolated from 
this species.59 The structures of myriastramides A and B are similar to that of 
haliclonamides; however differences in the amino acid sequence and heterocyclic rings 
differentiate these peptides from the myriastramides.59 Myriastramide C, which is the 
synthetic target of this chapter, has a distinctive structure from myriastramides A and B. 
The structures of myriastramides A and B were fully assigned, but insufficient amount 
isolated for myriastramide C led to the incomplete structure elucidation. The 
stereochemistry of the tryptophan residue was not successfully assigned either (Figure 
2.12).59 Myriastramide A was tested for cytotoxicity against ten different human tumour 
cell lines, but no activity was observed. Myriastamides B and C were not isolated with 
enough amounts to be tested in the same assay.59  
 
 
Figure 2.12: Structures of myriastramides A-C (2.21-2.23). The stereochemistry of the tryptophan 
residue on myriastramide C is not assigned. 	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2.1.3 Aims 
The aim of this project is to synthesise myriastramide C, and test it for biological activities. 
Myriastramide C is the most interesting member to synthesise of the myriastramide family, 
not only because it was not isolated in sufficient quantity for biological testing, but also for 
the failure in assigning the stereochemistry of the tryptophan residue. Although 
myriastramide A and B are not active, the structure of myriastramide C is distinct from 
them, which provides the possibility of biological activities. After achieving the synthesis, 
we will compare the NMR spectra to determine whether the stereochemistry on tryptophan 
is correct. Also, myriastramide C will be tested for biological activities. 
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2.2 Results and discussion 
2.2.1 Strategy 
Myriastramide C is a cyclic peptide containing eight amino acids, both natural and 
unnatural. Among them are two prolines, one tryptophan, three valines, one oxazole ring 
and one thiazole ring. As described in the structure elucidation article,59 all the valine and 
proline residues are in L-configuration. However, the authors failed to determine the 
stereochemistry of the tryptophan residue.59 Therefore in the synthesis, we will firstly 
assume the tryptophan is also in L-configuration and use L-tryptophan in the total synthesis.  
Retrosynthetically, several disconnections can be made to break down this macrocycle. The 
natural product will be assembled from three fragments: the thiazole-containing fragment 
2.24, the oxazole-containing fragment 2.25 and the dipeptide 2.26. They can be prepared 
from L-valine, L-proline, L-serine and L-tryptophan (Scheme 2.1). For the efficiency and 
yield of the synthesis, we proposed a convergent synthesis where the two fragments 2.24 
and 2.25 are of equal size. The macrolactamisation will be performed in the final stage of 
the synthesis, between the proline in 2.26 and the valine incorporated into the oxazole, 
which we considered as the least hindered position. 
 
	  
Scheme 2.3: Retrosynthetic analysis of myriastramide C. 	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In the coupling reactions, we envisioned to use PyBOP (2.27) for its high efficiency; and 
EDCI (2.28) with the aid of HOBt (Figure 2.13) mainly because of its water-soluble urea 
by-product. This by-product is easily removed by aqueous washes, thus simplifying the 
purification process of the peptides. EDCI and HOBt are used mainly for inter-fragment 
couplings so that the purification of the long and more polar peptide products can be easier.  
 
 
Figure 2.13: Structures of PyBOP (2.27) and EDCI∙HCl (2.28). 
2.2.2 Synthesis of fragments 2.24, 2.25 and 2.26 
2.2.2.1 Synthesis of thiazole containing fragment 2.24 
We started the synthesis by making 2.24, and the details are shown in Scheme 2.4. 
Beginning with N-protected tryptophan 2.29, we could convert this amino acid to its 
corresponding primary amide 2.30 by adding Boc anhydride, pyridine, and ammonium 
bicarbonate. The reaction pathway can be elucidated using Scheme 2.5. The amino acid and 
pyridine complex 2.31 would form a mixed anhydride 2.32 with Boc anhydride; then the 
ammonia derivative will react with it to yield the primary amide 2.33.60 2.30 was 
transformed into a thioamide 2.34 using Lawesson’s reagent, and a yield of 77% over two 
steps was obtained. A modified Hantzsch thiazole synthesis60 was performed on thioamide 
2.34 using ethyl bromopyruvate to form the thiazole 2.35 without epimerisation on the 
tryptophan chiral centre. After that, a standard deprotection of the ethyl ester and a 
coupling with valine methyl ester hydrochloride led to the final product 2.24 with a 
satisfying yield of 74% over three steps. 
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Scheme 2.4: Synthesis of 2.24. i. Boc2O (1.3 equiv.), NH4HCO3 (1.3 equiv.), pyridine (0.62 equiv.), MeCN, 
rt, overnight; ii. Lawesson’s reagent (0.6 equiv.), anhydrous THF, rt, overnight, 77% over two steps; iii. 
KHCO3 (8 equiv.), ethyl bromopyruvate (3 equiv.), TFAA (4 equiv.), pyridine (8.5 equiv.), DME, 0 ℃ to rt, 
overnight; iv. LiOH (3 equiv.), THF/H2O (3:1), 0 ℃, 6 h; v. valine methyl ester hydrochloride (1.3 equiv.), 
PyBOP (1.3 equiv.), DIPEA (2.2 equiv.), CH2Cl2, 0 ℃ to rt, overnight, 74% over three steps. 
 
 
Scheme 2.5: Formation of carboxamide. 
The original Hantzsch thiazole synthesis is known to lead to epimerisation of the 𝛼-chrial 
centre of the thiazole ring (Scheme 2.6).61 The reaction involves alkylation of the 
N-protected thioamide 2.36 with methyl or ethyl bromopyruvate in the presence of base, 
and epimerisation is possible due to the imine-enamine tautomerisation of the 
hydroxythiazoline intermediate 2.37. The epimerisation depends on the rate of the final 
dehydration step.  
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Scheme 2.6: Epimerisation at the 𝜶-chrial center of the thiazole ring. 
In order to target this issue, a modified Hantzsch synthesis was reported,61 where 8 equiv. 
of finely powdered KHCO3 was added to ensure the formation of the hydroxythiazoline 
derivative. The HBr formed from the first step is neutralised by the excess amount of 
KHCO3. By activation of the hydroxyl group in 2.37 by trifluoroacetic anhydride (TFAA) 
in pyridine, the following dehydration would proceed much faster and aromatisation takes 
place to form the thiazole without any epimerisation on the 𝛼-chiral center. After applying 
this method, we did not observe any additional signal for the diastereotopic 𝛼-proton in the 
1H NMR of 2.24, which indicated that no epimerisation has taken place in the reaction.  
The reaction between TFAA and pyridine will result in trifluoroacetylpyridinium 
trifluoroacetate 2.42 which equilibrates with the tetrahedral intermediate 2.43 (Figure 
2.14).62 This intermediate can activate the hydroxyl group in the hydroxyoxazoline 
derivative 2.37 by formation of a good leaving group, hence increase the rate of the 
dehydration step. 
 
 
Figure 2.14: The TFAA-pyridine complex and its two forms. 
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2.2.2.2 Synthesis of oxazole containing fragment 2.25 
The synthesis of oxazole containing fragment 2.25 is detailed in Scheme 2.7. We started 
firstly with Boc-valine 2.44, by coupling it with serine methyl ester hydrochloride using 
PyBOP as coupling reagent to form dipeptide 2.45. Then the formation of the oxazole 2.46 
was achieved in two steps63: first treating the peptide with DAST at low temperature 
(-78  ℃); then cyclisation under basic conditions with K2CO3 would give the oxazoline. The 
compound was then oxidised to the oxazole 2.25 using DBU and bromotrichloromethane. 
The reaction is initiated by the nucleophilic displacement of fluorine on sulfur by oxygen of 
the hydroxyl group (Scheme 2.8).64 The expected intermediate 2.46 was obtained in 75% 
yield after the cyclisation-oxidation process. Finally, fragment 2.25 was synthesised with 
methyl ester deprotection followed by coupling reaction with valine methyl ester 
hydrochloride from 2.46. 
 
 
Scheme 2.7: Synthesis of 2.25. i. L-serine methyl ester hydrochloride (1.3 equiv.), PyBOP (1.3 equiv.), 
DIPEA (2.2 equiv.), CH2Cl2, 0 ℃ to rt, overnight, 97%; ii. DAST (1.2 equiv.), CH2Cl2, -78 ℃, 1.5 h, then 
K2CO3 (1.3 equiv.), CH2Cl2, -78 ℃ to rt, 1 h; iii. DBU (1.2 equiv.), BrCCl3 (1.4 equiv.), CH2Cl2, -10 ℃ to 
rt, overnight, 75% over two steps; iv. LiOH (3 equiv.), THF/H2O (3:1), 0 ℃, 2 h; v. L-valine methyl ester 
hydrochloride (1.3 equiv.), PyBOP (1.3 equiv.), DIPEA (2.2 equiv.), CH2Cl2, 0 ℃ to rt, overnight, 83%. 
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Scheme 2.8: Mechanism of oxazole formation employing DAST/K2CO3 then DBU/BrCCl3. 
During the synthesis of 2.25, we have investigated another route to convert 2.45 into 2.46 
(Scheme 2.9). This route was applied in some successful synthesis of oxazole derivatives 
that will be discussed later in Chapter 3 (Figure 2.15). Interestingly, when this path was 
applied, the synthesis failed at step iii with no reaction observed overnight. One obvious 
difference between 2.46 and the examples given in Figure 2.15 is that it is lacking a methyl 
group on the oxazole ring. In theory, lacking an electron donating methyl group should 
make the bromine-bearing carbon atom more electron deficient and the reaction site less 
hindered, therefore making the nucleophilic attack on this carbon more readily. However, it 
is not applicable to make 2.46. 
 
 
Scheme 2.9: Failed attempt of synthesising oxazole derivative 2.46. i. Boc2O (1.1 equiv.), DMAP (0.3 
equiv.), CH2Cl2, rt, 2 h, then 1,1,3,3-tetramethylguanidine (1.5 equiv.), CH2Cl2, rt, 3 h, 88%; ii. NBS (1.1 
equiv.), CH2Cl2, rt, overnight, then TEA (1.5 equiv.), CH2Cl2, rt, 1 h, 64%; iii. DBU (1.3 equiv), CH3CN, rt, 
overnight. 
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Figure 2.15: Examples of oxazole compounds we have successfully synthesised in Chapter 3 by the 
approach discussed in Scheme 2.9. 
2.2.2.3 Synthesis of dipeptide Boc-Pro-Pro-OMe (2.26) 
Dipeptide fragment 2.26 was synthesised by coupling Boc proline 2.51 with proline methyl 
ester hydrochloride. Even though structurally simple, it was proved to be hard to synthesise: 
the Pro-Pro dipeptide appeared as two different isomers-cis and trans (Scheme 2.10). As a 
result, 2.26 will show different rotamers in NMR spectra. As illustrated in Figure 2.16, 
peaks for all protons in the 1H NMR are either doubled or multiplied. However, it was 
impossible to separate the rotamers, as they give identical retention factor (Rf) on TLC. 
This will not only make it hard to interpret the NMRs, but also complicates the 
purifications in the later part of the total synthesis.  
 
 
Scheme 2.10: Synthesis of 2.26. i. L-proline methyl ester hydrochloride (1.3 equiv.), PyBOP (1.3 equiv.), 
DIPEA (2.2 equiv.), CH2Cl2, 0 ℃ to rt, overnight, 97%. 
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Figure 2.16: 1H NMR spectrum of 2.26, the tBu and methyl peaks are clearly doubled and other peaks 
multiplied.  
2.2.3 Union of fragments 
Having achieved the synthesis of the three fragments, we sought to combine them together. 
The process is elucidated in Scheme 2.11. First we decided to couple 2.24 and 2.25 together 
as we could avoid having prolines in the product. Deprotections were performed to reveal 
the corresponding acid 2.52 and amine hydrochloride 2.53. Then EDCI was chosen to use 
as the coupling agent to couple them together to yield hexapeptide 2.54, mainly because of 
the ease of purification. 2.54 was further deprotected to 2.55, coupled with the 
hydrochloride salt 2.56 derived from 2.26, to provide the linear precursor 2.57 with the full 
peptide sequence and ready to be macrocyclised. As mentioned before, when the 
hexapeptide 2.54 was coupled with the proline-proline dipeptide 2.26, NMR shows a 
mixture of compounds, although on TLC the product seems to be pure. This can be easily 
observed by looking at the 𝛽 and 𝛾 carbon signals in 13C NMR spectrum of 2.54 (Figure 
2.17).  
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Scheme 2.11: Union of fragments. Only 2.56 and 2.57 in their desired forms are drawn. i. LiOH (3 equiv.), 
THF/H2O (3:1), 0 ℃, 2 h; ii. HCl (4.0 M in dioxane), rt, 1 h; iii. 2.52 (1 equiv.), 2.53 (1.4 equiv.), EDCI (2 
equiv.), HOBt (2 equiv.), DIPEA (2.5 equiv.), anhydrous DMF, 0 ℃ to rt, overnight, 62% from 2.25; iv. 
2.55 (1 equiv.), 2.56 (1.83 equiv.), EDCI (2 equiv.), HOBt (2 equiv.), DIPEA (2.5 equiv.), anhydrous DMF, 0 ℃ to rt, overnight, 71% from 2.54.  
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Figure 2.17: 𝜷 and 𝜸 carbon signals in the 13C NMR spectrum for compound 2.57. 
2.2.4 Macrocyclisation 
After completing the synthesis of the complete linear precursor 2.57, macrocyclisation was 
performed (Scheme 2.12). Firstly, the precursor needs to be deprotected on both ends, using 
standard methods to give the naked precursor 2.58. Then the macrocyclisation was 
performed in high dilution conditions (1 mM) using HATU as coupling agent for 72 h. 
After aqueous work-up, TLC showed two close spots, and they were partially separated by 
column chromatography. However, these two partially separated spots both showed correct 
mass in MALDI-TOF mass spectrometry (850.94 and 851.17 as base peaks which both fit 
[M+Na]+), indicating that they could be rotamers or epimers. Analytical HPLC was 
performed on both fractions, and we found several overlapped peaks from both of them. 
However, the peak intensities are different. The first fraction is significantly better, for 
there is one peak as the major component in the mixture (Figure 2.18). The HPLC was 
performed with standard analytical gradient (5:95 to 95:5 MeOH/H2O over 20 minutes). It 
needs to be optimised to give a better separation so that we can purify a larger amount for 
all the characterisation. Unfortunately, we were unable to purify the sample. Therefore we 
sent the first fraction to our collaborator in Aberdeen. To our delight, the mixture was 
successfully purified, and one pure compound was obtained.  
Although the mixture of products could be rotamers for the same molecule, we did not have 
solid evidence to support this conclusion. In theory, they could also be epimers. In the 
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future a various temperature NMR experiment should be performed to confirm the 
existence of rotamers. 
 
 
Scheme 2.12: Macrocyclisation, only the desired product is drawn. i. LiOH (3 equiv.), THF/H2O (3:1), 0 ℃; ii. HCl solution (4 M in dioxane), rt; iii. HATU (2 equiv.), DIPEA (3 equiv.), MeCN, rt, 72 h. 
 
 
Figure 2.18: HPLC spectrum of the first fraction. Four peaks are overlapped and the major one has the 
retention time of 16.011 min (5:95 to 95:5 MeOH/H2O over 20 min). 
2.2.5 Purification and identification of final product 
The final mixture was analysed by Prof. Marcel Jaspars in University of Aberdeen, and 
results obtained so far is shown in this section. The sample was purified through a 
Phenomenex strata 1g C8 cartigrade, using the following gradient (Table 2.1): 
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Time (min) Solvent A Solvent B 
0 30 70 
15 0 100 
25 0 100 
25.1 30 70 
Table 2.1: HPLC solvent gradient for the purification of final product. Solvent A = 95% water +5% 
methanol; Solvent B = 100% methanol 
The result did reveal four components similar to that shown in Figure 2.18, and the largest 
component (peak 4 in Figure 2.19 A) was of the most interest since it is the most abundant 
compound in the mixture. Further LCMS analysis of peak 4 gave the result matching 
natural myriastramide C (Figure 2.19 B). Furthermore, mixture of peaks 2 and 3 gave same 
result in the LCMS analysis. 
Peak 4 was taken for further NMR analysis. The preliminary result and comparison of the 
1H and 13C NMR data of the synthetic compound with the reported data58 are shown in 
Table 2.2. Both 1H and 13C NMR data are closely matching with the reported data of 
natural myriastramide C,59 except for the carbon signal for C29, which is 10 ppm different 
from the reported data. As a result, we could not conclude that the purified product is 
myriastramide C. Full characterisation as well as further studies by NMR and biological 
studies are underway. 
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B) 
 
 
 
 
Figure 2.19: A) HPLC separation of final product 2.23, peak 4 was taken into further NMR analysis. B) 
LCMS analysis of peak 4, the base peak (m/z 828.39) matches with myriastramide C. 
 
Residue Position 𝛿C 𝛿H 
  Natural Synthetic Natural Synthetic 
 
 
 
Val-1 
1 170.19 169.88     
2 60.28 60.65 4.15 4.09 
3 28.91 28.94 2.46 2.43 
4 17.54 17.61 0.85 0.89 
5 19.47 19.35 0.93 0.93 
NH   7.11 7.10 
6 160.99 161.85   
 
Oxz 
7 134.08 135.87   
8 141.42 141.55 7.96 7.96 
9 162.79 162.27   
 
 
Val-2 
10 52.32 52.3 5.22 5.19 
11 29.62 29.61 2.76 2.69 
12 20.09 20.13 1.11 1.12 
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13 17.63 17.86 1.12 1.10 
NH   8.12 7.61 
 
 
Pro-1 
14 171.19 171.24     
15 60.97 60.97 4.5 4.51 
16 31.23 31.51 2.70, 2.07 2.65, 2.12 
17 22.04 22.10 2.00, 1.80 2.02, 1.83 
18 46.56 46.84 3.62, 3.56 3.62 
 
 
Pro-2 
19 170.74 170.17     
20 58.52 58.88 4.51 4.49 
21 28.51 28.47 2.25, 1.85 2.30, 1.86 
22 24.93 24.88 2.16, 2.00 2.17, 2.02 
23 48.03 48.18 4.03, 3.81 4.06, 3.81 
 
 
 
Val-3 
24 170.19 170.20     
25 55.43 55.50 4.76 4.80 
26 31.7 31.46 2.16 2.17 
27 19.43 19.41 1.06 1.07 
28 18.14 17.95 0.97 0.98 
NH   7.21 7.25 
29 160.62 170.61   
 
Thz 
30 149.21 148.71     
31 124.14 124.33 7.85 7.88 
32 169.51 169.43     
 
 
Trp 
33 51.5 51.38 5.56 5.60 
34 32.19 31.8 3.47, 3.28 3.45, 3.33 
35 110.89 110.85     
36 122.8 122.73 6.95 6.96 
NH   8.06 7.26 
37 135.98 135.87     
 
 
Trp 
38 111.13 111.06 7.29 7.30 
39 122.18 122.18 7.13 7.14 
40 119.67 119.52 7.03 7.02 
41 118.37 118.26 7.48 7.46 
42 127.49 127.23     
NH   7.21 7.32 
Table 2.2: 1H and 13C NMR data in ppm for synthetic myriastramide C and natural myriastramide C59 
in CDCl3.  
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2.3 Conclusions and Future Work 
We have reached the last stage of the total synthesis of myriastramide C, further 
purification, identification and biological testing are underway. The thiazole ring was 
installed by a modified Hantzsch thiazole synthesis with no epimerisation at the 𝛼-stereocentre. The synthesis of Pro-Pro dipeptide 2.26 produced more than one conformer 
due to the ability of proline amide bonds to adapt both cis- and trans- conformations. The 
synthetic product 2.23 was observed as a mixture of several components possibly due to the 
Pro-Pro residue, and the 1H NMR spectrum is inconclusive. Therefore, further HPLC 
purification is required but it appeared challenging. Eventually, a pure compound was 
isolated thanks to our collaborator. Unfortunately, upon comparison of the NMR data of 
synthetic 2.23 with reported data in the literature, we could not draw the conclusion that 
2.23 is myriastramide C. The 10 ppm difference at C29 deserves further investigation. It 
also requires more comprehensive analysis to confirm the structure. In addition, it would be 
helpful to know if the products from the final macrocyclisation are rotamers, possibly by 
performing a various temperature NMR experiment. 
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2.4 Experimental 
2.4.1 General Experimental Methods 
Chemicals and general reagents were purchased from commercial suppliers, and unless 
stated otherwise were used without further purification. Anhydrous solvents were 
purchased and stored under argon atmosphere. Where necessary, solvents and reagents 
were purified according to standard methods. 
All air and/or moisture sensitive reactions were carried out under inert atmosphere of argon 
gas, in oven-dried glassware. Reaction were monitored by TLC using pre-coated aluminum 
plates coated with 0.14 mm of silica gel 60 containing a fluorescence indicator active at 
254 nm (Merck, Kieselgel 60 F254). Visualisation was carried out under UV-light (𝜆  254 nm) 
and/or by staining with, most commonly, cerium-ammonium molybdate or 10% aqueous 
KMnO4 or ninhydrin followed by heating. Flash column chromatography was performed 
with silica gel (MN Kieselgel 60, 40-63 𝜇m,230-400 Mesh ASTM). ‘Brine’ refers to a 
saturated aqueous solution of sodium chloride. The term in vacuo refers to the removal of 
solvents by the means of evaporation at reduced pressure, using a Buchi rotary evaporator. 
Melting points were obtained in open capillary tubes on an Electrothermal Melting Point 
Apparatus and are uncorrected. Polarmetry was recorded on an ADP220 polarimeter, in a 
solvent of MeOH. Infrared spectra were recorded on a PerkinElmer Spectrum 400 
FT-IR/FT-FIR spectrometer. Absorptions were recorded in wave numbers (cm-1). 1H NMR 
and 13C NMR were recorded on Bruker AC400 spectrometers (400 MHz for 1H and 100 
MHz for 13C). Spectral data were reprocessed using ACD Labs software or 
MESTRENOVA and referenced to the residual solvent peak (CDCl3, CD3OD or 
DMSO-d6). Characteristic splitting patterns due to spin spin coupling are expressed as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Chemical 
shifts are given in ppm and coupling constants are measured in Hz. 
Low-resolution mass spectra were obtained using LC-MS on a Shimadzu LCMS 2010EV 
spectrometer or MALDI-TOF on a Kratos Axima CFR spectrometer. High-resolution mass 
spectra were collected by EPSRC National Mass Spectrometry Facility (Swansea) using a 
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Thermofisher LTQ Orbitrap XL mass spectrometer. 
2.4.2 Experimental Details for Chapter 2 
Thioamide 2.34 
 
To a stirred solution of Boc-tryptophan 2.29 (2.5 g, 8.21 mmol, 1 equiv.) in CH3CN (30 mL) 
was added Boc2O (2.33g, 10.67 mmol, 1.3 equiv.), NH4HCO3 (843 mg, 10.67 mmol, 1.3 
equiv.) and pyridine (0.41 mL, 5.09 mmol, 0.62 equiv.). The resulting mixture was stirred 
overnight at rt. Solvent was evaporated in vacuo, and the mixture was dissolved in EtOAc 
(50 mL) then washed with 2 N HCl (50 mL). The aqueous layer was extracted with EtOAc 
(30 mL  ×  2). The combined organic layer was dried over MgSO4, filtered, and concentrated 
in vacuo to afford amide 2.30 as yellow oil and used in the next step without further 
purification. 
To a solution of amide 2.30 (8.21 mmol, 1 equiv.) in anhydrous THF (25 mL) was added 
Lawesson’s reagent (2 g, 4.93 mmol, 0.6 equiv.). The mixture was stirred at rt overnight. 
The mixture was purified by column chromatography (1:9 EtOAc/CH2Cl2) to provide 
thioamide 2.34 as a white solid (2.03 g, 77% over two steps); 1H NMR (400 MHz, CDCl3) 𝛿: 8.13 (brs, 1H, NH), 7.63 (d, 1H, J = 7.9 Hz, H-4), 7.40 (brs, 1H, NH), 7.27 (d, 1H, J = 
8.2 Hz, H-7), 7.18 (brs, 1H, NH), 7.12 (m, 1H, H-6), 7.05 (m, 1H, H-5), 6.98 (d, 1H, J = 
2.1 Hz, H-3), 5.37 (d, 1H, J = 5.3 Hz, NH), 4.66 (q, 1H, J = 7 Hz, H-1), 3.23 (m, 2H, H-2), 
1.32 (s, 9H, tBu) ppm. 
The spectroscopic data are consistent with those65 reported in the literature. 
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Boc-Trp-Thz-Val-OMe (2.24) 
 
To a suspension of pulverised KHCO3 (1.25 g, 12.48 mmol, 8 equiv.) in a solution of 
thioamide 2.34 (500 mg, 1.56 mmol, 1 equiv.) in DME (10 mL), ethyl bromopyruvate (0.59 
mL, 4.68 mmol, 3 equiv.) was added. The mixture was stirred under argon at rt for 2 h. The 
suspension was then cooled to 0 ℃, and a solution of TFAA (0.88 mL, 6.24 mmol, 4 
equiv.) and pyridine (1.07 mL, 13.26 mmol, 8.5 equiv.) in DME (10 mL) was then added. 
The reaction mixture was left warming up to rt overnight. Solvent was evaporated in vacuo. 
The residue was suspended in CHCl3 (30 mL) and this solution was washed with water (30 
mL). The aqueous layer was extracted with CHCl3 (30 mL  ×  2), and the combined organic 
layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by column chromatography (1:9 EtOAc/hexane) to afford thiazole 2.35 partially 
purified as yellow oil, and used in the next step without further purification. 
To a solution of 2.35 (1.56 mmol, 1 equiv.) in 10 mL of a mixture of THF/water (3:1) that 
had been cooled to 0 ℃ was added LiOH (112 mg, 4.68 mmol, 3 equiv.). The mixture was 
stirred at 0  ℃ for 6 h. The solution was diluted with water (10 mL), then acidified to pH 
1-2 with 2 N HCl aqueous solution. The aqueous layer was extracted with EtOAc (30 
mL  ×  3). The combined organic layer was dried over MgSO4, filtered, and concentrated in 
vacuo to provide the corresponding acid and used in the next step without further 
purification. 
To a solution of the acid (1.56 mmol, 1 equiv.) in CH2Cl2 (10 mL) was added L-valine 
methyl ester hydrochloride (340 mg, 2.03 mmol, 1.3 equiv.), PyBOP (1.06 g, 2.03 mmol, 
1.3 equiv.) and DIPEA (0.6 mL, 3.43 mmol, 2.2 equiv.), then stirred at 0 ℃ overnight. 
The mixture was washed with 2 N HCl (30 mL) and saturated aqueous NaHCO3 solution 
(30 mL). The organic layer was dried with MgSO4, filtered, and concentrated in vacuo. The 
residue was purified by column chromatography (1:4 EtOAc/petroleum ether) to afford 
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2.24 as a white solid (574 mg, 74% over three steps); mp: 58-62 °C; [α]D25 = +31.8 (c 0.22, 
CH3OH); IR (neat): 3342, 1667, 1541 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 8.11 (brs, 1H, 
NH), 7.88 (s, 1H, H-8), 7.71 (d, 1H, J = 9.2 Hz, H-4), 7.27 (d, J = 8.2 Hz, H-7), 7.11 (t, 1H, 
J = 7.5 Hz, H-6), 7.02 (t, 1H, J = 7.5 Hz, H-5), 6.83 (s, 1H, H-3), 5.30 (brs, 1H, H-1), 5.19 
(brs, 1H, NH), 4.67 (dd, 1H, J = 9.2, 5.2 Hz, H-9), 3.71 (s, 3H, H-13), 3.38 (m, 2H, H-2), 
2.23 (sptd, 1H, J = 6.8, 5.4 Hz, H-10), 1.36 (s, 9H, tBu), 0.96 (d, 3H, J = 6.9 Hz, H-11 or 
H-12), 0.94 (d, 3H, J = 6.9 Hz, H-11 or H-12) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 173.9, 
172.4, 161.1, 155.2, 149.4, 136.2, 127.7, 123.6, 123.4, 122.1, 119.7, 118.5, 111.3, 109.8, 
80.4, 57.2, 53.4, 52.2, 31.5, 30.9, 28.3 (3C), 19.1, 18.0 ppm; ES+ MS m/z 523 ([M+Na]+ 
100%); HRMS m/z calculated for C25H33N4O5S [M+H]+ 501.2166, found 501.2173. 
 
Boc-Val-Ser-OMe (2.45) 
 
To a solution of Boc-L-valine (2.44) (1.5 g, 6.9 mmol, 1 equiv.) in CH2Cl2 (20 mL) was 
added L-serine methyl ester hydrochloride (1.39 g, 8.97 mmol, 1.3 equiv.), PyBOP (4.67 g, 
8.97 mmol, 1.3 equiv.) and DIPEA (2.64 mL, 15.2 mmol, 2.2 equiv.). The reaction mixture 
was stirred at 0 ℃ overnight, then washed with 2 N HCl (30 mL) and saturated aqueous 
NaHCO3 (30 mL) solution. The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by column chromatography (2:3 to 3:2 
EtOAc/petroleum ether) to afford 2.45 as a white solid (2.14 g, 97%); 1H NMR (400 MHz, 
CDCl3) 𝛿: 6.89 (d, 1H, J = 7.4 Hz, NH), 5.11 (d, 1H, J = 8 Hz, NH), 4.61 (m, 1H, H-5), 
3.88 (d, 2H, J = 2.5 Hz, H-6), 3.84 (m, 1H, H-1), 3.72 (s, 3H, H-7), 2.03 (m, 1H, H-2), 1.37 
(s, 9H, tBu), 0.93 (d, 3H, J = 6.8 Hz, H-3 or H-4), 0.90 (d, 3H, J = 6.8 Hz, H-3 or H-4) 
ppm.  
The spectroscopic data are consistent with those66 reported in the literature. 
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Boc-Val-∆Ala-OMe (2.47) 
 
To a solution of Boc-Val-Ser-OMe (2.45) (500 mg, 1.57 mmol, 1 equiv.) in anhydrous 
CH2Cl2 (10 mL) was added DMAP (57.5 mg, 0.47 mmol, 0.3 equiv.) followed by Boc2O 
(376 mg, 1.73 mmol, 1.1 equiv.). The resulting mixture was stirred for 2 h at rt. Then TMG 
(0.3 mL, 2.36 mmol, 1.5 equiv.) was added, and the stirring was continued for another 3 h. 
The mixture was diluted with CH2Cl2 (20 mL) then washed with saturated KHSO4 and 
NaHCO3 (30 mL each), dried over MgSO4, filtered and concentrated in vacuo. The residue 
was purified by column chromatography (1:9 EtOAc/petroleum ether) to afford 2.47 as a 
white solid (412 mg, 88%); 1H NMR (400 MHz, CDCl3) 𝛿: 8.11 (brs, 1H, NH), 6.55 (s, 1H, 
H-5), 5.84 (d, 1H, J = 1.4 Hz, H-6), 4.95 (brs, 1H, NH), 3.98 (brs, 1H, H-1), 3.78 (s, 3H, 
H-7), 2.15 (dq, 1H, J = 12.8, 6.6 Hz, H-2), 0.92 (d, 3H, J = 6.8 Hz, H-3 or H-4), 0.86 (d, 
3H, J = 6.8 Hz, H-3 or H-4) ppm. 
The spectroscopic data are consistent with those67 reported in the literature. 
 
Boc-Val-ΔAla(β-Br)-OMe (2.48) 
 
To a solution of 2.47 (1 g, 2.37 mmol, 1 equiv.) in CH2Cl2 (20 mL) was added NBS (548 
mg, 3.08 mmol, 1.3 equiv.), and the mixture was stirred for 16 h at rt. Then TEA (0.5 mL, 
3.56 mmol, 1.5 equiv.) was added and stirring was continued for an additional hour. 
Solvent was removed in vacuo and the residue was partitioned between CH2Cl2 and 
saturated KHSO4 (50 mL each). The organic layer was washed with saturated KHSO4 and 
saturated NaHCO3 (50 mL each), dried over MgSO4, filtered, and concentrated in vacuo to 
afford 2.48 as a mixture of E/Z alkene as a white solid (573 mg, 64%); mp: 98-100 °C; 
[α]D25= -8.0 (c 1, CH3OH); IR (neat): 3300, 1736, 1678, 1537 cm-1; 1H NMR (400 MHz, 
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CDCl3, major isomer) 𝛿: 7.75 (brs, 1H, NH), 7.15 (s, 1H, H-5), 5.08 (d, 1H, J = 6.3 Hz, 
NH), 4.12 (m, 1H, H-1), 3.80 (s, 3H, H-6), 2.25 (m, 1H, H-2), 1.46 (s, 9H, tBu), 1.05 (d, 3H, 
J = 6.8 Hz, H-3 or H-4), 1.00 (d, 3H, J = 7 Hz, H-3 or H-4) ppm; 13C NMR (100 MHz, 
DMSO-d6 , major isomer) 𝛿: 171.5, 163.0, 155.9, 133.5, 114.0, 78.6, 59.7, 52.8, 31.0, 28.6 
(3C), 19.6, 8.3 ppm; ES+ MS m/z 401 ([M+Na]+ 100%); HRMS m/z calculated for 
C14H24BrN2O5 [M+H]+ 379.0868, found 379.0866. 
 
Boc-Val-Oxz-OMe (2.46) 
 
DAST (0.17 mL, 1.32 mmol, 1.2 equiv.) was added dropwise to a cold (-78 ℃) solution of 
Boc-Val-Ser-OMe (2.45) (486 mg, 1.1 mmol, 1 equiv.) in CH2Cl2 (25 mL) under argon. 
After the mixture was stirred for 1h at -78 ℃, anhydrous K2CO3 (182 mg, 1.32 mmol, 1.2 
equiv.) was added in one portion and mixture was allowed to warm to rt. The reaction 
mixture was poured into saturated aqueous NaHCO3 solution and extracted with CH2Cl2. 
The combined organic layer was dried over MgSO4, concentrated in vacuo to afford the 
crude oxazoline, and used in the next step without further purification. 
To a solution of the oxazoline in CH2Cl2 (20 mL) that was cooled to -10 ℃ was added 
DBU (0.2 mL, 1.32 mmol, 1.2 equiv.), followed by BrCCl3 (0.15 mL, 1.54 mmol, 1.4 
equiv.) dropwise. The mixture was stirred overnight while warming to rt. The mixture was 
washed with saturated aqueous NH4Cl solution (30 mL), and the aqueous phase was 
extracted with CH2Cl2 (50 mL  ×  3). The combined organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(1:4 EtOAc/petroleum ether) to afford 2.46 as a white solid (279 mg, 60% over two steps); 
1H NMR (400 MHz, CDCl3) 𝛿: 8.12 (s, 1H, H-5), 5.24 (d, 1H, J = 9 Hz, NH), 4.73 (dd, 
1H, J = 9 Hz, 6.2, H-1), 3.85 (s, 3H, H-6), 2.12 (m, 1H, H-2), 1.36 (s, 9H, tBu), 0.85 (m, 
6H, H-3 and H-4) ppm. 
The spectroscopic data are consistent with those 68 reported in the literature. 
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Boc-Val-Oxz-Val-OMe (2.25) 
 
To a solution of Boc-Val-Oxz-OMe (2.46) (534 mg, 1.79 mmol, 1 equiv.) in 10 mL of a 
mixture of THF/water (3:1) that had been cooled to 0 ℃ was added LiOH (128 mg, 5.37 
mmol, 3 equiv.). The mixture was stirred at 0 ℃ for 2 h. The solution was diluted with 
water (10 mL), and acidified to pH 1-2 with saturated 2 N HCl aqueous solution. The 
aqueous layer was extracted with EtOAc (30 mL  ×  3). The combined organic layer was 
dried over MgSO4, filtered, and concentrated in vacuo to provide corresponding acid and 
used in the next step without further purification. 
To a solution of the acid (1.79 mmol, 1 equiv.) in CH2Cl2 (10 mL) was added valine methyl 
ester hydrochloride (390 mg, 2.33 mmol, 1.3 equiv.), PyBOP (1.21 g, 2.33 mmol, 1.3 
equiv.) and DIPEA (0.69 mL, 3.94 mmol, 2.2 equiv.), and stirred at 0 ℃ overnight. The 
mixture was washed with 2 N HCl (30 mL) and saturated aqueous NaHCO3 (30 mL) 
solution and purified by column chromatography (1:4 EtOAc/petroleum ether) to afford 
2.25 as colorless oil (614 mg, 83% over three steps); mp: 58-60 °C; [α]D25 = +57.1 (c 0.07, 
CH3OH); IR (neat): 3402, 3318, 1715, 1676, 1598 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 
8.05 (s, 1H, H-5), 7.23 (d, 1H, J = 9 Hz, NH), 5.05 (d, 1H, J = 8.8 Hz, NH), 4.71 (m, 1H, 
H-1), 4.62 (dd, 1H, J = 9.1, 5.3 Hz, H-6), 3.70 (s, 3H, H-10), 2.23-2.08 (m, 2H, H-2 and 
H-7), 1.40 (s, 9H, tBu), 0.93 (dd, 6H, J = 6.9, 5.4 Hz, H-3 and H-4, or H-8 and H-9), 0.87 
(m, 6H, H-3 and H-4, or H-8 and H-9) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 172.1, 163.8, 
160.4, 155.3, 141.1, 135.7, 80.2, 56.8, 54.3, 52.2, 32.7, 31.5, 28.3 (3C), 19.0, 18.7, 18.0 
(2C) ppm; ES+ MS m/z 420 ([M+Na]+ 100%); HRMS m/z calculated for C19H32N3O6 
[M+H]+ 398.2285, found 398.2275. 
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Boc-Pro-Pro-OMe (2.26) 
 
To a solution of Boc-proline (2.51) (500 mg, 2.32 mmol, 1 equiv.) in CH2Cl2 (10 mL) was 
added proline methyl ester hydrochloride (500 mg, 3.02 mmol, 1.3 equiv.), PyBOP (1.57 g, 
3.02 mmol, 1.3 equiv.) and DIPEA (0.9 mL, 5.1 mmol, 2.2 equiv.), and stirred at 0 ℃ 
overnight. The mixture was washed with 2 N HCl (50 mL) and saturated aqueous NaHCO3 
(50 mL) solution and purified by column chromatography (3:2 EtOAc/petroleum ether) to 
afford 2.26 as colourless oil (740 mg, 97%). 
1H NMR (400 MHz, CDCl3, both isomers) 𝛿: 4.52-4.31 (m, 2H, H-4 and H-8), 3.74-3.28 
(m, 7H, H-1, H-5 and H-9), 2.19-1.73 (m, 8H, H-2, H-3, H-6 and H-7), 1.37, 1.31 (s, 9H, 
tBu) ppm. 
The spectroscopic data are consistent with those 69 reported in the literature. 
 
Linear precursor 2.57 
 
Boc-Trp-Trz-Val-OMe (2.24) (200 mg, 0.4 mmol) was dissolved in HCl solution (4.0 M in 
dioxane, 10 mL), and the solution was stirred for 2 h at rt. The mixture was co-evaporated 
with CH3CN, then CH2Cl2 twice each to afford the corresponding amine hydrochloride 
2.53 and used in the next step without further purification. 
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To a solution of Boc-Val-Oxz-Val-OMe (2.25) (232 mg, 0.56 mmol, 1 equiv., 1.4 equiv. to 
2) in 10 mL of a mixture of THF/water (3:1) that had been cooled to 0 ℃ was added LiOH 
(40 mg, 1.69 mmol, 3 equiv.). The mixture was stirred at 0 ℃ for 2 h. The solution was 
diluted with water (10 mL), and acidified to pH 1-2 with saturated 2 N HCl aqueous 
solution. The aqueous layer was extracted with EtOAc (30 mL  ×  3). The combined organic 
layer was dried over MgSO4, filtered, and concentrated in vacuo to provide corresponding 
acid 2.52 and used in the next step without further purification. 
A mixture of 2.53 (0.4 mmol, 1 equiv.) and DIPEA (0.17 mL, 1 mmol, 2.5 equiv.) in 
anhydrous DMF (5 mL) was stirred at rt for 10 min. In another flask, a mixture of 2.52 
(0.56 mmol, 1.4 equiv.), HOBt∙H2O (108 mg, 0.8 mmol, 2 equiv.) and EDCI (154 mg, 0.8 
mmol, 2 equiv.) in anhydrous DMF (5 mL) was stirred at rt for 10 min. The solution of 
amine was poured into the activated acid, and the resulting mixture was stirred overnight at 
rt. The solvent was removed in vacuo. The mixture was dissolved in EtOAc (50 mL), and 
washed with 2 N HCl, saturated NaHCO3 (50 mL each), filtered, then dried over MgSO4 
and concentrated in vacuo. The resulting residue was purified by column chromatography 
(1% to 2% MeOH/CH2Cl2) to afford 2.54 partially purified as yellow solid (266 mg). 
To a solution of 2.54 (263 mg, 0.34 mmol, 1 equiv.) in 10 mL of a mixture of THF/water 
(3:1) that had been cooled to 0 ℃ was added LiOH (25 mg, 1.03 mmol, 3 equiv.). The 
mixture was stirred at 0 ℃ for 2 h. The solution was diluted with water (10 mL), and 
acidified to pH 1-2 with saturated 2 N HCl aqueous solution. The aqueous layer was 
extracted with EtOAc (30 mL  ×  3). The combined organic layer was dried over MgSO4, 
filtered, and concentrated in vacuo to provide corresponding acid 2.55 and used in the next 
step without further purification. 
Boc-Pro-Pro-OMe (2.26) (168 mg, 0.51 mmol) was dissolved in HCl solution (4.0 M in 
dioxane, 5 mL), and the mixture was stirred for 2 h at rt. The mixture was co-evaporated 
with CH3CN, then CH2Cl2 twice each to afford the corresponding amine hydrochloride 
2.56 and used in the next step without further purification. 
A solution of 2.55 (0.34 mmol, 1 equiv.), HOBt∙H2O (93 mg, 0.69 mmol, 2 equiv.) and 
EDCI (131 mg, 0.69 mmol, 2 equiv.) in anhydrous DMF (5 mL) was stirred at rt for 10 min. 
In another flask, a solution of 2.56 (0.51 mmol, 1 equiv.) and DIPEA (0.15 mL, 0.86 mmol, 
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2.5 equiv.) in anhydrous DMF (5 mL) was stirred at rt for 10 min. The solution of amine 
was poured into the activated acid, and the resulting mixture was stirred overnight at rt. The 
solvent was removed in vacuo. The mixture was dissolved in EtOAc (50 mL), and washed 
with 2 N HCl, saturated NaHCO3 (50 mL each), filtered, then dried over MgSO4 and 
concentrated in vacuo. The resulting residue was purified by column chromatography (2-3% 
MeOH/CH2Cl2) to afford 2.57 as a yellow solid (281 mg, 85%); mp: 120-122 °C; [α]D25 = 
+160.0 (c 0.1, CH3OH); IR (neat): 3349, 1712, 1659, 1598 cm-1; 1H NMR (400 MHz, 
CDCl3, mixture of rotamers or epimers) 𝛿: 7.86 (m, 1H, H-17), 7.83-7.76 (m, 1H, H-5), 
7.31 (d, 1H, J = 7.7 Hz, H-16), 7.23-7.13 (m, 1H, H-13), 7.02 (m, 1H, H-14), 6.95 (m, 1H, 
H-15), 6.81-6.72 (m, 1H, H-12), 5.62 (m, 1H, H-10), 4.78-4.43 (m, 4H, H-1, H-18, H-22 
and H-26), 4.31 (m, 1H, H-6), 3.63 and 3.64 (s, 3H, H-30), 3.91-3.50 (m, 4H, H-23 and 
H-27), 3.48-3.22 (m, 2H, H-11), 2.25-1.81 (m, 11H, H-2, H-7, H-19, H-24, H-25, H-28, 
H-29), 1.42, 1.39 (s, 9H, tBu), 1.05-0.78 (m, 18H, H-3, H-4, H-8, H-9, H-20 and H-21) 
ppm; 13C NMR (100 MHz, CDCl3, major peaks) 𝛿: 171.7, 171.1, 169.8, 169.4, 169.2, 
162.9, 159.9, 159.6, 154.6, 148.7, 140.1, 135.1, 134.3, 126.3, 122.3, 122.1, 120.9, 118.4, 
117.4, 110.2, 108.7, 79.5, 57.7, 57.5, 57.1, 57.0, 54.7, 51.1, 50.5, 46.7, 45.6, 31.7, 31.4, 
30.6, 29.4, 27.7, 27.6, 27.4 (3C), 23.9, 23.8, 18.5, 18.4, 17.8, 17.1, 17.0 (2C) ppm; ES+ MS 
m/z 982 ([M+Na]+ 100%); HRMS m/z calculated for C48H65N9O10S [M+H]+ 960.4647, 
found 960.4671. 
 
 
 
 
 
 
 
 
 
 
 
	  64	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Synthetic Studies Towards 
Goadsporin 
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3.1 Introduction 
3.1.1 Streptomycetes are producers of a variety of antibiotics 
Actinomycetales are a family of Gram-positive bacteria, which have high content of G+C 
in their DNA.70 Streptomyces, is a member of this bacterial family. As saprophytic soil 
bacteria, they gain nutrients mainly from the degraded insoluble organic material by diverse 
enzymes.71 They receive appropriate signals to give rise to aerial hyphae that can provide 
the bacteria the ability to disperse and adapt to new environments. More importantly, 
streptomycetes also produce a wide variety of secondary metabolites, which include half of 
our known antibiotics.72, 73 These antibiotics are essential to our life as many of them have 
application in human medicine as anticancer, antibacterial agents, etc. The production of 
antibiotics in streptomycetes is largely due to the onset of morphological differentiation. 
3.1.2 Autoregulators in Streptomycetes 
3.1.2.1 𝜸-butyrolactone autoregulators 
The 𝛾 -butyrolactone A-factor [2-(6’-methylheptanoyl)-3R-hydroxymethyl-4-butenolide 
(3.1), Figure 3.1] is the most well-known autoregulator. It is an autoregulatory factor or 
sometimes referred to as a “microbial hormone” which induces secondary metabolism and 
cellular differentiateon in Streptomyces.74 The mechanism of A-factor exerting its role is 
that it will bind to certain receptors which act as a repressor for morphological and 
physiological differentiation in the absence of A-factor. For example, in the mechanism of 
the production of streptomycin in S. griseus, the signal from the A-factor is transferred 
from the receptor to a gene called strR.74 The A-factor receptor protein serves as a 
transcription factor for strR, and then the strR protein will induce the activation of the 
transcription of the streptomycin-production gene.74 
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Figure 3.1: Examples of autoregulatory factors having a 𝜸-butyrolactone ring (3.1-3.5). 
There are some other compounds that contain 𝛾-butyrolactone structure with effects 
similar to A-factor. In the past years, several A-factor homologues have been reported; 
results show that they are also autoregulators which control antibiotic production and 
cellular differentiation in Streptomyces.75 For example, virginiae butenolides A-C (3.3-3.5, 
Figure 3.1) were isolated and have the effect to control virginiamycin production76; factor I 
and A-factor homologues were isolated from different Streptomyces, having an A-factor 
activity on a S. griseus strain77. 
3.1.2.2 Avenolide 
The 4-substituted butenolide avenolide (3.6, Figure 3.2) is a structurally distinct 
autoregulator for Streptomyces avermitilis--the producer of well-known antibiotic drug 
avermectin.78 Its was discovered by Kitani et al. in 2011, where they found out that a 
wild-type culture broth could restore avermectin production in the aco mutant of S. 
avermitilis.78 The lack of the same ability from other type of autoregulator (A-factor, IM-2, 
etc.) suggested the possibility of a new autoregulator.78 After extracting 2000 L of 
wild-type culture broth, 1.2 mg of avenolide was purified, and it has a nanomolar activity in 
inducing the production of avermectin (minimum effective concentration 4 nM).78 
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Figure 3.2: Structure of avenolide (3.6). 
3.1.2.3 SRB1 and SRB2 
Two new autoregulators SRB1 and 2 (3.7 and 3.8, Figure 3.3) were discovered by Arakawa 
et al. in 2012,79 and they are structurally different from all the aforementioned 
autoregulators. Isolation was performed using Streptomyces rochei, where only 250 𝜇g of 
mixture of SRB1 and 2 was obtained from 160 L of culture. After extensive 1D and 2D 
NMR studies, their structures were established, and confirmed by chemical synthesis.79 
These two molecules were found responsible for the production of antibiotic lankacidin and 
lankamycin, and the minimum effective activities of SRB1 and SRB2 are 42 nM and 40 
nM, respectively.79 
 
 
Figure 3.3: Structures of SRB1 (3.7) and SRB2 (3.8). 
3.1.2.4 MMFs 
MMFs stand for the furan-type autoregulators in discovered from Streptomyces coelicolor 
that induce the production of methylenomycin (Mm). Analysis of the organic extracts of S. 
coelicolor by LCMS revealed five compounds MMFs 1-5 (3.9-3.13, Figure 3.4), and 
structures of MMFs 1 and 2 were elucidated by NMR analysis.80 The structures of the 
remaining three MMFs were confirmed by feeding deuterium labelled precursors to S. 
coelicolor W74.80 These five compounds share a 3-hydroxymethylfuran-4-carboxylic acid 
moiety and have different substituents at C-2. Among the five compounds, MMF1, MMF2 
and MMF4 were found to be able to restore the production of Mm in S. coelicolor W81.80 
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Figure 3.4: Structure of MMFs 1-5 (3.9-3.13). 
3.1.3 Goadsporin 
3.1.3.1 Fermentation and Purification of Goadsporin 
Goadsporin (3.14, Figure 3.5) was first isolated by Onaka H. et al in 2001.81 Cultured cells 
collected by centrifugation after 6 days of fermentation were extracted by 80% aqueous 
acetone solution, then purified by several different kinds of column chromatography. In the 
end, 316 mg of pure active compound was obtained from 10 L of culture broth.81 
The ring-shaped zone of Figure 3.6A is the sporulation and pigment production induced by 
goadsporin in S. lividans TK23. Also, actinorhodin production induced by goadsporin was 
examined in Bennett’s liquid medium (Figure 3.6B). The pigment is dose-dependent at less 
than 1.8 nM and will not form in the absence of goadsporin.81 
 
	  
Figure 3.5: Structure of goadsporin. 	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Figure 3.6: (A) Effects of goadsporin on the sporulation and pigment production of S. lividans TK23 on solid 
medium, 6 nM of goadsporin was absorbed on the paperdiscs. Left: surface of the paperdisc, white zone is the 
spore formation zone. Right: reverse side of the paperdisc, red pigment can be observed on the disc.81 (B) 
Diagram showing the effects of goadsporin on the red pigment production by S. lividans TK23 on Bennett’s 
liquid medium.81 
3.1.3.2 Biological activity of goadsporin 
Goadsporin has a variety of biological activities, including promoting morphogenesis in a 
wide variety of streptomycetes, promoting secondary metabolism in streptomycetes and 
antibiotic production.81 These activities prove that goadsporin is a very interesting natural 
product to synthesise in the laboratory, and testing the activities of the fragments of 
goadsporin are also of great interest.  
The induction of secondary metabolism and sporulation was carried out with 42 kinds of 
streptomycetes strains, and sporulation was observed in 76% of the strains (Figure 3.7) as a 
ring shaped zone, indicating the sporulation inducing effect of goadsporin is concentration 
dependent.81 Also, high concentration of goadsporin can inhibit the growth of the 
streptomycetes responding by sporulation.81 This is an effect that many antibiotics do not 
have. 
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Figure 3.7: Effects of goadsporin on the morphogenesis and pigments production of various 
streptomycetes on solid medium.81 
Goadsporin can also induce antibiotic production in other streptomycetes. 38 antinomycete 
strains were tested with goadsporin’s presence, and an inhibition zone was observed on the 
soft agar containing Bacillus subtilis ATCC6633.81 An actimycete TP-A0593 was found 
producing antibiotic against Bacillus subtilis around the paper disc containing goadsporin 
(Figure 3.8).81 The antibiotic activity of goadsporin was also studied. The result showed 
growth inhibition against streptomycetes but not against other microorganisms at 60 µμM, 
and it is a potential agrochemical for potato scab because of the growth inhibition of S. 
scabies.81 Having all the biological activities, goadsporin is a very useful tool for analysing 
the regulation of secondary metabolism and morphogenesis. 
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Figure 3.8: Effects of goadsporin on anitibiotics production by an unidentified actinomycete 
TP-A0593.81 
3.1.4 Aims 
The aim of this project is to continue my M. Sc. Project in University of Southampton to 
achieve the total synthesis of goadsporin and test its biological activities. Goadsporin’s 
interesting bioactivities and complex structure make it a fascinating synthetic target, and 
yet nobody has achieved its total synthesis. This project should also provide excellent 
training in both experimental techniques and chemistry theories. 
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3.2 Results and Discussion 
3.2.1 First generation synthesis 
3.2.1.1 Strategy 
Goadsporin is a natural product derived from a linear peptide containing 19 amino acids. 
The peptide has undergone numerous post-translational modifications yielding one oxazole, 
three methyl oxazole rings, two thiazole rings as well as two dehydroamino acids. In our 
first retrosynthesis, we have disconnected goadsporin into six fragments, as shown in 
Scheme 3.1. Each fragment has one heterocycle, and the free hydroxyl group is separated 
from the double bonds to make the molecules easier to handle. The hydroxyl group in 3.21 
is protected with TBDMS group. Compounds 3.25 and 3.26 are protected versions of 3.20 
and 3.23. Among these six fragmnets, the syntheses of 3.21, 3.22, 3.26 and 3.24 were 
already achieved in my previous study as a M. Sc. project at the University of 
Southampton.  
In order to synthesise 3.20 which has a dehydroamino acid fragment, the basic strategy was 
to start with a serine residue, and mask it with a protecting group which will stay intact 
when other protecting groups in the molecule are removed. For this purpose, the PMB 
group was selected, and 3.25 was synthesised instead of 3.20. However in the actual 
experiments, PMB was removed when deprotecting Boc under acidic conditions (4 M HCl 
in dioxane), but fortunately this did not have any negative effect on the overall synthesis. In 
fact, removal of both Boc and PMB groups simultaneously made the synthesis shorter.  
For the strategy yielding the double bonds in the molecule, we initially planned to do this 
after we have combined all six fragments, and that is why the hydroxyl group needed to be 
protected with TBDMS. However after getting some experience from the actual synthesis, 
when the peptides are getting longer and having more functional groups, reactions become 
harder to control, and the yields are dropping. For this reason, the double bonds will be 
introduced when we have synthesised the final two fragments 3.17 and 3.18, before the last 
coupling. 
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Scheme 3.1: First generation retrosynthesis of goadsporin. 
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3.2.1.2 Synthesis of 3.19 
We started the synthesis with 3.19 (Scheme 3.2). Initially, N-acetyl-L-alanine was selected 
as the starting material instead of N-Boc-L-alanine (3.27). However, when monitoring the 
first coupling with L-threonine methyl ester by TLC, the product was too polar compared 
with usual dipeptides, which made separation difficult due to the PyBOP by-products. We 
suspected that the reason was the protecting group on the amino group. Hence the 
protecting group was changed to Boc. The product dipeptide (3.28) became easier to purify 
which proved that acetyl group protected peptides are more polar than Boc protected 
peptides. 3.27 was first coupled with L-threonine methyl ester to give 3.28 using PyBOP as 
the coupling agent. Next formation of the methyl oxazole 3.29 was achieved using DAST 
and K2CO3 followed by DBU/BrCCl3 as discussed in Chapter 2.64 We managed to reach a 
yield of 56% over the first three steps. After deprotection of the methyl ester, the acid was 
further coupled with L-valine methyl ester to provide 3.30. Changing the protecting group 
from Boc to acetyl group finally afforded fragment 3.19. 
 
 
Scheme 3.2: Synthesis of 3.19. i. L-threonine methyl ester hydrochloride (1.2 equiv.), PyBOP (1.2 equiv.), 
DIPEA (2 equiv.), CH2Cl2, 0 ℃, overnight; ii. DAST (1.2 equiv.), K2CO3 (1.3 equiv.), CH2Cl2, -78 ℃ to rt, 
2 h, then DBU (1.2 equiv.), BrCCl3 (1.4 equiv.), CH2Cl2, -10 ℃ to rt, overnight, 56% over three steps. iii. 
LiOH (3 equiv.), THF/H2O (3:1), 0 ℃, 2 h; iv. L-valine methyl ester hydrochloride (1.2 equiv.), PyBOP (1.2 
equiv.), DIPEA (2 equiv.), CH2Cl2, 0 ℃, overnight, 79% over two steps; v. HCl solution (4.0 M in dioxane), 
rt, 95%; vi. AcCl (1.4 equiv.), TEA (2.2 equiv.), CH2Cl2, 0 ℃, 89%. 
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3.2.1.3 Synthesis of 3.25 
The synthesis of 3.25 was achieved according to Scheme 3.3. Boc protected serine 3.31 
was first selectively protected with PMB group82 to form 3.32 then coupled with 
L-threonine methyl ester to afford 3.33. The PMB protection goes through a three-step 
mechanism, in which 3.31 was first deprotonated by 2.2 equiv. of NaH at the carboxylic 
acid as well as the side chain OH group, then 1.1 equiv. of PMBCl was added. Since the 
side chain is more reactive than the deprotonated acid, the PMBCl will primarily react on 
the side chain. After the reaction has completed, the product will be acidified to regain its 
acidic form. The synthesis of oxazole 3.34 was achieved by the same method64 used in the 
synthesis of 3.29 (Scheme 3.2). After methyl ester deprotection, the free acid of 3.34 was 
further coupled with L-isoleucine methyl ester to afford 3.25. 
 
 
Scheme 3.3: Synthesis of 3.25. i. NaH (2.2 equiv.), PMBCl (1.1 equiv.), anhydrous DMF, 0 ℃ to rt, 18 h, 
81%; ii. L-threonine methyl ester hydrochloride (1.2 equiv.), PyBOP (1.2 equiv.), DIPEA (2 equiv.), CH2Cl2, 
0℃, overnight, 83%; iii. DAST (1.2 equiv.), K2CO3 (1.3 equiv.), CH2Cl2, -78 ℃ to rt, 2 h, then DBU (1.2 
equiv.), BrCCl3 (1.4 equiv.), CH2Cl2, -10 ℃ to rt, overnight, 59% over two steps; iv. LiOH (3 equiv.), 
THF/H2O (3:1), 0 ℃, 98%; v. L-isoleucine methyl ester hydrochloride (1.2 equiv.), PyBOP (1.2 equiv.), 
DIPEA (2 equiv.), CH2Cl2, 0 ℃, overnight, 73%. 
3.2.1.4 Synthesis of 3.22 
The synthesis of 3.22 was achieved in my earlier studies given in Scheme 3.4. The common 
oxazole formation method (DAST then DBU/BrCCl3) did not provide this fragment. 
Alternatively, we oxidised the dipeptide 3.35 to the ketone 3.36, followed by the cyclisation 
giving the oxazole ring. We only obtained a mediocre yield (27%), and this step became a 
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bottleneck for our synthesis. Therefore, we examined more methods to synthesise this 
fragment.  
 
 
Scheme 3.4: Synthetic route for 3.22 in previous work. i. L-threonine methyl ester hydrochloride (1.2 
equiv.), PyBOP (1.2 equiv.), DIPEA (2 equiv.), CH2Cl2, rt, overnight, 88%; ii. SO3·Py (5 equiv.), DMSO (10 
equiv.), DIPEA (5 equiv.), CH2Cl2, 0 ℃, 4 h, 27%; iii. PPh3 (2.2 equiv.), TEA (5 equiv.), I2 (2 equiv.), THF, 
-78 ℃ to rt, overnight, 81%; iv. LiOH (3 equiv.), THF/H2O (3:1), 0 ℃, 2 h, 83%; v. L-leucine methyl ester 
hydrochloride (1.2 equiv.), PyBOP (1.2 equiv.), DIPEA (2 equiv.), CH2Cl2, 0 ℃, overnight, 83%. 
A more recent method was reported by Ferreira et al.,83, 84 which by treating the methyl 
ester of β-bromodehydroaminobutyric acid derivative with DBU to form the oxazole with 
a higher yield and easier purification. It is interesting because Boc group was put onto the 
side chain OH group and used as a leaving group, where Boc is usually not for this purpose. 
1,1,2,2-Tetramethyl guanidine (TMG) was added as base to extract the 𝛼-proton on the 
threonine moiety, then OBoc would be eliminated to yield the alkene 3.39. We 
incorporated this method into our actual synthesis (Scheme 3.5). The dipeptide 3.36 was 
first made under standard coupling condition. Then a one-pot reaction using Boc2O, DMAP 
and TMG was performed to afford 3.39 with a yield of 69% over two steps. This 
elimination follows a trans-E2 mechanism to provide exclusively the Z-alkene.84 After that, 
bromination on the alkene was done using NBS and TEA to form compound 3.40 as a 1:1.7 
mixture of Z/E alkenes (as observed in NMR spectrum). The mechanism of this step 
involves the attack of the alkene on NBS to get brominated, then triethylamine as a base 
will deprotonate the 𝛽-position and reform the double bond between the 𝛼,𝛽 carbons 
(Scheme 3.6). Treating compound 3.40 with DBU will trigger an intramolecular conjugate 
addition to form the five-membered ring, followed by isomerisation to form the oxazole 
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3.38. Finally, using standard methyl ester deprotection and coupling conditions afforded 
fragment 3.22. 
 
 
Scheme 3.5: Improved synthesis of 3.22. i. L-threonine methyl ester (1.2 equiv.), PyBOP (1.2 equiv.), 
DIPEA (2 equiv.), CH2Cl2, 0 ℃ to rt; ii. DMAP (0.4 equiv.), Boc2O (1 equiv.), TMG (1.5 equiv.), CH3CN, rt, 
69% over two steps; iii. NBS (1.2 equiv.), TEA (1.5 equiv.), CH2Cl2, rt, 76%; iv. DBU (1.2 equiv.), CH3CN, 
rt, 74%; v. LiOH (3 equiv.), THF/H2O (3:1), 0 ℃, 2 h, 92%; vi. L-leucine methyl ester hydrochloride (1.2 
equiv.), PyBOP (1.5 equiv.), DIPEA (2.2 equiv.), CH2Cl2, 0 ℃, overnight, 74%. 
 
 
Scheme 3.6: Mechanism of bromination and oxazole formation. 
3.2.1.5 Union of fragments 
With all the six fragments in our hand, we then began to couple them together. Compounds 
3.42 and 3.43 were synthesised according to Scheme 3.7. We first attempted the synthesis 
of 3.42. Using ordinary deprotection methods to convert 3.21 and 3.22 to their 
corresponding acid and amine hydrochloride 3.44 and 3.45, followed by a coupling reaction 
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(1 equiv. 3.44, 1.2 equiv. PyBOP, 2 equiv. DIPEA and 1.2 equiv. amine 3.45) afforded 3.42. 
However, disappointing yield was obtained (17%).  
After the coupling of 3.44 and 3.45, an optimisation of the coupling method for 3.46 and 
3.47 was undertaken. Positive results came after applying larger excess of PyBOP (1.5 
equiv.) and the amine 3.47 (1.6 equiv.), with a final yield of 56%. We also improved the 
synthesis of 3.42 by using EDCI as coupling reagent and the yield was successfully 
improved to 60%. 
However, further coupling of 3.42 and 3.43 resulted in failure, as the product gave two 
overlapped peaks in HPLC (Figure 3.9). Efforts to separate these two peaks have failed. 
This is possibly due to racemisation of one of the amino acids at the C-terminus. The NMR 
spectra of the product were inconclusive, as the peaks are overlapped.  
 
 
Figure 3.9: HPLC trace of the coupling product from 3.42 and 3.43 (5:95 to 95:5 MeOH/H2O over 20 
min). The separation resulted in failure. 	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Scheme 3.7: Synthesis of 3.42 and 3.43. i. LiOH (3 equiv.), THF/H2O (3:1), 0 ℃; ii. HCl solution (4M in 
dioxane), rt; iii. 3.44 (1 equiv.), 3.45 (1.2 equiv.), PyBOP (1.2 equiv.), DIPEA (2 equiv.), CH2Cl2, 0 ℃, 
overnight, 17% from 3.21; iv. 3.44 (1 equiv.), 3.45(1.5 equiv.), EDCI (2 equiv.), HOBt (2 equiv.), DIPEA 
(1.6 equiv.), DMF, 0 ℃, overnight, 60% from 3.21. v. 3.46 (1 equiv.), 3.47 (1.6 equiv.) PyBOP (1.5 equiv.), 
DIPEA (2.2 equiv.), CH2Cl2, 0 ℃, overnight, 56% from 3.26. 
From the experience of making compounds 3.42 and 3.43, we found that as the peptides get 
longer, their polarity also increases. Therefore the coupling reaction towards peptide 3.48 
(Scheme 3.8) is better purified by column chromatography using MeOH/CH2Cl2 as eluent 
as they give better separation for polar compounds. In addition, the coupling of 3.49 and 
3.50 was finished using another method due to purification problems. The EDCI condition 
(EDCI 2 equiv., HOBt 2 equiv., DIPEA 1.6 equiv.) was proved to be superior (66% yield). 
Washing the crude reaction mixture with 2 N HCl followed by saturated NaHCO3 made the 
purification easier, due to the water solubility of the urea by-product. We realised that 
EDCI coupling method is more suitable for coupling reactions of longer peptides in 
solution phase, hence we decided to employ this method more in future. In the following 
step, the deprotection of Boc group also removed the PMB group. Hence in the product 
3.48, there is no PMB group and this was confirmed by both NMR and mass spectrometry. 
After getting compound 3.48, the dehydration step to introduce dehydroalanine was carried 
out. Typical methods are available in the literature, where moieties to be dehydrated are 
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transformed into a good leaving group including mesyl85, tosyl86 or triflate87 groups. Here, 
we applied the milder tosyl chloride, where the reaction worked well to form compound 
3.51 with more than 80% yield (Scheme 3.8).  
 
 
Scheme 3.8: Synthesis of 3.51. i. LiOH (3 equiv.), THF/H2O (3:1), 0 ℃; ii. HCl solution (4M in dioxane), rt; 
iii. 3.49 (1 equiv.), 3.50 (1.5 equiv.), EDCI (2 equiv.), HOBt (2 equiv.), DIPEA (1.6 equiv.), DMF, 0 ℃, 
overnight, 66% from 3.19. iv. TsCl (3 equiv.), TEA (4 equiv.), DMAP (15 mol%), CH2Cl2, overnight, 0 ℃, 
82%.  
Although the 1H NMR spectrum of 3.48 and 3.51 was conclusive, it also showed additional 
splittings. We could see this clearly from the singlet peaks resulting from the methyl groups 
in pure 3.51, where they have split into several singlets and one of them has the highest 
intensity. This observation could indicates that epimerisation at certain chiral centre and/or 
formation of different rotamers has taken place (Figure 3.10). Moreover, because further 
coupling between 3.42 and 3.43 was unsuccessful, all materials had been consumed. 
Having these disappointing results, we decided to improve the retrosynthesis and start the 
synthesis again. During the synthesis, we found out that epimerisation and/or different 
rotamers have formed from inter-fragment coupling reactions, and it increased the 
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difficulty of the synthesis. Hence we proposed the second generation synthesis targeting 
these issues.  
 
 
Figure 3.10: Part of compound 3.51’s 1H NMR spectrum. Peaks around 2.00 ppm and between 2.50 to 
2.60 ppm should be three singlets, however they present additional splittings. 
3.2.2 Second generation synthesis 
3.2.2.1 Strategy 
We found out a few disadvantages in the first generation synthesis of goadsporin as we 
carried out our synthesis. Firstly, five out of six fragments have chiral centres in their 
C-termini, giving opportunities for epimerisation to take place when conducting 
inter-fragment coupling reactions, which is a serious issue for the synthesis. Secondly, 
when coupling two peptides together, occasionally the product peptide will appear as more 
than one rotamer. Fortunately, this will only complicate the identification and purification 
of products but will not compromise the synthesis. These two effects, however, cannot be 
confirmed or distinguished by MS analysis and would give similar results in NMR spectra. 
Therefore, we could not tell if an epimerisation had happened when we spotted the problem. 
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For this reason, an epimerisation-free method would be preferable. As elucidated in 
Scheme 3.9, epimerisation is most likely to take place at the C-terminal amino acid.88 This 
is due to the ability of the activated acid to form an oxazolone intermediate 3.53. Under 
basic conditions, 3.53 can be further deprotonated to give aromatic intermediate 3.54; 
hence subsequent epimerisation would happen. The most effective solution to this problem 
is to leave no chiral centre at the C-termini of each fragment.  
 
 
Scheme 3.9: Mechanism of epimerisation during a coupling reaction.88 
When peptides are long (typically after inter-fragment couplings), side chain modifications 
become more difficult to perform, and the chance for side reactions would increase 
dramatically. Hence the formation of dehydroamino acids should be preferably 
accomplished before coupling of fragments. 
After taking the previous results into consideration, an improved strategy was purposed 
(Scheme 3.10). Every fragment (apart from 3.62) was designed to have no chiral centre in 
the C-terminus to minimise the possibility of epimerisation during inter-fragment coupling 
reactions. Secondly, the dehydroalanine moieties in 3.58 and 3.61 will be formed during the 
synthesis of small fragments, and we have later found out that they are safe to be coupled 
further with other fragments.  
In short, the synthesis is made easier: the possibility of epimerisation is minimised; more 
modifications will be done in small peptides means reactions will be more efficient, and 
can be conducted in milder conditions; the hydroxyl group in fragment 3.59 does not need 
to be protected any more, making the synthetic route slightly simpler. 
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Scheme 3.10: Second generation disconnection of goadsporin. 
Although we had to resynthesise all the six fragments for the second generation, synthesis 
for the six new fragments proceeded much faster. In the following text, all the 
intermediates that had been synthesised previously will not be discussed; only the details 
for new compounds will be given. Fragment 3.60 is an intermediate in previous work, 
hence it will not be discussed. 
3.2.2.2 Synthesis of fragments 3.58 and 3.61 that contain dehydroalanine residues 
The synthesis of 3.58 and 3.61 was accomplished according to Scheme 3.11. For compound 
3.58, synthesis from 3.32 to 3.33 was carried out using a new coupling reagent ethyl 
2-cyano-2-(hydroxyimino)acetate (Oxyma) together with EDCI. Oxyma is a newly 
developed coupling reagent for peptides, which is a non-explosive replacement for HOBt, 
withsuperior efficiency.89 The method reported by Ferreira et al.83 used in previous work 
was applied again to form oxazole 3.34. Deprotection of the Boc group in 3.34 and 
subsequent coupling with Boc-valine gave compound 3.65, with the PMB group was also 
removed. The final stage is to form the dehydroalanine residue, and we used the same 
method as in step ii. With this method, 3.58 was formed with a yield of 74%.  
NHO
O
N
O
NH O
HN
O
N
O
N
H
H
N
O
S
N N
H
O
OH
H
N
O
N
H
O
O
N
N
H
O
H
N
O
O
N O
HN
O
NH
S
N O
HN
O
OH
Goadsporin (3.14)
N
H
O
O
N O
N
H
O
O
N O
N
H
O
S
N O
HN
O
NH
OH
O
O
N
H
O
O
O
N O
N
H
O
O
N O
O
N
H S
N O
HN
O
O
+
++
+
3.60
3.593.583.57
3.61 3.62
O
O
H
NO
O O
H
NO
O
H
N
O
O
OH
NO
O
	  84	  
The synthesis of 3.61 is shown from intermediate 3.66, and this intermediate was already 
made in previous work. Removal of Boc group under acidic conditions reveals the amine, 
then it was coupled with Boc-L-leucine to afford 3.67, ready to be dehydrated to form the 
double bond. The dehydroalanine residue in 3.61 was made using the same method 
described above with a yield of 79%. 
 
 
Scheme 3.11: Synthesis of 3.58 and 3.61. i. L-threonine methyl ester hydrochloride (1.2 equiv.), EDCI (2 
equiv.), Oxyma (2 equiv.), DIPEA (2 equiv.), CH2Cl2, 0 ℃, overnight, 78%; ii. Boc2O (1.3 equiv.), DMAP 
(0.4 equiv.), MeCN, rt, 3 h, then TMG (3 equiv.), MeCN, rt, 2 h, 59%; iii. NBS (1.2 equiv.), TEA (1.5 equiv.), 
CH2Cl2, rt, 17 h; iv. DBU (1.2 equiv.), CH3CN, rt, 1 h, 28% over two steps; v. HCl solution (4.0 M in 
dioxane), rt; vi. Boc-L-Valine (1.2 equiv.), PyBOP (1.2 equiv.), DIPEA (2.2 equiv.), CH2Cl2, 0 ℃, overnight, 
69% over two steps; vii. Boc2O (1.1 equiv.), DMAP (0.3 equiv.), MeCN, rt, 3 h, then TMG (6 equiv.), MeCN, 
rt, overnight, 74%; viii. HCl solution (4.0 M in dioxane), rt, 2 h; ix. Boc-L-Leucine hydrate (1.4 equiv.), 
PyBOP (1.4 equiv.), DIPEA (2.2 equiv.), CH2Cl2, 0 ℃, overnight, 82% over two steps; x. Boc2O (1.5 equiv.), 
DMAP (0.4 equiv.), MeCN, rt, 3 h, then TMG (4 equiv.), MeCN, rt, 2 h, 79%. 	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3.2.2.3 Synthesis of fragments 3.57, 3.59 and 3.62 
The synthesis of 3.57, 3.59 and 3.62 are shown in Scheme 3.12. The synthesis of 3.29, 3.68 
and 3.24 was all achieved in previous work. Taking off the Boc group on 3.29 in acidic 
condition and acetylation of the fragment complete the synthesis of 3.57. The only 
difference between 3.59 and 3.62 compared to 3.21 and 3.24 is the slight change of their 
amino acid sequences and the protecting group on the serine side chain. Hence the 
synthesis for them was straightforward: deprotection of the Boc groups on 3.68 and 3.24 
then couple them with corresponding amino acid, Boc-isoleucine for 3.59 and Boc-alanine 
for 3.62. 
 
 
Scheme 3.12: Synthesis of 3.57, 3.59 and 3.62. i. HCl solution (4.0 M in dioxane), rt; ii. AcCl (1.4 equiv.), 
TEA (2.2 equiv.), CH2Cl2, 0 ℃ , 82% over two steps; iii. HCl solution (4.0 M in dioxane), rt; iv. 
Boc-L-isoleucine (1.4 equiv.), PyBOP (1.4 equiv.), DIPEA (2.2 equiv.), CH2Cl2, 0 ℃, overnight; v. HCl 
solution (4.0 M in dioxane), rt; vi. Boc-L-alanine (1.4 equiv.), PyBOP (1.4 equiv.), DIPEA (2.2 equiv.), 
CH2Cl2, 0 ℃, overnight, 82% over two steps. 
3.2.2.4 Union of fragments 
The assembly was conducted after synthesising all the second generation fragments 
(Scheme 3.13). Unfortunately due to the time limit of my PhD study, we only managed to 
couple 3.57 and 3.59. The EDCI condition was applied again to couple these two fragments 
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together and we received a satisfying 83% yield for 3.69. No additional splitting was 
observed in the NMR spectrum, and purity of the product was proved by analytical HPLC, 
which showed no overlapping peak together with the product peak (Figure 3.11). 
 
 
Scheme 3.13: Synthesis of 3.69. i. LiOH (3 equiv.), THF/H2O (3:1), 0  ℃; ii. HCl solution (4M in dioxane), rt; 
iii. 3.70 (1 equiv.), 3.71 (1.5 equiv.), EDCI (2 equiv.), HOBt (2 equiv.), DIPEA (2 equiv.), DMF, 0  ℃, 
overnight, 58% from 3.59.  
 
 
Figure 3.11: HPLC trace of 3.69. Peak at 11.348 min represents the coupling product. Gradient: 5/95 to 95/5 
MeOH:H2O over 20 min. 
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3.3 Conclusions and future work 
Unfortunately the synthesis of goadsporin was not completed and needs to be continued in 
the future. During the path of our synthesis, we decided to alter the first generation 
synthesis so that we could avoid having epimerisation issues. We initially disconnected 
goadsporin into six equally sized fragments and the synthesis of each of them was without 
much difficulty (four of them were synthesised in previous work). However we began to 
have problems once we started to couple the fragments together. Firstly, the synthetic 
yields of these coupling reactions tend to be worse compared to coupling reactions in small 
peptides. This is not difficult to understand since longer peptides have more functional 
groups and are larger in size, therefore coupling reactions between them will be more 
sterically hindered and have more chance for side-reactions. Secondly, some of the large 
peptides showed additional splitting in their NMR spectra, which could result from: 
epimerisation during the coupling reaction; and/or the formation of different rotamers. If a 
chiral centre presents 𝛼 to the activated carboxylic acid, there is a chance of epimerisation 
during the coupling reaction, and this is the simplest issue to be avoided. Since we needed 
to remake the fragments, we altered the retrosynthesis. 
In the second generation synthesis, none of the fragments (except for 3.62 which is at the 
C-terminus of goadsporin) has an epimerisable chiral centre, which eliminated the 
probability of epimerisation during fragment couplings. We hoped that this would help the 
overall synthesis. All the new fragments have been synthesised, and we have coupled 3.59 
and 3.60 to afford a bigger fragment 3.69. This time we didn’t observe any additional 
splitting in its NMR spectra. Although the synthesis is still to be continued, we hope the 
strategic changes we have made would also help the coupling reactions between the other 
four fragments. In the future, coupling all the fragments together will finish the total 
synthesis; goadsporin as well as the fragments can be all tested to find out which part of 
goadsporin is responsible for its activities. 
 
 
 
	  88	  
3.4 Experimental 
3.4.1 General Experimental Methods 
Chemicals and general reagents were purchased from commercial suppliers, and unless 
stated otherwise were used without further purification. Anhydrous solvents were 
purchased and stored under argon atmosphere. Where necessary, solvents and reagents 
were purified according to standard methods. 
All air and/or moisture sensitive reactions were carried out under inert atmosphere of argon 
gas, in oven-dried glassware. Reactions were monitored by TLC using pre-coated 
aluminum plates coated with 0.14 mm of silica gel 60 containing a fluorescence indicator 
active at 254 nm (Merck, Kieselgel 60 F254). Visualisation was carried out under UV-light 
(𝜆  254 nm) and/or by staining with, most commonly, cerium-ammonium molybdate or 10% 
aqueous KMnO4 or ninhydrin followed by heating. Flash column chromatography was 
performed with silica gel (MN Kieselgel 60, 40-63 𝜇m,230-400 Mesh ASTM). ‘Brine’ 
refers to a satuated aqueous solution of sodium chloride. The term in vacuo refers to the 
removal of solvents by the means of evaporation at reduced pressure, using a Buchi rotary 
evaporator. 
Melting points were obtained in open capillary tubes on an Electrothermal Melting Point 
Apparatus and are uncorrected. Polarmetry was recorded on an ADP220 polarimeter, in a 
solvent of MeOH or CH2Cl2. Infrared spectra were recorded on a PerkinElmer Spectrum 
400 FT-IR/FT-FIR spectrometer. Absorptions were recorded in wave numbers (cm-1). 1H 
NMR and 13C NMR were recorded on Bruker AC400 spectrometers (400 MHz for 1H and 
100 MHz for 13C). Spectral data were reprocessed using ACD Labs software or 
MESTRENOVA and referenced to the residual solvent peak (CDCl3, CD3OD or 
DMSO-d6). Characteristic splitting patterns due to spin spin coupling are expressed as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Chemical 
shifts are given in ppm and coupling constants are measured in Hz. 
Low-resolution mass spectra were obtained using LC-MS on a Shimadzu LCMS 2010EV 
spectrometer or MALDI-TOF on a Kratos Axima CFR spectrometer. High-resolution mass 
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spectra were collected by EPSRC National Mass Spectrometry Facility (Swansea) using a 
Thermofisher LTQ Orbitrap XL mass spectrometer. 
3.4.2 Experimental Details for Chapter 3 
Boc-Ala-MeOxa-Val-OMe (3.30) 
 
To a solution of Boc-L-alanine (3.27) (998 mg, 5.27 mmol, 1 equiv.) in CH2Cl2 (15 mL) 
was added L-threonine methyl ester hydrochloride (1.07 g, 6.33 mmol, 1.2 equiv.), PyBOP 
(3.29 g, 6.33 mmol, 1.2 equiv.) and DIPEA (1.83 mL, 10.54 mmol, 2 equiv.). The resulting 
mixture was stirred at 0 ℃ overnight under argon and concentrated in vacuo. The residue 
was purified by column chromatography (3:2 EtOAc/hexane) to afford 3.28 partially 
purified and used in the next step without further purification. 
DAST (0.84 mL, 6.33 mmol, 1.2 equiv.) was added dropwise to a cold (-78 ℃) solution of 
Boc-Ala-Thr-OMe (3.28) (5.27 mmol, 1 equiv.) in anhydrous CH2Cl2 (15 mL) under argon. 
After the mixture was stirred for 1 h at -78 ℃, anhydrous K2CO3 (874 mg, 6.33 mmol, 1.2 
equiv.) was added in one portion and the mixture was allowed to warm to rt. The reaction 
mixture was poured into saturated aqueous NaHCO3 solution (50 mL) and extracted with 
CH2Cl2 (30 mL  ×  3). The combined organic layer was dried over MgSO4, concentrated in 
vacuo to afford the oxazoline, and used in the next step without further purification. 
To a solution of the oxazoline (5.27 mmol, 1 equiv.) in CH2Cl2 (15 mL) that was cooled to 
-10 ℃ was added DBU (0.95 mL, 6.33 mmol, 1.2 equiv.), followed by BrCCl3 (0.73 mL, 
7.38 mmol, 1.4 equiv.) dropwise. The mixture was stirred overnight while warming to rt. 
The mixture was washed with saturated aqueous NH4Cl solution (30 mL), and the aqueous 
phase was extracted with CH2Cl2 (50 mL  ×  3). The combined organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (2:3 EtOAc/hexane) to afford 3.29 as a white solid (846 mg, 56% over 
three steps). 
3.30
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To a solution of Boc-Ala-MeOxa-OMe (3.29) (846 mg, 2.98 mmol, 1 equiv.) in 10 mL of a 
mixture of THF/water (3:1) that had been cooled to 0 ℃ was added LiOH (214 mg, 8.94 
mmol, 3 equiv.). The reaction mixture was stirred at 0 ℃ overnight. The solution was 
diluted with water (10 mL), and acidified to pH 1-2 with saturated KHSO4 aqueous solution. 
The aqueous layer was extracted with EtOAc (30 mL  ×  3). The combined organic layer 
was dried over MgSO4, filtered, and concentrated in vacuo to provide the corresponding 
acid as a white solid and used in the next step without further purification. 
To a solution of the acid (2.98 mmol, 1 equiv.) in CH2Cl2 (15 mL) was added L-valine 
methyl ester hydrochloride (599.4 mg, 3.57 mmol, 1.2 equiv.), PyBOP (1.85 g, 3.57 mmol, 
1.2 equiv.) and DIPEA (1.04 mL, 5.96 mmol, 2 equiv.). The reaction mixture was stirred at 
0 ℃ overnight under argon. The mixture was purified by column chromatography (3:7 
EtOAc/hexane) to afford 3.30 as colorless oil (896.4 mg, 79% over two steps); [α]D25 = 
-41.6 (c 0.36, CH2Cl2); IR (neat): 3327, 1673, 1635, 1515 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 5.02 (brs, 1H, H-1), 4.84 (brs, 1H, NH), 4.57 (m, 1H, H-4), 3.68 (s, 3H, H-8), 2.53 (s, 
3H, H-3), 2.18 (m, 1H, H-5), 1.45 (d, 3H, J = 6.7 Hz, H-2), 1.40 (s, 9H, tBu), 0.92 (brs, 6H, 
H-6 and H-7) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 171.3, 160.74, 160.69, 153.9, 152.5, 
127.6, 79.2, 55.7, 51.1, 43.7, 30.4, 27.3 (3C), 19.1, 18.1, 17.0, 10.7 ppm; ES+ MS m/z 406 
([M+Na]+ 100%); HRMS m/z calculated for C18H30N3O6 [M+H]+ 384.2135, found 
384.2127. 
 
Ac-Ala-MeOxa-Val-OMe (3.19) 
 
The dried compound 3.30 (896.4 mg, 2.34 mmol) was dissolved in HCl solution (4.0 M in 
dioxane, 10 mL), and the solution was stirred for 2 h at rt. The solvent was co-evaporated 
with CH3CN, then CH2Cl2 twice each to afford the corresponding amine hydrochloride and 
used in the next step. 
To a solution of the amine hydrochloride (2.34 mmol, 1 equiv.) in CH2Cl2 (15 mL) that was 
3.19
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cooled to 0 ℃  was added acetyl chloride (0.233 mL, 3.28 mmol, 1.4 equiv.) and 
triethylamine (0.718 mL, 5.15 mmol, 2.2 equiv.). The mixture was stirred for 2 h under 
argon. The precipitate was filtered off and the solution was purified by column 
chromatography (7:3 EtOAc/hexane) to afford 3.19 as a white solid (645 mg, 85% over two 
steps); mp: 56-62 °C; [α]D25 = -47.5 (c 0.4, CH2Cl2); IR (neat): 3413, 3295, 1663, 1517 cm-1; 
1H NMR (400 MHz, CDCl3) 𝛿: 7.28 (d, 1H, J = 8.8 Hz, NH), 6.18 (d, 1H, J = 7.2 Hz, NH), 
5.17 (m, 1H, H-2), 4.58 (t, 1H, J = 6.9 Hz, H-5), 3.70 (s, 3H, H-9), 2.52 (s, 3H, H-4), 2.18 
(q, 1H, J = 6.4 Hz, H-6), 2.00 (s, 3H, H-1), 1.45 (d, 3H, J = 6.8 Hz, H-3), 0.93 (d, 3H, J = 
3.2 Hz, H-7), 0.92 (d, 3H, J = 3.2 Hz, H-8) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 171.4, 
168.5, 160.6, 160.4, 152.7, 127.6, 55.7, 51.2, 42.2, 30.4, 22.2, 18.8, 18.0, 17.0, 10.7 ppm; 
ES+ MS m/z 348 ([M+Na]+ 100%); HRMS m/z calculated for C15H24N3O5 [M+H]+ 
326.1716, found 326.1710. 
 
Boc-Ser(OPMB)-Thr-OMe (3.33) 
 
To a solution of Boc-L-serine (3.31) (3g, 14.62 mmol, 1 equiv.) in anhydrous CH2Cl2 (30 
mL) that was cooled to 0 ℃  was added NaH (60% in mineral oil, 1.2 g, 30 mmol, 2.2 
equiv.), and the slurry was stirred at 0 ℃ for 1 h. PMBCl (2.17 mL, 16 mmol, 1.1 equiv.) 
was added dropwise. The ice bath was removed, and the mixture was stirred for 18 h while 
warming up to rt. The reaction mixture was diluted with water, then washed with EtOAc 
(50 mL  ×  2). The aqueous layer was acidified using 2 N HCl to pH 1-2, then extracted with 
EtOAc (50 mL  ×  3). The combined organic layer was dried over MgSO4, filtered and 
concentrated in vacuo to afford 3.32 as yellow oil (3.87 g, 81%), the product was used in 
the next step without further purification. 
To a solution of Boc-Ser(OPMB)-OH (3.32) (570 mg, 1.75 mmol, 1 equiv.) in CH2Cl2 (10 
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mL) was added L-threonine methyl ester hydrochloride (357 mg, 2.1 mmol, 1.2 equiv.), 
PyBOP (1.09 g, 2.1 mmol, 1.2 equiv.) and DIPEA (0.61 mL, 3.5 mmol, 2 equiv.). The 
reaction mixture was stirred at 0 ℃ overnight under argon. The mixture was purified by 
column chromatography (1:1 EtOAc/hexane) to afford 3.33 as colorless oil (639 mg, 83%); 
[α]D25 = -3.8 (c 0.26, CH2Cl2); IR (neat): 3339, 1673, 1616, 1513 cm-1; 1H NMR (400 MHz, 
CDCl3) 𝛿: 7.21 (d, 1H, J = 7.3 Hz, NH); 7.16 (d, 2H, J = 7.8 Hz, H-4 and H-5), 6.78 (d, 
2H, J = 7.5 Hz, H-6 and H-7), 5.42 (d, 1H, J = 7 Hz, NH), 4.53 (d, 1H, J = 9 Hz, H-1), 4.41 
(s, 2H, H-3), 4.24 (m, 2H, H-9 and H-10), 3.79 (d, 1H, J = 8.8 Hz, H-2), 3.72 (s, 3H, H-12), 
3.65 (s, 3H, H-8), 3.52 (m, 1H, H-2), 2.78 (brs, 1H, OH), 1.37 (s, 9H, tBu), 1.09 (d, 3H, J = 
6 Hz, H-11) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 171.03, 171.0, 159.4, 155.5, 129.6 (2C), 
129.4, 113.9 (2C), 80.4, 73.2, 69.6, 68.2, 57.4, 55.3, 54.2, 52.6, 28.3 (3C), 19.9 ppm; ES+ 
MS m/z 463 ([M+Na]+ 100%); HRMS m/z calculated for C21H33N2O8 [M+H]+ 441.2236, 
found 441.2229. 
 
Boc-Ser(OPMB)-MeOxa-Ile-OMe (3.25) 
 
DAST (0.13 mL, 0.91 mmol, 1.2 equiv.) was added dropwise to a cold (-78 ℃) solution of 
3.33 in anhydrous CH2Cl2 (10 mL) under argon. After the mixture was stirred for 1 h at -78 ℃, anhydrous K2CO3 (136 mg, 0.97 mmol, 1.2 equiv.) was added in one portion and the 
mixture was allowed to warm to rt. The reaction mixture was poured into saturated aqueous 
NaHCO3 (30 mL) solution and extracted with CH2Cl2 (30 mL  ×  3). The combined organic 
layers was dried over MgSO4, concentrated in vacuo to afford the oxazoline, and used in 
the next step without further purification. 
To a solution of the oxazoline in CH2Cl2 (10 mL) that was cooled to -10 ℃ was added 
DBU (0.14 mL, 0.97 mmol, 1.2 equiv.), followed by BrCCl3 (0.11 mL, 1.13 mmol, 1.4 
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equiv.) dropwise. The mixture was stirred overnight while warming to rt. The mixture was 
washed with saturated aqueous NH4Cl solution (30 mL), and the aqueous phase was 
extracted with CH2Cl2 (50 mL  ×  3). The combined organic layers was dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(3:7 EtOAc/hexane) to afford 3.34 as colorless oil (200 mg, 59% over two steps). 
To a solution of 3.34 (200 mg, 0.48 mmol, 1 equiv.) in 10 mL of a mixture of THF/water 
(3:1) that had been cooled to 0 ℃ was added LiOH (34.3 mg, 1.44 mmol, 3 equiv.), and 
stirred at 0 ℃ overnight. The solution was diluted with water (10 mL), and acidified to pH 
1-2 with saturated KHSO4 aqueous solution. The aqueous layer was extracted with EtOAc 
(30 mL  ×  3). The combined organic layer was dried over MgSO4, filtered, and concentrated 
in vacuo to provide the corresponding acid as a white solid (189 mg) and used in the next 
step without further purification. 
To a solution of the acid (189 mg, 0.47 mmol, 1 equiv.) in CH2Cl2 (10 mL) was added 
L-isoleucine methyl ester hydrochloride (101 mg, 0.56 mmol, 1.2 equiv.), PyBOP (290 mg, 
0.56 mmol, 1.2 equiv.) and DIPEA (0.16 mL, 0.94 mmol, 2 equiv.). The reaction mixture 
was stirred at 0 ℃ overnight under argon and concentrated in vacuo. The residue was 
purified by column chromatography (1:4 EtOAc/hexane) to afford 3.25 as colorless oil (181 
mg, 73%); [α]D25 = -9.0 (c 0.66, CH2Cl2); IR (neat): 2964, 1738, 1715, 1635, 1513 cm-1; 1H 
NMR (400 MHz, CDCl3) 𝛿: 7.26 (d, 1H, J = 8.4 Hz, NH); 7.08 (d, 2H, J = 7.8 Hz, H-4 and 
H-5), 6.78 (d, 2H, J = 7.7 Hz, H-6 and H-7), 5.34 (m, 1H, H-1), 4.91 (brs, 1H, NH), 4.61 
(m, 1H, H-10), 4.41 (d, 1H, J = 11.8 Hz, H-3), 4.35 (d, 1H, J = 11.8 Hz, H-3), 3.72 (s, 3H, 
H-8), 3.67 (s, 3H, H-15), 3.79-3.63 (m, 2H, H-2), 2.52 (s, 3H, H-9), 1.90 (m, 1H, H-11), 
1.39 (s, 9H, tBu), 1.51-1.30 (m, 2H, H-13), 0.89 (m, 6H, H-12 and H-14) ppm; 13C NMR 
(100 MHz, CDCl3) 𝛿: 172.2, 161.6, 159.4, 159.3, 153.6, 129.5, 129.3 (2C), 128.9, 113.8 
(2C), 80.3, 72.9, 69.9, 56.0, 55.3, 52.1, 49.3, 38.0, 36.7, 28.3 (3C), 25.3, 15.5, 11.7, 11.5 
ppm; ES+ MS m/z 556 ([M+Na]+ 100%); HRMS m/z calculated for C27H40N3O8 [M+H]+ 
534.2815, found 534.2823. 
 
 
 
	  94	  
Boc-Gly-Z-ΔAbu-OMe (3.39) 
 
To a solution of Boc-L-glycine (3.35) (1 g, 5.7 mmol, 1 equiv.) in CH2Cl2 (15 mL) was 
added L-threonine methyl ester hydrochloride (1.16 g, 6.8 mmol, 1.2 equiv.), PyBOP (3.56 
g, 6.8 mmol, 1.2 equiv.) and DIPEA (1.98 mL, 11.4 mmol, 2 equiv.). The reaction mixture 
was stirred at 0 ℃ overnight under argon. The mixture was diluted with CH2Cl2 (50 mL), 
washed with 2 N HCl (50 mL), saturated NaHCO3 (50 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by column chromatography (3:7 to 3:2 
EtOAc/hexane) to afford 3.36 partially purified (2.04 g) and used in the next step without 
further purification. 
To a solution of 3.36 (2.04g, 7 mmol, 1 equiv.) in anhydrous CH3CN was added DMAP 
(343 mg, 2.8 mmol, 0.4 equiv.) followed by Boc2O (1.68g, 7.7 mmol, 1.1 equiv.). The 
resulting mixture was stirred for 2 h at rt. Then TMG (1.31 mL, 10.5 mmol, 1.5 equiv.) was 
added, and the stirring was continued for 3 h. The solvent was removed in vacuo, and the 
residue was partitioned between Et2O (60 mL) and saturated KHSO4 (50 mL). The organic 
phase was washed with saturated KHSO4 and NaHCO3 (50 mL each), dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified by column chromatography 
(3:7 to 2:3 EtOAc/petroleum ether) to afford 3.39 as a white solid (839 mg, 54% over two 
steps); 1H NMR (400 MHz, CDCl3) 𝛿: 7.44 (s, 1H, NH); 6.78 (q, 1H, J = 7.2 Hz, H-3), 
5.18 (brs, 1H, NH), 3.85 (d, 2H, J = 5 Hz, H-1), 3.70 (s, 3H, H-4), 1.71 (d, 3H, J = 7.2 Hz, 
H-2), 1.40 (s, 9H, tBu) ppm. 
The spectroscopic data are consistent with those 84 reported in the literature. 
 
 
 
 
 
3.39
	  95	  
Boc-Gly-ΔAbu(β-Br)-OMe (3.40) 
 
To a solution of Boc-Gly-Z-ΔAbu-OMe (3.39) (791 mg, 2.9 mmol, 1 equiv.) in CH2Cl2 (20 
mL) was added NBS (620 mg, 3.48 mmol, 1.2 equiv.), and the mixture was stirred for 16 h 
at rt. Then TEA (0.61 mL, 4.35 mmol, 1.5 equiv.) was added, and stirring was continued 
for an additional hour. The solvent was removed in vacuo and the residue was partitioned 
between CH2Cl2 and saturated KHSO4 (50 mL each). The organic phase was washed with 
saturated KHSO4 and saturated NaHCO3 (50 mL each), dried over MgSO4, filtered, and 
concentrated in vacuo to afford 3.40 as a 1.7:1 mixture of E/Z alkene (774 mg, 76%); 1H 
NMR (400 MHz, CDCl3, 1.7:1 mixture of E/Z alkenes) 𝛿: 7.98 (brs, 1H, NH, E isomer), 
7.82 (brs, 1H, NH, Z isomer), 5.25 (brs, 1H, NH, E isomer), 5.17 (brs, 1H, NH, Z isomer), 
3.81 (d, 2H, J = 5.9 Hz, H-1, Z isomer), 3.79 (d, 2H, J = 6 Hz, H-1, E isomer), 3.74 (s, 3H, 
H-3, E isomer), 3.73 (s, 3H, H-3, Z isomer), 2.50 (s, 3H, H-2, Z isomer), 2.31 (s, 3H, H-2, 
E isomer), 1.40 (s, 9H, tBu, Z isomer), 1.39 (s, 9H, tBu, E isomer) ppm. 
The spectroscopic data are consistent with those 84 reported in the literature. 
 
Boc-Gly-MeOxa-OMe (3.38) 
 
To a solution of Boc-Gly-ΔAbu(β-Br)-OMe (3.40) (718 mg, 2.05 mmol, 1 equiv.) in 
CH3CN was added DBU (0.37 mL, 2.46 mmol, 1.2 equiv.), the mixture was stirred for 1 h 
at rt. Solvent was removed in vacuo, the residue was dissolved in CH2Cl2 (50 mL) and 
washed with saturated KHSO4 (50 mL). The aqueous layer was extracted with CH2Cl2 (30 
mL  ×  2), and the combined organic layer was dried over MgSO4, filtered and concentrated 
in vacuo. The residue was purified by column chromatography (3:7 EtOAc/petroleum ether) 
to afford 3.38 as colorless oil (409 mg, 74%); 1H NMR (400 MHz, CDCl3) 𝛿: 5.46 (brs, 
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1H, NH); 4.35 (d, 2H, J = 6 Hz, H-1), 3.81 (s, 3H, H-3), 2.52 (s, 3H, H-2), 1.37 (s, 9H, tBu), 
ppm. 
The spectroscopic data are consistent with those 84 reported in the literature. 
 
Boc-Gly-MeOxa-Leu-OMe (3.22) 
 
To a solution of Boc-Gly-MeOxa-OMe (3.38) (400 mg, 1.48 mmol, 1 equiv.) in 10 mL of a 
mixture of THF/water (3:1) that had been cooled to 0 ℃ was added LiOH (106 mg, 4.44 
mmol, 3 equiv.), and stirred at 0 ℃ overnight. The solution was diluted with water (15 
mL), and acidified to pH 1-2 with saturated KHSO4 aqueous solution. The aqueous layer 
was extracted with EtOAc (30 mL  ×  3). The combined organic layer was dried over 
MgSO4, filtered, and concentrated in vacuo to provide the corresponding acid as a white 
solid (347 mg, 92%). 
To a solution of the acid (347 mg, 1.35 mmol, 1 equiv.) in CH2Cl2 (10 mL) was added 
L-leucine methyl ester hydrochloride (295 mg, 1.63 mmol, 1.2 equiv.), PyBOP (1.05 g, 
2.03 mmol, 1.5 equiv.) and DIPEA (0.52 mL, 2.97 mmol, 2 equiv.), and stirred at 0 ℃ 
overnight. The mixture was purified by column chromatography (3:7 EtOAc/hexane) to 
afford 3.22 as colourless oil (381 mg, 74%); [α]D25 = -1.8 (c 0.53, CH3OH); IR (neat): 3332, 
1714, 1655, 1512 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 7.23 (d, 1H, J = 8.8 Hz, NH), 5.40 
(brs, 1H, NH), 4.71 (m, 1H, H-3), 4.33 (d, 2H, J = 5.9 Hz, H-1), 3.70 (s, 3H, H-8), 2.53 (s, 
3H, H-2), 1.74-1.57 (m, 3H, H-4 and H-5), 1.42 (s, 9H, tBu), 0.91 (d, 6H, J = 6.2 Hz, H-6 
and H-7) ppm; 13C NMR: (100 MHz, CDCl3) 𝛿 ppm 173.2, 161.5, 158.2, 155.6, 153.7, 
128.7, 77.1, 52.2, 50.1, 41.4, 37.7, 28.3 (3C), 24.8, 22.8, 21.7, 11.5 ppm; ES+ MS m/z 406 
([M+Na]+ 100%); HRMS m/z calculated for C18H29N3O6Na [M+Na]+ 406.1954, found 
406.1949. 
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Boc-Leu-Thz-Ser(OTBDMS)-Gly-Gly-MeOxa-Leu-OMe (3.42) 
 
Method 1: 
To a solution of Boc-Leu-Thz-Ser(OTBDMS)-Gly-OMe (3.21) (330 mg, 0.56 mmol, 1 
equiv.) in 10 mL of a mixture of THF/water (3:1) that had been cooled to 0 ℃ was added 
LiOH (40.6 mg, 1.69 mmol, 3 equiv.). The mixture was stirred at 0 ℃ for 2 h. The 
solution was diluted with water (10 mL), and acidified to pH 1-2 with saturated KHSO4 
aqueous solution. The aqueous layer was extracted with EtOAc (30 mL   ×  3). The 
combined organic layer was dried over MgSO4, filtered, and concentrated in vacuo to 
provide corresponding acid 3.44 as a white solid and used in the next step without further 
purification. 
The dried compound Boc-Gly-MeOxz-Leu-OMe (3.22) (259.3 mg, 0.68 mmol) was 
dissolved in HCl solution (4.0 M in dioxane, 5 mL), and the solution was stirred for 2 h 
under argon. The mixture was co-evaporated with CH3CN, then CH2Cl2 twice each to 
afford the corresponding amine hydrochloride 3.45 and used in the next step. 
To a solution of 3.44 (0.56 mmol, 1 equiv.) in CH2Cl2 (10 mL) was added 3.45 (0.68 mmol, 
1.2 equiv.), PyBOP (325 mg, 0.68 mmol, 1.2 equiv.) and DIPEA (0.2 mL, 1.13 mmol, 2 
equiv.). The mixture was stirred at 0 ℃ overnight under argon and concentrated in vacuo. 
The mixture was purified by repeat column chromatography (7:3 EtOAc/hexane then 3:97 
MeOH/CH2Cl2) to afford 3.42 as white solid (81 mg, 17%). 
 
Method 2: 
Procedures for the deprotection steps are the same as Method 1. 
A solution of 3.44 (0.69 mmol, 1 equiv.), HOBt∙H2O (186.2 mg, 1.38 mmol, 2 equiv.) and 
EDCI (263.8 mg, 1.38 mmol, 2 equiv.) in anhydrous DMF (5 mL) was stirred at rt for 4 
min. In another flask, a solution of 3.45 (0.9 mmol, 1.3 equiv.) and DIPEA (0.19 mL, 1.1 
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mmol, 1.6 equiv.) in anhydrous DMF (5 mL) was stirred at rt for 4 min. The solution of 
amine was poured into the activated peptide, and the resulting mixture was stirred 
overnight at rt. The mixture was diluted with EtOAc (100 mL), and washed with 2 N HCl, 
saturated NaHCO3 (100 mL each), filtered, then dried over MgSO4 and concentrated in 
vacuo. The resulting residue was purified by column chromatography (1% to 2% 
MeOH/CH2Cl2) to afford 3.42 as a white solid (345 mg, 60%); mp: 66-70 °C; [α]D25 = -4.2 
(c 0.7, CH2Cl2); IR (neat): 3309, 1744, 1662, 1529 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 
8.26 (brs, 1H, NH), 7.78 (s, 1H, H-6), 7.48 (d, 1H, J = 7.7 Hz, NH), 7.41 (brs, 1H, NH), 
6.98 (m, 1H, NH), 5.34 (d, 1H, J = 7.7 Hz, NH), 4.94 (brs, 1H, H-17), 4.66 (m, 1H, H-1), 
4.52 (dd, 1H, J = 15.9, 5.5 Hz, H-15), 4.45 (brs, 1H, H-7), 4.24 (d, 1H, J = 16.1 Hz, H-15), 
4.03 (d, 1H, J = 9.5 Hz, H-8), 3.95 (brs, 2H, H-14), 3.87 (m, 1H, H-8), 3.66 (s, 3H, H-22), 
2.41 (s, 3H, H-16), 1.69 (m, 6H, H-2, H-3, H-18 and H-19), 1.37 (s, 9H, tBu), 0.89 (m, 6H, 
H-20 and H-21), 0.84 (s, 6H, H-4 and H-5), 0.81 (m, 9H, H-11, H-12 and H-13), 0.00 (s, 
6H, H-9 and H-10), ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 173.6, 172.8, 169.7, 168.7, 
161.3, 160.6, 156.7, 154.3, 152.8, 147.7, 127.6, 122.8, 79.2, 61.3, 55.0, 51.4, 49.9, 49.2, 
42.5, 42.2, 40.2, 35.4, 27.4 (3C), 24.8 (3C), 23.8, 22.1, 21.9 (2C), 20.7 (2C), 17.2, 10.7, 
-6.5 ppm; ES+ MS m/z 860 ([M+Na]+ 100%); HRMS m/z calculated for C38H64N7O10SSi 
[M+H]+ 838.4205, found 838.4201. 
 
Boc-Ser(OPMB)-Oxa-Ala-Gly-Thz-Val-OMe (3.43) 
 
To a solution of Boc-Ser(OPMB)-Oxz-Ala-OMe (3.26) (440 mg, 0.92 mmol, 1 equiv.) in 
10 mL of a mixture of THF/water (3:1) that had been cooled to 0 ℃ was added LiOH 
(66.4 mg, 2.76 mmol, 3 equiv.). The mixture was stirred at 0 ℃ for 2 h. The solution was 
diluted with water (10 mL), and acidified to pH 1-2 with saturated KHSO4 aqueous solution. 
The aqueous layer was extracted with EtOAc (30 mL  ×  3). The combined organic layer 
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was dried over MgSO4, filtered, and concentrated in vacuo to provide corresponding acid 
3.46 as a white solid and used in the next step without further purification. 
The dried compound Boc-Gly-Thz-Val-OMe (3.24) (580.2 mg, 1.47 mmol) was dissolved 
in HCl solution (4.0 M in dioxane, 10 mL), and the mixture was stirred for 2 h under argon. 
The mixture was co-evaporated with CH3CN, then CH2Cl2 twice each to afford the 
corresponding amine hydrochloride 3.47 and used in the next step without further 
purification. 
To a solution of 3.46 (0.92 mmol, 1 equiv.) in CH2Cl2 (10 mL) was added 3.47 (1.47 mmol, 
1.6 equiv.), PyBOP (717.9 mg, 1.38 mmol, 1.5 equiv.) and DIPEA (0.35 mL, 2.02 mmol, 
2.2 equiv.). The mixture was stirred at 0 ℃ overnight under argon and concentrated in 
vacuo. The residue was purified by repeat column chromatography (4:1 EtOAc/hexane then 
2% MeOH/CH2Cl2) to afford 3.43 as a white solid (372 mg, 56%); mp: 52-58 °C; [α]D25 = 
-8.3 (c 0.36, CH2Cl2); IR (neat): 3304, 1664, 1599, 1539, 1513 cm-1; 1H NMR (400 MHz, 
CDCl3) 𝛿: 8.06 (s, 1H, H-9), 7.93 (s, 1H, H-13), 7.66 (d, 1H, J = 8.3 Hz, NH), 7.07 (d, 2H, 
J = 7.5 Hz, H-4 and H-5), 6.78 (d, 2H, J = 7.5 Hz, H-6 and H-7), 5.39 (m, 1H, NH), 4.96 
(m, 1H, H-1), 4.73 (m, 1H, H-14), 4.63 (m, 3H, H-3 and H-10), 4.37 (dd, 2H, J = 18.9, 11.7 
Hz, H-12), 3.82-3.75 (m, 1H, H-2), 3.73 (s, 3H, H-18), 3.70 (s, 3H, H-8), 3.74-3.66 (m, 1H, 
H-2), 2.20 (m, 1H, H-15), 1.47 (d, 3H, J = 5.1 Hz, H-11), 1.39 (s, 9H, tBu), 0.93 (d, 3H, J = 
6.3 Hz, H-17), 0.92 (d, 3H, J = 6.3 Hz, H-16), ppm; 13C NMR: (100 MHz, CDCl3) 𝛿 ppm 
171.3, 171.0, 166.8, 161.7, 160.1, 159.8, 159.7, 158.4, 148.2, 140.7, 134.5, 128.4 (2C), 
128.2, 123.2, 112.9 (2C), 79.5, 72.0, 68.7, 56.2, 54.2, 51.2, 48.4, 47.5, 40.1, 30.4, 27.3 (3C), 
18.1, 17.0, 16.3 ppm; ES+ MS m/z 739 ([M+Na]+ 100%); HRMS m/z calculated for 
C33H44N6O10S [M+H]+ 717.2918, found 717.2914. 
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Ac-Ala-MeOxa-Val-Ser-MeOxa-Ile-OMe (3.48) 
 
To a solution of Ac-Ala-MeOxz-Val-OMe (3.19) (126 mg, 0.39 mmol, 1 equiv.) in 10 mL 
of a mixture of THF/water (3:1) that had been cooled to 0 ℃ was added LiOH (28 mg, 
2.17 mmol, 3 equiv.). The mixture was stirred at 0 ℃ for 2 h. The solution was diluted 
with water (10 mL), and acidified to pH 1-2 with saturated KHSO4 aqueous solution. The 
aqueous layer was extracted with EtOAc (30 mL  ×  3). The combined organic layer was 
dried over MgSO4, filtered, and concentrated in vacuo to provide the corresponding acid 
3.49 as a white solid and used in the next step without further purification. 
The dried compound Boc-Ser(OPMB)-MeOxz-Ile-OMe (3.25) (313 mg, 0.59 mmol) was 
dissolved in HCl solution (4.0 M in dioxane, 10 mL), and the solution was stirred for 2 h 
under argon. The mixture was co-evaporated with CH3CN, then CH2Cl2 twice each to 
afford the corresponding amine hydrochloride 3.50 and used in the next step without 
further purification. 
A solution of 3.49 (0.39 mmol, 1 equiv.), HOBt∙H2O (106 mg, 0.78 mmol, 2 equiv.) and 
EDCI (150 mg, 0.78 mmol, 2 equiv.) in anhydrous DMF (1.5 mL) was stirred at rt for 4 
min. In another flask, a solution of 3.50 (1.5 equiv.) and DIPEA (0.11 mL, 0.63 mmol, 1.6 
equiv.) in anhydrous DMF (1.5 mL) was stirred at rt for 4 min. The solution of amine was 
poured into the activated acid, and the resulting mixture was stirred overnight at rt. The 
mixture was diluted with EtOAc (100 mL), and washed with 2 N HCl (30 mL  ×  2), 
saturated NaHCO3 (30 mL  ×  2) and brine (100 mL), filtered, then dried over MgSO4 and 
concentrated in vacuo. The resulting residue was purified by column chromatography (1% 
to 4% MeOH/CH2Cl2) to afford 3.48 as a white solid (157 mg, 66%); mp: 66-68 °C; [α]D25 
= -50.6 (c 1.1, CH3OH); IR (neat): 3403, 1739, 1647, 1514 cm-1; 1H NMR (400 MHz, 
CDCl3) 𝛿: 7.53 (d, 1H, J = 8.8 Hz, NH), 7.30 (m, 2H, NH), 6.62 (m, 1H, NH), 5.13 (m, 2H, 
H-2 and H-9), 4.60 (dd, 1H, J = 8.9 Hz, 5.3, H-12), 4.43 (m, 1H, H-5), 3.92 (m, 2H, H-10), 
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3.68 (s, 3H, H-17), 2.51 (s, 3H, H-4), 2.45 (s, 3H, H-11), 2.16 (m, 1H, H-6), 2.00 (s, 3H, 
H-1), 1.90 (m, 1H, H-13), 1.47-1.39 (m, 1H, H-15), 1.42 (d, 3H, J = 7 Hz, H-3), 1.17 (m, 
1H, H-15), 0.98 (m, 6H, H-7 and H-8), 0.86 (m, 6H, H-14 and H-16), ppm; 13C NMR (100 
MHz, CDCl3) 𝛿: 172.3, 171.6, 169.7, 162.1, 161.6, 161.4, 158.5, 154.1, 153.7, 128.9, 
128.6, 62.9, 58.7, 56.1, 52.1, 49.7, 43.0, 37.9, 31.1, 25.3, 23.2, 19.7, 19.2, 18.6, 15.6, 11.7, 
11.6, 11.5 ppm; ES+ MS m/z 629 ([M+Na]+ 100%); HRMS m/z calculated for C28H43N6O9 
[M+H]+ 607.3091, found 607.3077. 
 
Ac-Ala-MeOxa-Val-∆Ala-MeOxa-Ile-OMe (3.51) 
 
To a solution of Ac-Ala-MeOxa-Val-Ser-MeOxa-Ile-OMe (3.48) (117 mg, 0.193 mmol, 1 
equiv.) in CH2Cl2 (3 mL) that was cooled to 0 ℃ was added TsCl (110.4 mg, 0.58 mmol, 
3 equiv.), followed by TEA (0.107 mL, 0.77 mmol, 4 equiv.) and DMAP (3.5 mg, 29 µμmol, 
15 mol%). The resulting mixture was stirred overnight while warming to rt. The mixture 
was diluted with CH2Cl2 (10 mL), washed with 1 N HCl, saturated NaHCO3 and brine (10 
mL each), filtered, dried over MgSO4 and concentrated in vacuo. The residue was purified 
by column chromatography (1% to 3% MeOH/CH2Cl2) to afford 3.51 as a white solid (93 
mg, 82%); mp: 70-74 °C; [α]D25 = -27.3 (c 1.06, CH3OH); IR (neat): 3281, 1732, 1651, 
1515 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 7.43 (d, 1H, J = 8.9 Hz, NH); 7.27 (d, 1H, J = 
8.9 Hz, NH), 6.39 (s, 1H, H-9), 6.11 (m, 1H, NH), 5.64 (s, 1H, H-10), 5.16 (m, 1H, H-2), 
4.64 (m, 1H, H-12), 4.48 (m, 1H, H-5), 3.71 (s, 3H, H-17), 2.59 (s, 3H, H-4), 2.53 (s, 3H, 
H-11), 2.25 (m, 1H, H-6), 2.00 (s, 3H, H-1), 1.94 (m, 1H, H-13), 1.46 (d, 3H, J = 6.9 Hz, 
H-3), 1.53-1.39 (m, 1H, H-15), 1.22 (m, 1H, H-15), 1.01 (m, 6H, H-7 and H-8), 0.90 (m, 
6H, H-14 and H-16) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 172.3, 170.4, 169.4, 161.5, 
161.1, 155.1, 154.7, 153.8, 129.5, 128.6, 127.7, 104.4, 58.9, 56.1, 52.1, 43.1, 37.9, 31.4, 
25.3, 23.3, 19.9, 19.3, 18.5, 18.3, 15.6, 11.9, 11.7, 11.5 ppm; ES+ MS m/z 611 ([M+Na]+ 
1
87
6
5
4
3
2
3.51
O
N
H O
N
O
N
H O
H
N
HH
O
N N
H
O
O
O
17
16
15
14
13
11
109
12
	  102	  
100%); HRMS m/z calculated for C28H41N6O8 [M+H]+ 589.2986, found 589.2973. 
 
Boc-Ser(OPMB)-Z-∆Abu-OMe (3.63) 
 
To a solution of Boc-Ser(OPMB)-Thr-OMe (3.33) (1.8 g, 4.09 mmol, 1 equiv.) in 
anhydrous CH3CN was added DMAP (149 mg, 1.23 mmol, 0.3 equiv.) followed by Boc2O 
(1.16 g, 5.32 mmol, 1.3 equiv.). The resulting mixture was stirred for 3 h at rt. Then TMG 
(0.77 mL, 6.14 mmol, 1.5 equiv.) was added, and the stirring was continued for 3 h. The 
solvent was removed in vacuo, and the residue was partitioned between CH2Cl2 (80 mL) 
and saturated KHSO4 (50 mL). The organic phase was washed with saturated KHSO4 and 
NaHCO3 (50 mL each), dried over MgSO4, filtered and concentrated in vacuo. The residue 
was purified by column chromatography (1:9 to 3:7 EtOAc/petroleum ether) to afford 3.63 
as colorless oil (1.02 g, 59%); [α]D25 = +3.1 (c 0.32, CH3OH); IR (neat): 3298, 1721, 1681, 
1512 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 7.18 (d, 2H, J = 8.8 Hz, aromatic protons), 6.8 
(d, 2H, J = 8.8 Hz, aromatic protons), 6.74 (q, 1H, J = 7.2 Hz, H-10), 5.39 (brs, 1H, NH), 
4.45 (m, 2H, H-3), 4.32 (brs, 1H, H-1), 3.85 (m, 1H, H-2), 3.73 (s, 3H, H-11), 3.67 (s, 3H, 
H-8), 3.54 (dd, 1H, J = 9.3, 6.7 Hz, H-2), 1.66 (d, 3H, J = 7.2 Hz, H-9), 1.39 (s, 9H, tBu) 
ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 168.7, 164.6, 159.4, 155.5, 134.4, 129.6, 129.4 (2C), 
125.8, 113.9 (2C), 80.3, 73.2, 69.6, 55.3, 54.2, 52.3, 28.3 (3C), 14.6 ppm; ES+ MS m/z 445 
([M+Na]+ 100%); HRMS m/z calculated for C21H31N2O7 [M+H]+ 423.2126, found 
423.2123. 
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Boc-Ser(OPMB)-MeOxz-OMe (3.34) 
 
To a solution of Boc-Ser(OPMB)-Z-∆Abu-OMe (3.63) (1 g, 2.37 mmol, 1 equiv.) in 
CH2Cl2 (20 mL) was added NBS (548 mg, 3.08 mmol, 1.3 equiv.), and the mixture was 
stirred for 16 h at rt. Then TEA (0.5 mL, 3.56 mmol, 1.5 equiv.) was added and stirring was 
continued for an additional hour. The solvent was removed in vacuo and the residue was 
partitioned between CH2Cl2 and saturated KHSO4 (50 mL each). The organic phase was 
washed with saturated KHSO4 and saturated NaHCO3 (50 mL each), dried over MgSO4, 
filtered, and concentrated in vacuo to afford 3.64 as a mixture of E/Z alkene and used in the 
next step without further purification. 
To a solution of bromide 3.64 (2.26 mmol, 1 equiv.) in CH3CN (20 mL) was added DBU 
(0.44 mL, 2.94 mmol, 1.3 equiv., 2% in solution), and the mixture was stirred for 1 h at rt. 
Solvent was removed in vacuo, and the residue was dissolved in CH2Cl2 (50 mL), then 
washed with saturated KHSO4 (50 mL) and the aqueous layer was extracted with CH2Cl2 
(30 mL  ×  2). The combined organic layer was dried over MgSO4, filtered and concentrated 
in vacuo. The residue was purified by column chromatography (1:9 to 3:7 
EtOAc/petroleum ether) to afford 3.34 as colorless oil (282 mg, 28% over two steps); [α]D25 
= -20 (c 0.1, CH3OH); IR (neat): 3323, 1714, 1614 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 
7.08 (d, 2H, J = 8.5 Hz, aromatic protons), 6.77 (d, 2H, J = 8.7 Hz, aromatic protons), 5.40 
(d, 1H, J = 7.4 Hz, NH), 4.96 (brs, 1H, H-1), 4.36 (dd, 2H, J = 18.9, 11.7 Hz, H-3), 3.83 (s, 
3H, H-10), 3.76 (m, 1H, H-2), 3.73 (s, 3H, H-8), 3.68 (dd, 1H, J = 9.7, 4.5 Hz, H-2), 2.52 
(s, 3H, H-9), 1.37 (s, 9H, tBu) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 161.6, 159.5, 158.3, 
128.3 (2C), 126.5, 112.8 (2C), 71.8, 69.1, 54.2, 51.0, 27.3 (3C), 11.0 ppm; ES+ MS m/z 443 
([M+Na]+ 100%); HRMS m/z calculated for C21H29N2O7 [M+H]+ 421.1969, found 
421.1969. 
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Boc-Val-∆Ala-MeOxz-OMe (3.58) 
 
The dried compound Boc-Ser(OPMB)-MeOxz-OMe (3.34) (266 mg, 0.63 mmol, 1 equiv.) 
was dissolved in HCl solution (4.0 M in dioxane, 10 mL), and the solution was stirred for 2 
h under argon. The mixture was co-evaporated with CH3CN, then CH2Cl2 twice each to 
afford the corresponding amine hydrochloride with PMB removed and used in the next step 
without further purification. 
To a solution of the amine hydrochloride (0.63 mmol, 1 equiv.) in CH2Cl2 (10 mL) was 
added Boc-L-valine (179 mg, 0.82 mmol, 1.3 equiv.), PyBOP (428 mg, 0.82 mmol, 1.3 
equiv.) and DIPEA (0.24 mL, 1.39 mmol, 2.2 equiv.), and stirred at 0 ℃ overnight. The 
mixture was washed with 2 N HCl and saturated aqueous NaHCO3 solution (20 mL each) 
and purified by column chromatography (1:1 to 7:3 EtOAc/petroleum ether) to afford 3.65 
as a white solid (175 mg, 69%). 
To a solution of Boc-Val-Ser-MeOxz-OMe (3.65) (155 mg, 0.39 mmol, 1 equiv.) in 
anhydrous CH3CN (10 mL) was added DMAP (14.2 mg, 0.12 mmol, 0.3 equiv.) followed 
by Boc2O (93.1 g, 0.43 mmol, 1.1 equiv.). The resulting mixture was stirred for 2 h at rt. 
Then TMG (0.29 mL, 2.33 mmol, 6 equiv.) was added, and the stirring was continued 
overnight. The solvent was removed in vacuo, and the residue was partitioned between 
CH2Cl2 and saturated KHSO4 (30 mL each). The organic phase was washed with saturated 
KHSO4 and NaHCO3 (30 mL each), dried over MgSO4, filtered and concentrated in vacuo. 
The residue was purified by column chromatography (1:4 EtOAc/petroleum ether) to afford 
3.58 as a white solid (109 mg, 74%); mp: 58-62 °C; [α]D25 = +183.3 (c 0.06, CH3OH); IR 
(neat): 3345, 1718, 1502 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 8.28 (brs, 1H, NH), 6.43 (s, 
1H, H-5), 5.63 (s, 1H, H-6), 5.06 (d, 1H, J = 7.7 Hz, NH), 4.07 (brs, 1H, H-1), 3.85 (s, 3H, 
H-8), 2.59 (s, 3H, H-7), 2.17 (m, 1H, H-2), 1.39 (s, 9H, tBu), 0.95 (d, 3H, J = 6.8 Hz, H-3 
or H-4), 0.87 (d, 3H, J = 6.9 Hz, H-3 or H-4) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 171.1, 
162.3, 157.4, 156.1, 155.8, 128.0, 127.7, 103.8, 80.1, 60.4, 52.0, 31.0, 28.3 (3C), 19.4, 17.4, 
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12.2 ppm; ES+ MS m/z 404 ([M+Na]+ 100%); HRMS m/z calculated for C18H28N3O6 
[M+H]+ 382.1972, found 382.1973. 
 
Boc-Leu-Ser-Oxz-OMe (3.67) 
 
The dried compound Boc-Ser(OPMB)-Oxz-OMe (3.66) (714.8 mg, 1.76 mmol, 1 equiv.) 
was dissolved in HCl solution (4.0 M in dioxane, 15 mL), and the solution was stirred for 2 
h under argon. The mixture was co-evaporated with CH3CN, then CH2Cl2 twice each to 
afford the corresponding amine hydrochloride with PMB removed and used in the next step 
without further purification. 
To a solution of the amine hydrochloride (1.76 mmol, 1 equiv.) in CH2Cl2 (20 mL) was 
added Boc-L-leucine hydrate (613 mg, 2.46 mmol, 1.4 equiv.), PyBOP (1.28 g, 2.46 mmol, 
1.4 equiv.) and DIPEA (0.7 mL, 3.87 mmol, 2.2 equiv.), and stirred at 0 ℃ overnight. The 
mixture was washed with 2 N HCl and saturated aqueous NaHCO3 solution (30 mL each) 
and purified by column chromatography (3:7 to 2:3 EtOAc/petroleum ether) to afford 3.67 
as a white solid (576 mg, 82%); mp: 46-48 °C; [α]D25 = -66.6 (c 0.3, CH3OH); IR (neat): 
3319, 1739, 1663, 1526 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 8.13 (s, 1H, H-8), 7.26 (d, 
1H, J = 8.3 Hz, NH), 5.27 (m, 1H, H-6), 5.03 (d, 1H, J = 6.4 Hz, NH), 4.01 (m, 3H, H-7 
and H-1), 3.83 (s, 3H, H-9), 2.00 (brs, 1H, OH), 1.59 (m, 2H, H-2 or H-3), 1.47 (m, 1H, 
H-2 or H-3), 1.35 (s, 9H, tBu), 0.87 (d, 3H, J = 6.8 Hz, H-4 or H-5), 0.85 (d, 3H, J = 6.8 
Hz, H-4 or H-5) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 172.0, 161.8, 160.3, 155.0, 143.4, 
132.1, 79.4, 62.0, 52.4, 51.2, 48.6, 39.8, 27.2 (3C), 23.7, 22.0, 20.8 ppm; ES+ MS m/z 422 
([M+Na]+ 100%); HRMS m/z calculated for C18H30N3O7 [M+H]+ 400.2084, found 
400.2076. 
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Boc-Leu-∆Ala-Oxz-OMe (3.61) 
 
To a solution of Boc-Leu-Ser-Oxz-OMe (3.67) (132 mg, 0.33 mmol, 1 equiv.) in anhydrous 
CH3CN was added DMAP (16.1 mg, 0.13 mmol, 0.4 equiv.) followed by Boc2O (108 mg, 
0.49 mmol, 1.5 equiv.). The resulting mixture was stirred for 3 h at rt. Then TMG (0.165 
mL, 1.32 mmol, 4 equiv.) was added, and the stirring was continued for 3 h. The solvent 
was removed in vacuo, and the residue was partitioned between CH2Cl2 (30 mL) and 
saturated KHSO4 (30 mL). The organic layer was washed with saturated KHSO4 and 
NaHCO3 (30 mL each), dried over MgSO4, filtered and concentrated in vacuo. The residue 
was purified by column chromatography (1:4 to 3:7 EtOAc/petroleum ether) to afford 3.61 
as a white solid (100 mg, 79%); mp: 40-44 °C; [α]D25 = -32.1 (c 0.28, CH3OH); IR (neat): 
3341, 1735, 1686, 1523 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 8.52 (brs, 1H, NH), 8.13 (s, 
1H, H-8), 6.47 (s, 1H, H-6), 5.71 (s, 1H, H-7), 4.89 (brs, 1H, NH), 4.19 (brs, 1H, H-1), 3.85 
(s, 3H, H-9), 1.68 (m, 2H, H-2 or H-3), 1.48 (m, 1H, H-2 or H-3), 1.39 (s, 9H, tBu), 0.90 (d, 
6H, J = 5.1 Hz, H-4 and H-5) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 171.0, 160.1, 157.9, 
143.5, 132.8, 126.8, 103.9, 51.2, 40.0, 27.2 (3C), 22.8, 22.0, 20.7 ppm; ES+ MS m/z 404 
([M+Na]+ 100%); HRMS m/z calculated for C18H27N3O6Na [M+Na]+ 404.1972, found 
404.1792. 
 
Ac-Ala-MeOxz-OMe (3.57) 
 
Boc-Ala-MeOxz-OMe (3.29) (0.98 g, 3.45 mmol, 1 equiv.) was dissolved in HCl solution 
(4.0 M in dioxane, 15 mL), and the solution was stirred for 2 h under argon. The mixture 
was co-evaporated with CH3CN, then CH2Cl2 twice each to afford the corresponding amine 
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hydrochloride and used in the next step without further purification. 
To a solution of the amine hydrochloride (3.45 mmol, 1 equiv.) in CH2Cl2 (20 mL) that was 
cooled to 0  ℃ was added acetyl chloride (0.344 mL, 4.84 mmol, 1.4 equiv.) and TEA (1.06 
mL, 7.6 mmol, 2.2 equiv.). The mixture was stirred for 2 h under argon. The precipitate 
was filtered off and the solution was purified by column chromatography (2% 
MeOH/CH2Cl2) to afford 3.57 as a white solid (642 mg, 82% over two steps); mp: 120-122 
°C; [α]D25 = -145.4 (c 0.22, CH3OH); IR (neat): 3265, 1739, 1724 cm-1; 1H NMR (400 MHz, 
CDCl3) 𝛿: 6.46 (s, 1H, J = 7.5 Hz, NH), 5.18 (dq, 1H, J = 8, 7 Hz, H-2), 3.84 (s, 3H, H-5), 
2.54 (s, 3H, H-1), 1.96 (s, 3H, H-1), 1.46 (d, 3H, J = 7 Hz, H-3), ppm; 13C NMR (100 MHz, 
CDCl3) 𝛿: 169.6, 162.9, 162.5, 156.6, 127.2, 52.0, 43.3, 23.1, 20.0, 12.0 ppm; ES+ MS m/z 
227 ([M+H]+ 100%); HRMS m/z calculated for C10H15N2O4 [M+H]+ 227.1026, found 
227.1025. 
 
Boc-Ala-Gly-Thz-Val-OMe (3.62) 
 
Boc-Gly-Thz-Val-OMe (3.24) (1.4 g, 3.79 mmol, 1 equiv.) was dissolved in HCl solution 
(4.0 M in dioxane, 15 mL), and the solution was stirred for 2 h under argon. The mixture 
was co-evaporated with CH3CN, then CH2Cl2 twice each to afford the corresponding amine 
hydrochloride and used in the next step without further purification. 
To a solution of the amine hydrochloride (3.79 mmol, 1 equiv.) in CH2Cl2 (20 mL) was 
added Boc alanine methyl ester hydrochloride (1 g, 5.3 mmol, 1.4 equiv.), PyBOP (2.75 g, 
5.3 mmol, 1.4 equiv.) and DIPEA (1.45 mL, 8.34 mmol, 2.2 equiv.), and stirred at 0  ℃ 
overnight. The mixture was washed with 2 N HCl and saturated aqueous NaHCO3 solution 
(50 mL each) and purified by column chromatography (1:4 to 3:7 EtOAc/petroleum ether) 
to afford 3.62 as a white solid (1.37 g, 82% over two steps); mp: 37-39 °C; [α]D25 = -5.5 (c 
0.18, CH3OH); IR (neat): 3309, 1741, 1710, 1664, 1538 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 7.96 (s, 1H, H-4), 7.67 (d, 1H, J = 9 Hz, NH), 7.14 (brs, 1H, NH), 4.99 (brs, 1H, NH), 
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4.67 (m, 2H, H-3), 4.63 (dd, 1H, J = 9, 5.4 Hz, H-5), 4.19 (m, 1H, H-1), 3.70 (s, 3H, H-9), 
2.22 (sptd, 1H, J = 6.8, 5.4 Hz, H-6), 1.35 (s, 9H, tBu), 1.33 (d, 3H, J = 7.2 Hz, H-2, 
overlaped with tBu), 0.95 (d, 3H, J = 6.5 Hz, H-7 or H-8), 0.93 (d, 3H, J = 6.5 Hz, H-7 or 
H-8), ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 173.2, 172.3, 168.1, 160.8, 160.7, 155.7, 149.1, 
124.4, 80.4, 57.3, 52.2, 40.9, 31.4, 28.3 (3C), 19.1 (2C), 18.0 ppm; ES+ MS m/z 465 
([M+Na]+ 100%); HRMS m/z calculated for C19H31N4O6S [M+H]+ 443.1958, found 
443.1967. 
 
Boc-Ile-Leu-Thz-Ser-Gly-OMe (3.59) 
 
Boc-Leu-Thz-Ser-Gly-OMe (3.68) (1.4 g, 3.79 mmol, 1 equiv.) was dissolved in HCl 
solution (4.0 M in dioxane, 15 mL), and the solution was stirred for 2 h under argon. The 
mixture was co-evaporated with CH3CN, then CH2Cl2 twice each to afford the 
corresponding amine hydrochloride and used in the next step without further purification. 
To a solution of the amine hydrochloride (3.79 mmol, 1 equiv.) in CH2Cl2 (15 mL) was 
added Boc-isoleucine (511 mg, 2.21 mmol, 1.4 equiv.), PyBOP (1.15 g, 2.21 mmol, 1.4 
equiv.) and DIPEA (0.61 mL, 3.48 mmol, 2.2 equiv.), and stirred at 0 ℃ overnight. The 
mixture was washed with 2 N HCl and saturated aqueous NaHCO3 solution (30 mL each) 
and purified by column chromatography (2:3 to 3:2 EtOAc/petroleum ether) to afford 3.59 
as a white solid (765 mg, 82% over two steps); mp: 198-202 °C; [α]D25 = +147.0 (c 0.034, 
CH3OH); IR (neat): 3333, 3285, 1682, 1658, 1535 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 
7.96 (s, 1H, H-11), 5.25 (m, 1H, H-6), 4.59 (m, 1H, H-12), 4.02 (m, 1H, H-1), 3.99 (brs, 2H, 
H-14), 3.80 (m, 1H, H-13), 3.73 (dd, 1H, J = 11.4, 5.7 Hz, H-13), 3.68 (s, 3H, H-15), 
1.87-1.58 (m, 4H, H-2, H-7 and H-8), 1.43 (m, 1H, H-4), 1.36 (s, 9H, tBu), 1.05 (m, 1H, 
H-4), 0.89 (m, 6H, H-9 and H-10), 0.80 (m, 6H, H-3 and H-5), ppm; 13C NMR (100 MHz, 
(CD3)SO) 𝛿: 175.0, 171.9, 170.1 (2C), 159.9, 155.3, 149.0, 124.0, 78.0, 61.7, 58.8, 54.6, 
51.7, 49.1, 43.0, 40.7, 35.7, 28.1 (3C), 24.5, 24.0, 23.2, 20.9, 15.5, 10.6 ppm; ES+ MS m/z 
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608 ([M+Na]+ 100%); HRMS m/z calculated for C26H44N5O8S [M+H]+ 586.2910, found 
586.2898. 
 
Boc-Ile-Leu-Thz-Ser-Gly-Gly-MeOxz-OMe (3.69) 
 
To a solution of Boc-Ile-Leu-Thz-Ser-Gly-OMe (3.59) (329 mg, 0.58 mmol, 1 equiv.) in 10 
mL of a mixture of THF/water (3:1) that had been cooled to 0 ℃ was added LiOH (42 mg, 
1.74 mmol, 3 equiv.). The mixture was stirred at 0  ℃ for 2 h. The solution was diluted 
with water (10 mL), and acidified to pH 1-2 with saturated KHSO4 aqueous solution. The 
aqueous layer was extracted with EtOAc (30 mL  ×  3). The combined organic layer was 
dried over MgSO4, filtered, and concentrated in vacuo to provide corresponding acid 3.70 
as a white solid and used in the next step without further purification. 
The dried compound Boc-Gly-MeOxz-OMe (3.60) (224 mg, 0.82 mmol, 1.4 equiv. to 3.59) 
was dissolved in HCl solution (4.0 M in dioxane, 5 mL), and the solution was stirred for 2 
h under argon. The mixture was co-evaporated with CH3CN, then CH2Cl2 twice each to 
afford the corresponding amine hydrochloride 3.71 and used in the next step without 
further purification. 
A solution of 3.70 (0.58 mmol, 1 equiv.), HOBt∙H2O (157 mg, 1.16 mmol, 2 equiv.) and 
EDCI (223 mg, 1.16 mmol, 2 equiv.) in anhydrous DMF (5 mL) was stirred at rt for 10 min. 
In another flask, a solution of 3.71 (0.82 mmol, 1.4 equiv.) and DIPEA (0.25 mL, 1.45 
mmol, 2.5 equiv.) in anhydrous DMF (5 mL) was stirred at rt for 10 min. The solution of 
amine was poured into the activated acid, and the resulting mixture was stirred overnight at 
rt. The mixture was diluted with EtOAc (30 mL), and washed with 2 N HCl, saturated 
NaHCO3 (30 mL each), filtered, then dried over MgSO4 and concentrated in vacuo. The 
resulting residue was purified by column chromatography (3% to 5% MeOH/CH2Cl2) to 
afford 3.69 as a white solid (347 mg, 83% from 3.59); mp: 158-162 °C; [α]D25 = +20.0 (c 
0.1, CH3OH); IR (neat): 3312, 1727, 1688, 1652, 1538 cm-1; 1H NMR (400 MHz, 
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DMSO-d6) 𝛿: 8.69 (d, 1H, J = 8 Hz, NH), 8.53 (t, 1H, J = 5.8 Hz, NH), 8.45 (t, 1H, J = 5.8 
Hz, NH), 8.19 (s, 1H, H-11), 8.07 (d, 1H, J = 7.5 Hz, NH), 6.81 (d, 1H, J = 8.8 Hz, NH), 
5.21 (m, 1H, H-6), 4.5 (m, 1H, H-12), 4.37 (d, 2H, J = 5.8 Hz, H-15), 3.78 (s, 3H, H-17), 
3.85-3.64 (m, 5H, H-1, H-13 and H-14), 2.54 (s, 3H, H-16), 1.75 (m, 4H, H-7, H-8, and 
H-2), 1.42 (m, 1H, H-3), 1.38 (s, 9H, tBu), 1.11 (m, 1H, H-3), 0.90 (m, 6H, H-9 and H-10), 
0.81 (m, 6H, H-4 and H-5) ppm; 13C NMR (100 MHz, DMSO-d6) 𝛿: 175.0, 171.9, 170.0, 
169.1, 161.9, 160.1, 159.0, 156.2, 155.3, 149.0, 126.6, 124.0, 78.0, 61.7, 58.8, 54.9, 51.5, 
49.1, 43.0, 42.0, 35.7, 35.6, 28.1 (3C), 24.5, 24.0, 23.1, 20.9, 15.5, 11.7, 10.6 ppm; ES+ MS 
m/z 747 ([M+Na]+ 100%); HRMS m/z calculated for C32H50N7O10S [M+H]+ 724.3340, 
found 724.3337. 
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Chapter 4: Total Synthesis of Breitfussin B 
- A Rare Teraryl Alkaloid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  112	  
4.1 Introduction 
4.1.1 Alkaloid natural products 
Alkaloids as an important branch of natural products are playing key roles in many 
disciplines, including medicine, chemistry and also biology. The definition of alkaloid 
varies from one field to another90-92 and each field focus on different aspects. For example, 
chemists see the chemical properties of alkaloids as more important and define these 
natural products to have heterocyclic nitrogen atoms and basic chemical properties.92 
However, the biologists pointed out that alkaloids should also have pharmacological 
activities and medicinal value.90 Nevertheless, all definitions from different fields are based 
on the acknowledgement of the significance of alkaloids. Many achievements would not be 
possible without alkaloids, such as development of some anti-malarial and anti-cancer 
agents.92 Several examples of alkaloid drugs are given in Figure 4.1 including the 
aforementioned morphine, and they are all natural products. 
 
 
Figure 4.1: Structures of some alkaloid drugs. 
4.1.2 Oxazole-containing alkaloids 
Oxazole is a common moiety present in many natural products. It is a five-membered ring 
containing one oxygen and one nitrogen separated by one carbon atom. The biosynthesis of 
oxazole is a post-translational modification process driven by enzymes starting from either 
a serine (forms oxazole, R = H) or a threonine (forms methyl oxazole, R = Me) amino acid 
residue in the precursor molecule.93 The mechanism is shown in Scheme 4.1. The hydroxyl 
group on the amino acid side chain can perform a cyclisation reaction with the carbonyl 
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group on the amide bond (𝛽 to the side chain). Then subsequent dehydration and oxidation 
would yield the aromatic heterocycle oxazole. 
 
 
Scheme 4.1: General mechanism of biosynthetic process for oxazole. 
Oxazole-containing alkaloids are now becoming increasingly popular as synthetic targets 
for chemists because of their interesting structure and biological activities. However, it is 
challenging to synthesise some oxazoles in structurally complicated natural products due to 
the interference of other functional groups and/or structural rigidity. There are a number of 
methods available in the literature to form oxazoles, and some of them are going to be 
discussed in later sections. Here some oxazole-contafining bioactive alkaloids will be 
introduced including their isolation, activities and synthesis. 
4.1.2.1 Calyculins 
(+)-Calyculin A (4.4, Figure 4.2) was isolated from Discodermia calyx collected from 
Japan in 1986, and was found to be cytotoxic against L1210 leukemia cells.94 The structure 
of calyculin A comprises a polyhydroxylated C28 fatty acid with a 2,4-disubstituted oxazole 
moiety.94 The biological activities of calyculin A was extensively studied by Suganuma et 
al.,95 and they found out that calyculin A is a tumour promoter by binding to the okadaic 
acid (4.5) receptors, with KD values within nanomolar range. Similar to okadaic acid, it also 
has inhibitory activity for protein phosphatases with comparable potency,95 although their 
structures are not related (Figure 4.2). 
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Figure 4.2: Structures of (+)-calyculin A (4.4) and okadaic acid (4.5). 
The synthesis of calyculin A has been widely studied from 1992 to 2010.96-100 The first 
total synthesis of (+)-calyculin A was accomplished by Evans et al.96 where the natural 
product was disconnected into C1-C25 and C26-C37 subunits (Scheme 4.2). Since these two 
fragments have 15 chiral centres, auxiliary-based asymmetric synthetic methods such as 
aldol, hydroxylation, alkylation and Michael reactions were used.96 A number of 
enolate-based reactions (examples given in Scheme 4.2) were incorporated into a complex 
total synthesis for the first time.96 
 
 
Scheme 4.2: Retrosynthesis of calyculin A and examples of enolate-based reactions.96 i. TiCl4, DIPEA, 
CH2Cl2, 0 ℃, then (MeO)2CH2, BF3.OEt2, 20 ℃, 80%; ii. Ti(O-i-Pr)Cl3, DIPEA, CH2Cl2, 0 ℃; then 
tert-butyl acrylate, 88%. 
The 2,4-disubstituted oxazole moiety in calyculin A was synthesised in four steps from 
dipeptide 4.12 (Scheme 4.3). Cyclisation using SOCl2 and pyridine from 4.12 formed the 
oxazoline intermediate 4.13 in 78% yield. After further protection on the amino group in 
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good yield, enolisation of 4.14 followed by oxidative elimination finally afforded the 
desired oxazole derivative 4.15.96 
 
 
Scheme 4.3: Synthesis of oxazole derivative 4.15.96 i. SOCl2, pyridine, 9:1 Et2O/THF, 0 ℃, 78%; ii. 
(Boc)2O, DMAP, MeCN, 88%; iii. KHMDS, PhSeCl, THF, -78 ℃; iv. 30% aqueous H2O2, CH2Cl2, pyridine, 
0 ℃, 57% over two steps. 
4.1.2.2 Neopeltolide 
In 2007, Wright et al. isolated neopeltolide (4.16, Figure 4.3) from a deep-water sponge 
Neopeltidae daedalopelta.101 This novel natural product was later found to be a strong 
growth inhibitor of fungal pathogen Candida albicans.101 It was also discovered to have 
potent inhibitory activity against the proliferation of several cancer cell lines, all with IC50 
within nanomolar range. The best activity found was 0.56 nM against P388 murine 
leukemia.101  
 
 
Figure 4.3: The original and revised structures of neopeltolide (4.16). 
The total synthesis of neopeltolide was reported not long after its isolation.102, 103 However, 
authors of the two early total syntheses found out that the structure of neopeltolide was 
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mistakenly assigned, the stereochemistry of C11 and C13 should be S instead of R (Figure 
4.3).102, 103 Both groups attempted the synthesis of the original proposed neopeltolide first 
and found out some differences in their NMR spectra compared to the natural product.  
4.1.2.3 Diazonamides A and B 
The isolation of two unique and heavily modified cyclic peptides diazonamide A and B 
(4.17 and 4.18, Figure 4.4) from the colonial ascidian Diazona chinensis was reported in 
1991 by Lindquist and Fenical.104 Although they have gone through complicated 
post-translational modifications, these two natural products are constructed from three 
natural amino acids: valine, tryptophan and tyrosine. Diazonamide A was found to be 
potently cytotoxic (IC50 < 15 ng/mL) in vitro against HCT-116 human colon carcinoma and 
B-16 murine melanoma cancer cell lines.104 However, diazonamide B was found to be less 
active.104 
 
 
Figure 4.4: Structures of diazonamide A (4.17) and B (4.18). 
The unique bisindole and bisoxazole structure and fascinating bioactivities of diazonamide 
A have drawn significant attention to its total synthetic studies.105-108 The first total 
synthesis was published by Nicolaou et al. in 2002.105 Oxazole ring was synthesised using 
Robinson-Gabriel cyclodehydration from keto amide intermediate 4.22 with 52% yield 
(Scheme 4.4).105 This result has proven this method to be suitable for oxazole formation 
within complicated a structure. 
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Scheme 4.4: Construction of the C10 quaternary centre and formation of second oxazole.105 i. 
POCl3/pyridine (1:4), 25 ℃, 2 h, 52%. 
4.1.2.4 Pimprinine, labradorins 1 and 2 
Pimprinine (4.25, Scheme 4.5) is the first 5-(3-indolyl)oxazole natural product and was 
isolated in 1963 from Streptomyces pimprina by Joshi and Taylor.109 Since NMR 
instrumentation was not readily available in the 1960s, the authors confirmed the structure 
of pimprinine by synthesising it (Scheme 4.5). The oxazole was formed by a method 
similar to Robinson-Gabriel cyclodehydration.109 The pharmacological activity of 
pimprinine was studied by Naik et al.,110 and they found that pimprinine exhibits low level 
of antimicrobial activity, significant anticonvulsant and antitremorine activity.110  
 
 
Scheme 4.5: Synthesis of pimprinine (4.25).109 i. Ac2O, pyridine; ii. 6 N HCl, MeOH, 60 ℃, 0.5 h; iii. 
POCl3, reflux, 4 h. 
Likewise, labradorins 1 and 2 (4.29 and 4.30, Scheme 4.6) belong to the family of 
5-(3-indolyl)oxazole natural products. The isolation of these two natural products was 
achieved from Pseudomonas syringae in 2002, and they were both found to be cytotoxic 
against a number of cancer cell lines.111 Labradorin 1 was more active (IC50 from 3.5 to 9.8 𝜇g/mL) than labradorin 2.111 Due to the limited source of labradorin 2, the authors also 
made it from commercially available tryptamine for a larger supply, in which they applied 
NH HN
O O
N
O
N
H
O
N
NH
Cbz
Boc
O
NH HN
O O
N
O
N
H
NH
Cbz
Boc
O
H
N
O
O
Br Br
i.
4.19 4.20
N
H
O
NH2 .HBr
i.
N
O
HN O
ii.
N
O
N
O O
iii.
N
H
O
N
4.26
4.274.26 4.28
4.25
	  118	  
the route in Scheme 4.6.111 The oxidation and cyclisation steps are worth noting, for they 
are the same steps we need to perform in the total synthesis of breitfussin B. 
 
 
Scheme 4.6: Synthesis of labradorin 2 (4.30)111 and structure of labradorin 1 (4.29). i. TEA, caproyl 
chloride, toluene, 0 ℃ to rt, overnight; ii. DDQ, THF/H2O (9:1), 5 min, rt; iii. POCl3, reflux, 1.5 h. 
4.1.2.5 Breitfussin A and B 
There are few literature publications on breitfussin A and B (4.34 and 4.35, Figure 4.5). 
They are two recently isolated natural alkaloids from Arctic hydrozoan Thuiaria breitfussi 
belonging to the family Sertulariidae in 2007. However, the structures were only elucidated 
by Hanssen et al.112 in 2012 using a combination of computational methods: atomic-force 
microscopy (AFM); computer-aided structure elucidation (CASE) and the calculation of 
13C NMR shifts using electronic structure calculations (DFT).112 They are highly 
unsaturated compounds,112 and they also are 5-(3-indolyl)oxazole compounds. As they are 
completetly heterocyclic and do not contain many protons, NMR-based structure 
elucidation was challenging. As a result, computational and AFM methods were used 
instead. Probably due to the low amount of material isolated, they have not been tested for 
biological activity.  
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Figure 4.5: Structures of breitfussin A and B. 
The first total synthesis of breitfussin A and B was reported by Pandey et al. early 2015.113 
The basic strategy involveds two palladium-catalysed cross coupling reactions to assemble 
the indole and pyrrole rings onto the oxazole core (Scheme 4.7 and 4.8).113 Iodination of 
indole-oxazole fragment 4.38 was achieved by a metalation/iodination strategy (Scheme 
4.7). The reaction gives the 4-iodo derivative 4.39 as major product, and a second 
iodination provided the 2,4-diiododerivative 4.40.113 
 
 
Scheme 4.7: Synthesis of indole-oxazole intermediate 4.40.113 i. Pd(dppf)Cl2, K3PO4, toluene/H2O, 80 ℃, 
83%; ii. 10% aq HCl, THF, 0 ℃, 89%. iii. LiHMDS, -78 ℃, then I2, -78 ℃. 
As illustrated in Scheme 4.8, the installation of the pyrrole moiety onto 4.40 by another 
palladium-catalysed cross coupling reaction provided 4.41, the precursor for breitfussins A 
and B.113 Deprotections led to the completion of breitfussin A; bromination of C2 of 
pyrrole followed by deprotection provided breitfussin B113. The iodine on C2 of oxazole 
was removed in acidic condition simultaneously during the deprotection steps. However, 
the authors tested neither of the two natural products for biological activities. 
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Scheme 4.8: Final steps in the first total synthesis of breitfussins A and B.113 i. Pd(dppf)Cl2, Cs2CO3, 
dioxane/H2O, rt, 61%; ii. 1) TMSOTf, Et3N, CH2Cl2, 0 ℃ to rt. 2) TBAF, THF, 0 ℃, 64%; iii. NBS, THF, 
-78 ℃ to rt, 57% (based on recovered starting material); iv. 1) TFA, CH2Cl2, 0 ℃ to rt. 2) TBAF, THF, 0 ℃, 67%. 
4.1.3 Synthesis of 5-(3-indolyl)oxazole derivatives 
The examples given in the introduction of diazonamide A, pimprinine and labradorins have 
briefly demonstrated how 5-(3-indolyl)oxazole natural products can be made. The most 
crucial part of making such derivatives is to construct the oxazole ring, and there is more 
than one way to do so. The Robinson-Gabriel cyclodehydration is used commonly, 
although there are several variations of it. The POCl3 method mentioned before would be 
one of these variations. The synthesis usually starts from a 3-aminoacetyl indole derivative 
4.43 that is going to be coupled to form an amide 4.45; or from an amide 4.44 that will be 
oxidised by DDQ. The subsequent cyclodehydration can be done with several different 
methods: POCl3/pyridine105,114; C2Cl6/Ph3P115; or classically, concentrated H2SO4116. 
General scheme for Robinson-Gabriel cyclodehydration is given as Scheme 4.9.  
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Scheme 4.9: Robinson-Gabriel cyclodehydration. 
In 2008, Kumar et al. reported a different approach,117 where they selected 
3-acetyl-1-benzenesulfonylindole (4.47) as starting material (Scheme 4.10). Reacting 4.47 
with hydroxy(tosyloxy)iodobenzene would form 4.48. Subsequent application of 
hexamethylenetetramine (HMTA) followed by refluxing in HCl gave the salt 4.49.117 By 
reacting 4.49 with various acid chlorides would afforded the amido ketone 4.50.117 Oxazole 
4.51 was formed using p-toluenesulfonic acid.117 This strategy was tested with several 
different acid chlorides, and overall yields range from 24% to 32% over six steps.117 
 
 
Scheme 4.10: Kumar’s synthesis of 5-(3-indolyl)oxazole compounds.117 i. C6H5I(OH)OTs, MeCN, rt, 86%; 
ii. HMTA, CHCl3; iii. HCl, reflux, 91% over two steps; iv. RCOCl, TEA, 0 to 5 ℃, 68-79%; v. PTSA, EtOH, 
reflux, 72-82%; vi. NaOH, EtOH/H2O, reflux, 73-83%. 	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The methodology reported by Xiang et al.118 provided a different angle for approaching 
5-(3-indolyl)oxazole compounds. This simple one-pot method (Scheme 4.11) was tested 
over a broad range of substituents on the 2-position of oxazole.118 Alkyl, aromatic, oxygen 
and sulfur-containing substituents are well tolerated with this approach, proving the 
potential it has to be a universal method of constructing 5-(3-indolyl)oxazole 
compounds.118 
 
 
Scheme 4.11: Xiang’s synthesis of 5-(3-indolyl)oxazole compounds.118 i. I2 (2.0 equiv.), DMSO, 110 ℃, 
51% to 82%. 
Another protocol reported by He et al.119 provided a mild and efficient way towards 
5-(3-indolyl)oxazoles. Reaction between a terminal alkyne, a nitrile and an oxidising agent 
under the catalysis of a gold complex would generate a 2,5-disubstituted oxazole in good 
yields (Scheme 4.12). This reaction can tolerate a wide range of substituents, including 
indole. It has been applied in the synthesis of pimprinine and WS-30581 B, where it 
proceeded in yields of 87% and 71% respectively (Scheme 4.10).119 
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Scheme 4.12: Mechanism and examples of gold catalysed [2+2+1] cyclisation.119 i. Ph3PAuNTf2 (5 mol%), 
8-methylquinoline N-oxide (1.3 equiv.), RCN (0.1 M), 60 ℃, 3 h; ii. TFA, THF, rt. 
4.1.4 Other oxazole synthesis methods 
As a variation of the Robinson-Gabriel synthesis, Wipf and Miller reported a versatile 
method to synthesise highly substituted and functionalised oxazoles from commercially 
available amino acid derivatives.120 Oxidation of amino acid side chain is fulfilled by 
treatment of Dess-Martin periodinane, which produces the corresponding ketone (Scheme 
4.13). This ketone is subject to a cyclodehydration by adding PPh3 and iodine in the 
presence of triethylamine. According to Wipf’s experiments, this method generally 
provides good (55-81%) yield.120  
 
 
Scheme 4.13: Wipf’s oxazole synthesis.120 i. DMP (1.2 equiv.), CH2Cl2, 1 h, rt; ii. PPh3 (2 equiv.), I2 (2 
equiv.), TEA (4 equiv.), CH2Cl2, rt, 15 min or 8 h, 58-81% over two steps. 
Wipf reported another method for the synthesis of 2,5-disubstituted and 2,4,5-trisubstituted 
oxazoles by a mild silica-mediated cycloisomerisation of propargyl amides (Scheme 4.14 A) 
in 2004.121 This reaction was proved to be versatile as it can be applied to produce 
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2,5-disubstituted oxazoles, 2,4,5-trisubstituted oxazoles, Oxazol-5-yl Acetates and 
2,4,5-Trisubstituted Polyunsaturated Oxazolyl Ketone (Scheme 4.14 B).121  
 
 
Scheme 4.14: Wipf’s silica-mediated oxazole synthesis.121 i. silica gel (300%, w/w), CH2Cl2, rt, 24 h; ii. 
silica gel (300%, w/w), CH2Cl2, rt, 72 h, 90%; iii. SiO2, CH2Cl2, rt, 58%. 
A classical approach towards monosubstituted oxazole derivatives is through reaction of 
tosylmethyl isocyanide (TosMIC) and an aldehyde, which is called Van Leusen Oxazole 
Synthesis (Scheme 4.15).122 But as one of the first oxazole synthesis methods, Fischer 
oxazole synthesis was published in 1896, where an aldehyde and a cyanohydrin combines 
to form a 2,5-disubstituted oxazole in the presence of anhydrous HCl (Scheme 4.16 A).123	  
The mechanism (Scheme 4.16 B) involves a nucleophilic attack of the imine 4.76 on the 
electrophilic carbon of aldehyde 4.77, followed by cyclisation and loss of water. 
Isomerisation of intermediate 4.78 would produce oxazoline 4.79, which is subsequently 
aromatised into oxazole 4.75 with loss of HCl.124	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Scheme 4.15: Van Leusen Oxazole Synthesis.122 
 
 
Scheme 4.16: Fischer oxazole synthesis.123, 124 
4.1.5 Aims 
The unique teraryl structures of breitfussins A and B each contain a 3,4,6-trisubstituted 
indole, a 2,5-disubstituted oxazole, and a mono or disubstituted pyrrole, making them to be 
potential interesting bioactive compounds. For this reason, they have drawn our interest to 
synthesise it in the laboratory. To start with, we would achieve the total synthesis of 
breitfussin B and test it for biological activities. 
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4.2 Results and discussion 
4.2.1 Strategy 
Breitfussin B (4.35) is composed of three moieties: a brominated pyrrole derivative, an 
oxazole derivative and a modified indole. The retrosynthetic analysis is shown in Scheme 
4.17; the first and most important disconnection would be to open the oxazole ring of 
breitfussin B, which gives 𝛽-amidoketone moiety at the center of the molecule. This 
moiety will be cyclised by a condensation reaction at the end of the synthesis. The carbonyl 
alpha to the indole can be then reduced to give an amide intermediate. This carbonyl group 
can result from a selective oxidation reaction. The next and obvious disconnection would 
be to open the amide bond to give a pyrrole derivative 4.82 and a tryptamine derivative 
4.83. The synthesis of these two fragments can be initiated from two cheap commercially 
available starting materials: methyl pyrrole-2-carboxylate (4.84) and 2,6-dinitrotoluene 
(4.85). The main effort at the early stage of the synthesis was put into making 4.82 and 
4.83. 
 
Scheme 4.17: Retrosynthesis of breifussin B. 
 
N
HBr
O O
N
HN
Br
Breitfussin B (4.35)
N
HBr
O
O HN O
HN
Br
N
HBr
O
HN O
HN
Br
H
NBr O
OH
+
N
HBr
O
NH2
4.82
4.83
H
N
O
O
4.84
NO2
NO2
4.85
	  127	  
However, before starting the synthesis, we needed to investigate the feasibility of the 
proposed synthetic route. In fact, the main difficulty for this total synthesis, apart from the 
final oxazole formation, is to put the substituents on the indole and pyrrole moieties. 
Therefore, we decided to carry out a synthesis of a model compound 4.86 (Scheme 4.18), 
which is a simplified version of breitfussin B with no modification on any of the 
heterocycles. The purpose of this is to test the subsequent reactions after synthesising 4.82 
and 4.83 to make sure the two precious fragments will not be wasted, since making them 
could be complicated. The model synthesis is in total only four steps long, which was not 
time-consuming. 
4.2.2 Synthesis of model compound 4.86 
The synthesis of compound 4.86 is shown in Scheme 4.18. In this system, methyl 
pyrrole-2-carboxylate (4.84) is chosen as the starting material. The first step is the 
deprotection of the methyl ester, which in practice proved to be harder than normal methyl 
ester deprotection. The hydrolysis of methyl ester, from our previous experiences, usually 
completes in 2 h stirring with LiOH (3 equiv.) in THF/H2O at room temperature. However, 
the reaction is very slow for this ester. We soon found out that stronger base (KOH), 
heating (55 ℃) and longer reaction time (overnight) would be preferable for this hydrolysis. 
This could be the result of the electron-donating effect of the pyrrole group which 
decreases the nucleophilicity of the carbonyl carbon. After obtaining the acid 4.87, it was 
then coupled with tryptamine using standard EDCI/HOBt method. This step gave 
compound 4.88 with a nice 74% yield over two steps. Next, oxidation of the 𝛼-position of 
the indole ring was performed using DDQ as oxidising agent. Here 2 equiv. of DDQ is 
necessary to carry out the task. This selective oxidation, which was discovered by 
Yonemitsu and Oikawa can be explained by a four-step mechanism (Scheme 4.19):125 
dehydrogenation, water addition, second dehydrogenation and isomerisation. DDQ is 
known as a strong electron acceptor, therefore the initial step of the oxidation would be the 
hydride transfer of the 𝛼-carbon to the indole, which is induced by the electron rich 
nitrogen atom. DDQ is subsequently reduced into 2,3-dichloro-5,6-dicyanohydroquinone 
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(DDH). Water is essential for this reaction and will insert into intermediate 4.90 to form the 𝛼-hydroxyindole derivative 4.91. After another round of dehydrogenation, ketone 4.89 will 
be formed by tautomerisation of enol 4.92. It was proved in practice that DDQ is very 
suitable for this reaction, affording compound 4.89 in nearly quantitative yield (98%). 
Finally, Robinson-Gabriel oxazole synthesis105 was performed, using POCl3 and pyridine 
as reagent and solvent. The yield in this step is not very good (18%), but since this was 
only a model for the total synthesis, we did not attampt to improve it. After trying these few 
reactions, we became more confident in the actual synthesis of breitfussin B. Now we need 
to move on to the synthesis of methyl 5-bromopyrrole-2-carboxylic acid (4.82) and 
6-bromo-4-methoxytryptamine (4.83). 
 
 
Scheme 4.18: Synthesis of compound 4.86. i. KOH (3 equiv.), THF/H2O (3:1), 55 ℃, overnight; ii. 
tryptamine (1.2 equiv.), EDCI (1.3 equiv.), HOBt (0.2 equiv.), DIPEA (2.2 equiv.), anhydrous DMF, rt, 3 h, 
74% over two steps; iii. DDQ (2 equiv.), THF/H2O (9:1), 0 ℃, 2 h, 98%; iv. POCl3/pyridine (1:4), rt, 3 h, 
18%. 	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Scheme 4.19: Mechanism of DDQ oxidation.125 
4.2.3 Synthesis of 6-bromo-4-methoxytryptamine (4.83) 
We proposed the retrosynthesis for 4.83 as shown in Scheme 4.20. Tryptamine 4.83 can be 
synthesised by alkylating its corresponding indole 4.93, which can be made by 
Leimgruber-Batcho indole synthesis from 2-methoxy-4-bromo-6-nitrotoluene (4.94). 
Finally the molecule was disconnected to the cheap starting material 2,6-dinitrotoluene 
(4.85).  
 
 
Scheme 4.20: Retrosynthesis of 6-bromo-4-methoxytryptamine (4.83). 
The actual synthesis is shown in Scheme 4.21. 2,6-dinitrotoluene (4.85) was selectively 
brominated at the 4-position with DBDMH (1,3-dibromo-5,5-dimethylhydantoin) to give 
compound 4.95. Then one of the nitro groups on 4.95 was reduced to the amine using Zinin 
reduction126 with ammonium sulfide to afford compound 4.96. The amino group was 
subsequently transformed into a hydroxyl group using Sandmeyer reaction. Reaction of 
4.96 with sodium nitrite in acidic conditions gave the diazonium salt. This salt would then 
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be quenched by water, affording the phenol derivative 2-hydroxy-4-bromo-6-nitro toluene 
(4.97).127 The first three steps all gave superb yields above 85%. The methyl group was 
then added to the molecule by deprotonating the hydroxyl group by sodium hydride, and 
alkylation using methyl iodide to give 4.94.  
At this point, Leimgruber-Batcho indole synthesis is ready to be carried out on compound 
4.94. The indole 4.93 was prepared in two steps (Scheme 4.22). The first step is to form an 
enamine intermediate. We first tested this reaction with DMFDMA 
(N,N-dimethylformamide dimethyl acetal) as the only reagent and DMF as solvent, 
refluxed at 150 ℃ overnight, but no reaction happened. We then found in the literature122 
that using copper iodide as catalyst will speed up the reaction. However, no reaction was 
detected by TLC after continuous reflux with 2 mol% of copper iodide in the reaction 
mixture. It was then found that pyrrolidine is necessary for this reaction,128 as adding 1.2 
equiv. of pyrrolidine successfully pushed the reaction and reduced the temperature required, 
from 140 ℃ to 110 ℃. The reason is probably due to the insufficient basicity of 
DMFDMA itself to deprotonate the starting material 4.94. After simple work-up, the crude 
enamine was put into the second step that would reductively cyclise the molecule into 
indole 4.93 with zinc powder and acetic acid. Overall, Leimgruber-Batcho indole synthesis 
in this case gave a moderate yield of 54% over two steps. 
Indole derivative 4.93 has to be alkylated in order to obtain tryptamine 4.83. To do so, 4.93 
was first reacted with oxalyl chloride to form intermediate 4.98, and then ammonia solution 
was added to substitute the acid chloride into amide 4.99. This reaction has been confirmed 
to be successful by both 1H and 13C NMR spectrometry. Finally, reducing the amide and 
ketone carbonyl groups should yield the target fragment tryptamine 4.83. However, the 
reduction using LiAlH4 did not happen as expected. Despite several attempts to try to make 
it work, the reactions only gave inseparable mixtures and inconclusive NMR spectra. Due 
to these difficulties, we needed another method to make the tryptamine 4.83. 
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Scheme 4.21: Synthesis of indole derivative 4.93 and failed synthesis of 4.83. i. DBDMH (0.55 equiv.), 
H2SO4, rt, 1 h, 90%; ii. pyridine (5 equiv.), ammonium sulfide (3 equiv.), EtOH, 80 ℃, 3 h, 86%; iii. sodium 
nitrite (1.1 equiv.), H2SO4, H2O, 0 ℃ then 140 ℃, 2 h, 92%; iv. sodium hydride (1.3 equiv.), CH3I (1.3 
equiv.), anhydrous DMF, 0 ℃ to rt, 4 h, 63%; v. DMFDMA (3 equiv.), pyrrolidine (1.2 equiv.), anhydrous 
DMF, 110  ℃, 4 h; vi. zinc powder (11 equiv.), AcOH/H2O (4/1), 75 ℃ to 85 ℃, 5 h, 54% over two steps; 
vii. oxalyl chloride (8 equiv.), diethyl ether, 45 ℃, overnight; viii. ammonia (0.5M in dioxane) (20 equiv.), rt, 
overnight; ix. LiAlH4 (5 equiv.), anhydrous THF, 75 ℃, overnight. 
 
 
Scheme 4.22: Conditions for Leimgruber-Batcho indole synthesis. 
A new synthetic route towards 4.83 was proposed later and shown in Scheme 4.23. Starting 
from indole 4.93, 1-dimethylamino-2-nitroethylene (DMANE) was added with TFA as 
solvent to form the alkylated product 4.102 in 67% yield as a bright red solid. This solid 
was then subject to a reduction reaction using NaBH4 and boron trifluoride diethyl etherate 
to simultaneously reduce the alkene and nitro group. The specially substituted tryptamine 
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4.83 was successfully made by this way, however difficulty was encountered in purifying 
the product, as it was too polar to be eluted out from a silica column. Therefore the yield of 
this step cannot be calculated. We could only calculate the yield later in the synthesis after 
protecting the amine with the Boc group as an overall yield of two steps. 
 
 
Scheme 4.23: Synthesis of 4.83. i. DMANE (1.0 equiv.), TFA, rt, 0.5 h, 67%; ii. NaBH4 (6 equiv.), 
BF3∙(OEt)2 (6 equiv.), THF, 70 ℃ to 90 ℃, 5 h. 
4.2.4 Synthesis of methyl 5-bromopyrrole-2-carboxylate (4.82) 
The synthesis of 4.82 only involves two steps: a bromination step from methyl 
2-pyrrolecarboxylate (4.84) and an ester hydrolysis (Scheme 4.24). The bromination at C5 
of 4.84 proved to be difficult as the compound is preferably brominated at C4 or tend to be 
di- or tri-brominated. We first applied the method reported by Trost et al.129 However, 
reacting 4.84 with 1 equiv. of NBS in low temperature did not provide us any of the desired 
bromide. Then we found in the literature that reacting 4.84 with 1.25 equiv. of bromine and 
catalytic amount of iodine in refluxing CCl4 gave approximately 33% of 5-brominated 
product.130 The reaction time needs to be short and carefully monitored, typically 20-30 
min, otherwise the undesired bromination products will dominate. In practice, we managed 
to achieve a 28% yield of 4.103 with 30 min of reaction time. The yield of the reaction is 
low because the selectivity towards 4-bromination is higher due to the electron 
withdrawing ester group (meta-directing). However, this method is the only method that is 
giving us an acceptable yield of the desired product. The low yield of this reaction did not 
concern us because this is a quick and easy reaction to reproduce, and we could remake 
4.103 without much difficulty. 
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Scheme 4.24: Synthesis of 4.82. i. Br2 (1.25 equiv.), I2 (catalytic), CCl4, 80 ℃, 0.5 h, 28%; ii. KOH (6 
equiv.), THF/H2O (3/1), 60 ℃, 48 h. 
Next, the methyl ester on 4.103 was hydrolysed by using KOH in THF and H2O. This is an 
even tougher ester to hydrolyse than 4.84, which requires heating (60 ℃) and long reaction 
time (48 h), yet sometimes we still have to remove some unconsumed starting material 
even after these harsh conditions. 
4.2.5 Combination of 4.82 and 4.83 and synthesis for the precursor of breifussin B 
After we achieved the synthesis of 4.82, we focused our attention on coupling the two 
fragments 4.82 and 4.83 together. All the steps are shown in Scheme 4.25. The coupling 
between tryptamine 4.82 and acid 4.83 was conducted using EDCI as coupling reagent to 
form the amide 4.104 with an unexpectedly low yield of 17% from 4.83. The reason for the 
poor yield was found out later as a combination of two aspects, and they will be discussed 
later. After managing to combine both fragments together, we needed to explore how to 
oxidise the indolic position to form the amido ketone moiety prior to the final cyclisation, 
according to our retrosynthesis. Similarly to the model synthesis, DDQ was chosen to carry 
out this task. However in practice, the reaction did not give the desired ketone, but was only 
able to give the alcohol product 4.105. All the efforts that try to oxidise the alcohol to the 
ketone have resulted in failure. Therefore, we need to find an alternative way to avoid this 
problem. Also, due to the poor yield of step i, all the materials were consumed before we 
can finish the synthesis. Intermediate 4.104 needed to be resynthesised, and in a better way. 
We also managed to increase the yields for tryptamine derivative 4.83 in our new efforts, 
the details will be discussed in the following sections. 
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Scheme 4.25: Further reactions towards breitfussin B. i. 4.82 (2.1 equiv.), PyBOP (1.3 equiv.), DIPEA 
(2.5 equiv.), CH2Cl2, rt, overnight, 17% from 4.83; ii. DDQ (2 equiv.), THF/H2O (9/1), rt, overnight, 52%.  
To alter and improve the synthetic route (Scheme 4.26), we discovered that the oxidation 
step could also be performed on the tryptamine itself, before coupling with acid 4.82. 
However before the oxidation, the amine needs to be protected. Hence we tried to protect 
the tryptamine derivative 4.83 with Boc, and achieved a poor yield of 20% over two steps 
from the nitroalkene 4.102. This result indicates that the reduction step (from 4.102 to 4.83) 
was inefficient as Boc protection of primary amines are usually very high yielding, 
according to both literature examples131-133 and our previous experience. Moreover, this 
would be one of the reasons why the amide coupling step was so inefficient (step i. in 
Scheme 4.25). Therefore, it would be of great help for the overall synthesis to increase the 
yield of the tryptamine derivative 4.83 before going further.  
As shown in Scheme 4.26, dividing the reduction from 4.102 to 4.83 into two steps would 
help to increase the yields of the synthesis. Instead of reducing both the alkene moiety and 
the nitro group in a single step, we first reduced the alkene alone using NaBH4 in 55% yield. 
Then 4.107 was further reduced by applying zinc powder and HCl to give the tryptamine 
4.83. Boc protection of 4.83 revealed a satisfying yield of 76% over two steps. Therefore, 
the overall synthetic yield towards Boc tryptamine 4.108 from 4.102 was 42%. Comparing 
with the yield we achieved before, the yield was more than doubled. Happy with this result, 
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we used DDQ to oxidise 4.108 and produced the desired ketone 4.109 in 78% yield. 
Deprotection of Boc group followed by coupling with the bromopyrrole acid 4.82 finally 
yielded the desired breitfussin B precursor 4.106. 
The pyrrole carboxylic acid derivative 4.82 was reported to be unstable and prone to 
decarboxylation,134 and it could be another reason for the low yield of the amide coupling 
in Scheme 4.25. Goodreid et al.135 reported a direct coupling method using a metal 
carboxylate salt of acid 4.82, as the lithium salt is much more stable than its free acid form. 
In their screening for the best coupling reagent, HBTU stood out to give the best yield and 
gave no side products. Hence we carried out experiments using this method. After careful 
preparation of the acid 4.82, it was dissolved in anhydrous DMF and 1 equiv. of LiOH was 
added and the mixture stirred vigorously for 1 h to generate the lithium salt. HBTU was 
added to the solution of the salt and stirred for another 1 h. The deprotected amine 
hydrochloride was firstly neutralised by DIPEA then added to the reaction mixture. The 
reaction was carried out at room temperature overnight to give a satisfactory yield, 59% 
from 4.109. 
	  
Scheme 4.26: Improved synthetic route of 4.106. i. NaBH4 (2 equiv.), THF, MeOH, rt, 1 h, 55%; ii. Zn 
powder (18 equiv.), MeOH, HCl (2 M), 87 ℃, 3 h; iii. Boc2O (1.1 equiv.), TEA (2 equiv.), THF, rt, overnight, 
76% over two steps; iv. DDQ (2 equiv.), THF, rt, overnight, 78%; v. HCl (4 M), rt, 1 h; vi. 4.82 (1 equiv.), 
LiOH (1 equiv.), HBTU (1.1 equiv.), DIPEA (1.1 equiv.), DMF, rt, overnight, 59% over two steps. 	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4.2.6 Final cyclisation 
The final step of the synthesis is to cyclise the amido ketone moiety in 4.106 into an 
oxazole. The basic strategy is to go through a Bischler–Napieralski type mechanism 
(Scheme 4.27) and it will be conducted by modified methods of the well-known 
Robinson-Gabriel cyclodehydration. All the methods listed in Table 4.1 belong to the same 
type of reaction, which is commonly used for carrying out this task. Unfortunately, none of 
them worked in this case whatsoever. In harsh conditions (Entry 1 and 5), the starting 
material tends to degrade, and the reaction gives an inseparable mixture. In the more widely 
used methods (Entry 2 and 3), no reaction indicated that 4.106 is unreactive which probably 
due to the higher steric hindrance than the model compound and the electron withdrawing 
effect of the side chains on the two aromatic rings. Even increasing the quality of the 
leaving group (from chloride to iodide) and using a stronger base (DBU) did not help, as 
elucidated in Entry 4. 
 
 
Scheme 4.27: The final cyclisation will go through a Bischler-Napieralski type mechanism. 
 
 
 
 
 
 
 
4.106 4.111 4.112 4.35
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Entry Reagents Solvents T (℃) Results 
1 POCl3 pyridine rt SM degradation 
2 PPh3, C2Cl6, TEA CH2Cl2 rt, 40 No reaction 
3 PPh3, I2, TEA CH2Cl2 rt, 40 No reaction 
4 PPh3, I2, DBU CH2Cl2 rt, 40 No reaction 
5 N/A H2SO4 rt SM degradation 
Table 4.1: Exploration of final cyclisation consitions. SM: starting material 
Having these disappointing results, we began to wonder if we needed to improve the 
precursor before the cyclisation. In order to circumvent the Bischler-Napieralski route we 
decided to deactivate the indole ring by protecting its amino group. This could enforce the 
Robinson-Gabriel cyclodehydration. We first tried Boc anhydride (2.2 equiv.) and DMAP 
(0.2 equiv.) to functionalise the NHs on both heterocycles (Scheme 4.28). However only 
the nitrogen on the indole was protected (compound 4.113) instead of both and this result 
was confirmed by comparing the 1H and 13C NMR spectra of 4.113 with previous 
intermediates. This protection step, in fact, would only need to use 1.1 equiv. of Boc 
anhydride to produce the same result. Cyclisation of the amido ketone moiety was carried 
out on the protected intermediate 4.113, where the POCl3/pyridine method was applied. To 
our delight, the desired oxazole derivative 4.114 was successfully formed with 52% yield. 
This result indicated that the reason the cyclisation would not happen with the “naked” 
intermediate 4.106 was probably due to the high electron density of the indole ring in the 
molecule.  
The final stage for this total synthesis would be the deprotection of the Boc protecting 
group on the indole ring. Common acidic condition (4M HCl in dioxane) was applied to 
this reaction however it did not manage to afford breitfussin B. Upon work-up, it simply 
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gave back the starting material 4.114. The starting material even precipitated from the 
reaction solution after treating with HCl in dioxane, presumably due to the protonation of 
the basic oxazole nitrogen atom by acid. Further attempts using methanol as solvent 
successfully avoided the precipitation issue, but still gave no reaction. Fortunately, 
changing the acid for deprotection from HCl to TFA gave a positive result: the Boc group 
was successfully removed and upon basifying, breitfussin B was finally synthesised in a 
yield of 91% for the last step.  
 
 
Scheme 4.28: Final cyclisation and deprotection. i. Boc2O (1.1 equiv.), DMAP (0.2 equiv.), anhydrous 
THF, rt, overnight, 66%; ii. POCl3/pyridine (1:2), rt, 1 h, 52%; iii. TFA/Et3SiH (95:5), rt, 2 h, 91%. 
Hence, the total synthesis of breitfussin B was completed in 15 linear steps with an overall 
yield of 0.8%. Both 1H and 13C NMR spectra confirmed the structure and were identical to 
the reported data (Table 4.2).112 The biological activity of breitfussin B is being evaluated 
by our collaborator at the Helmholtz Centre for Infection Research in Germany. 
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Position 𝛿C 𝛿H 
 Natural Synthetic Natural Synthetic 
1 56.0 56.0 3.95 3.96 
2 154.1 154.1   
3 104.5 104.5 6.73 6.74 
4 115.8 115.8   
5 108.5 108.5 7.25 7.26 
6 138.9 139.0   
7 113.1 113.2   
8 104.4 104.5   
9 124.1 124.1 7.77 7.78 
NH   11.73 11.73 
10 146.5 146.5   
11 123.2 123.2 7.35 7.36 
12 153.4 153.5   
13 122.3 122.3   
14 111.2 111.2 6.71 6.72 
15 112.1 112.1 6.26 6.27 
16 102.4 102.4   
NH   12.54 12.55 
Table 4.2: 1H and 13C NMR data in ppm for synthetic breitfussin B and natural breitfussin B112 in 
DMSO-d6. 
4.2.7 Biological evaluation of breitfussin B 
With the total synthesis of breitfussin B accomplished, we were ready to investigate its 
biological activity. The natural product as well as intermediates 4.106 and 4.113 were 
tested for antimicrobial and anticancer activity (Table 4.3). While all three compounds had 
weak activity against the human HCT-116 colon carcinoma cell line, breitfussin B was 
significantly active at 1 mg/mL against Gram-positive bacterial strains. The synthetic 
intermediates were less active, providing an initial SAR on the importance of the central 
oxazole ring. The weaker activity of breitfussin B against the cancer cell line suggests a 
selective toxicity for its bacterial target.  
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Cell line or strain MIC (mg/mL) 
 4.106 4.113 4.35 
HCT-116 colon carcinoma 28.3 ± 4.9 29.5 ± 0.6 23.0 ± 4.0 
Bacillus subtilis DSM-10 > 64 > 64 2 
Micrococcus luteus DSM-1790 16-32 4 1 
Staphylococcus aureus Newman 8 > 64 2 
Mycobacterium smegmatis mc2155 64 > 64 64 
Chromobacterium violaceum DSM-30191 > 64 > 64 > 64 
Pseudomonas aeruginosa PA14 > 64 > 64 > 64 
Escherichia coli DSM-1116 > 64 > 64 > 64 
Escherichia coli (TolC-deficient) 16 > 64 8 
Candida albicans DSM-1665 > 64 > 64 > 64 
Pichia anomala DSM-6766 > 64 > 64 8 
Mucor hiemalis DSM-2656 > 64 > 64 > 64 
Table 4.3: Biological evaluation of breitfussin B (4.35) and synthetic intermediates. 
We tested breitfussin B against sensitive and MRSA/VISA Staphylocccus aureus strains 
with ampicillin and vancomycin as positive controls (Table 4.4). The natural product 
retains its activity in the resistant strains, indicating that breitfussin B is a promising lead 
for the future development of novel antibiotics. 
 
Strain MIC (mg/mL) 
 4.35 ampicillin vancomycin 
S. aureus Newmana 1-2 0.5 0.5 
S. aureus N315b 1-2 64 0.25 
S. aureus Mu50c 2 64 4 
aMethicillin sensitive strain  bMRSA strain  cMRSA/VISA strain 
Table 4.4: Biological evaluation of breitfussin B (4.35) against S. aureus strains. 
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4.3 Conclusions and Future Work 
The total synthesis of breitfussin B was successfully completed, and the synthetic product 
is being tested for biological activities. Several difficulties were encountered in the 
synthesis, and we have overcome all of them. Firstly, in the synthesis of tryptamine 
derivative 4.83, it was found out that reducing the double bond and nitro group separately 
gives a better overall yield than reducing them together in a single step. Secondly, 
oxidation of the indolic position does not work on 4.104, however it will work on 4.108 
before it is coupled with 4.82. Thirdly, it would be preferable to couple the acid 4.82 in its 
lithium salt form rather than the free acid as the free acid is found to be unstable. Finally, 
the oxazole cyclisation step proved to be tricky, with failures from five different methods. 
Fortunately, by protecting the indole NH with Boc group, the cyclisation was successful.  
Since no biological data were reported in the structure elucidation paper,112 we will be 
testing it for biological activities. Currently, we have found out that breitfussin B is a good 
anti-microbial agent against Gram-positive bacterial strains. In the future, we will be 
looking at the synthesis of breitfussin A. We have envisioned that to install the iodine into 
the molecule might be possible at the end of the synthesis, and further investigations will 
need to be carried out. 
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4.4 Experimental 
4.4.1 General Experimental Methods 
Chemicals and general reagents were purchased from commercial suppliers, and unless 
stated otherwise were used without further purification. Anhydrous solvents were 
purchased and stored under argon atmosphere. Where necessary, solvents and reagents 
were purified according to standard methods. 
All air and/or moisture sensitive reactions were carried out under inert atmosphere of argon 
gas, in oven-dried glassware. Reaction were monitored by TLC using pre-coated aluminum 
plates coated with 0.14 mm of silica gel 60 containing a fluorescence indicator active at 
254 nm (Merck, Kieselgel 60 F254). Visualisation was carried out under UV-light (𝜆  254 nm) 
and/or by staining with, most commonly, cerium-ammonium molybdate or 10% aqueous 
KMnO4 or ninhydrin followed by heating. Flash column chromatographies was performed 
with silica gel (MN Kieselgel 60, 40-63 𝜇m,230-400 Mesh ASTM). ‘Brine’ refers to a 
satuated aqueous solution of sodium chloride. The term in vacuo refers to the removal of 
solvents by the means of evaporation at reduced pressure, using a Buchi rotary evaporator. 
Melting points were obtained in open capillary tubes on an Electrothermal Melting Point 
Apparatus and are uncorrected. Infrared spectra were recorded on a PerkinElmer Spectrum 
400 FT-IR/FT-FIR spectrometer. Absorptions were recorded in wave numbers (cm-1). 1H 
NMR and 13C NMR were recorded on Bruker AC400 spectrometers (400 MHz for 1H and 
100 MHz for 13C). Spectral data were reprocessed using ACD Labs software or 
MESTRENOVA and referenced to the residual solvent peak (CDCl3, CD3OD or 
DMSO-d6). Characteristic splitting patterns due to spin spin coupling are expressed as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. Chemical 
shifts are given in ppm and coupling constants are measured in Hz. 
Low-resolution mass spectra were obtained using LC-MS on a Shimadzu LCMS 2010EV 
spectrometer or MALDI-TOF on a Kratos Axima CFR spectrometer. High-resolution mass 
spectra were collected by EPSRC National Mass Spectrometry Facility (Swansea) using a 
Thermofisher LTQ Orbitrap XL mass spectrometer. 
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4.4.2 Experimental Details for Chapter 4 
N-(2-(1H-Indol-3-yl)ethyl)-1H-pyrrole-2-carboxamide (4.88) 
 
To a solution of methyl pyrrole-2-carboxylate (4.84) (500 mg, 4 mmol, 1 equiv.) in 10 mL 
of a mixture of THF/water (3:1) was added KOH (673 mg, 12 mmol, 3 equiv.). The 
mixture was stirred at 55 ℃ overnight. The solution was diluted with water (10 mL), and 
acidified to pH 1-2 with saturated 2 N HCl aqueous solution. The aqueous layer was 
extracted with EtOAc (30 mL  ×  3). The combined organic layer was dried over MgSO4, 
filtered, and concentrated in vacuo to provide acid 4.87 and used in the next step without 
further purification. 
To a solution of acid 4.87 (4 mmol, 1 equiv.) in anhydrous DMF (10 mL) was added 
tryptamine (765 mg, 4.8 mmol, 1.2 equiv.), EDCI (1 g, 5.2 mmol, 1.3 equiv.), HOBt (110 
mg, 0.8 mmol, 0.2 equiv.) and DIPEA (1.5 mL, 8.8 mmol, 2.2 equiv.). The resulting 
mixture was stirred at rt for 3 h. Solvent was removed in vacuo, and the residue was 
dissolved in EtOAc (50 mL), and washed with 2 N HCl and saturated NaHCO3 (50 mL 
each), filtered, then dried over MgSO4 and concentrated in vacuo. The resulting residue 
was purified by column chromatography (2:3 to 3:2 EtOAc/petroleum ether) to afford 4.88 
as a cream colored solid (750 mg, 74% over two steps); 1H NMR (400 MHz, CDCl3) 𝛿: 
9.56 (brs, 1H, NH); 8.20 (brs, 1H, NH), 7.57 (d, 1H, J = 7.8 Hz, H-7), 7.31 (d, 1H, J = 8 
Hz, H-10), 7.14 (td, J = 7.6, 1.1 Hz, H-9), 7.06 (m, 1H, H-8), 6.99 (s, 1H, H-6), 6.82 (td, 
1H, J = 2.7, 1.3 Hz, H-1), 6.32 (m, 1H, H-3), 6.11 (dt, 1H, J = 3.6, 2.6 Hz, H-2), 6.06 (brs, 
1H, NH), 3.68 (m, 2H, H-4), 2.99 (t, 2H, J = 6.5 Hz, H-5) ppm. 
The spectroscopic data are consistent with those 136 reported in the literature. 
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N-(2-(1H-Indol-3-yl)-2-oxoethyl)-1H-pyrrole-2-carboxamide (4.89) 
 
To a stirred solution of N-(2-(1H-indol-3-yl)ethyl)-1H-pyrrole-2-carboxamide (4.88) (107 
mg, 0.42 mmol, 1 equiv.) in 5 mL of a mixture of THF and water (9:1) that was cooled to 0 ℃ was added DDQ (192 mg, 0.85 mmol, 2 equiv.), and the resulting solution was stirred 
for 2 h at 0 ℃. The mixture was diluted with EtOAc (20 mL), then washed with saturated 
NaHCO3 (20 mL). The organic layer was dried with MgSO4, filtered, and concentrated in 
vacuo to afford 4.89 as brown solid (110 mg, 98%); mp: decomposes at 250 °C; IR (neat): 
3411, 3207, 1683, 1627 cm-1; 1H NMR (400 MHz, DMSO-d6) 𝛿: 12.01 (brs, 1H, NH), 
11.47 (brs, 1H, NH), 8.48 (d, 1H, J = 3.1 Hz, NH), 8.28 (m, 1H, H-5), 8.17 (m, 1H, H-1), 
7.49 (m, 1H, H-4), 7.21 (m, 2H, H-2 and H-3), 6.88 (td, J = 2.4, 1.5 Hz, H-9), 6.86 (ddd, 
1H, J = 3.6, 2.4, 1.5 Hz, H-7), 6.12 (dt, J = 3.6, 2.4 Hz, H-8), 4.60 (d, 2H, J = 5.9 Hz, H-6) 
ppm; 13C NMR (100 MHz, DMSO-d6) 𝛿: 190.7, 160.1, 136.4, 133.5, 126.1, 125.4, 122.8, 
121.8, 121.4, 121.1, 114.0, 112.1, 110.2, 108.6, 45.6 ppm; ES+ MS m/z 289 ([M+Na]+, 
100%); HRMS m/z calculated for C15H14N3O2 [M+H]+ 268.1086, found 268.1084. 
 
5-(1H-Indol-3-yl)-2-(1H-pyrrol-2-yl)oxazole (4.86) 
 
POCl3 (117 µμ L, 1.26 mmol, 5.4 equiv.) was added to a solution of 
N-(2-(1H-indol-3-yl)-2-oxoethyl)-1H-pyrrole-2-carboxamide (4.89) (61 mg, 0.229 mmol, 1 
equiv.) in pyridine (2.5 mL) at rt. The resulting mixture was stirred for 3 h at rt. The 
mixture was washed with 2 N HCl and saturated NaHCO3 (20 mL each). The organic layer 
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was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by 
column chromatography (1:4 EtOAc/petroleum ether) to afford 4.86 as white solid (10 mg, 
18%); mp: 216-218 °C; IR (neat): 3350, 3176, 3141, 1630, 1615 cm-1; 1H NMR (400 MHz, 
DMSO-d6) 𝛿: 11.84 (brs, 1H, NH), 11.58 (brs, 1H, NH), 7.95 (d, 1H, J = 7.8 Hz, H-1), 
7.84 (d, 1H, J = 2.5 Hz, H-5), 7.49 (d, 1H, J = 8 Hz, H-4), 7.46 (s, 1H, H-6), 7.20 (m, 2H, 
H-2 and H-3), 6.99 (td, 1H, J = 2.6, 1.5 Hz, H-9), 6.77 (ddd, 1H, J = 3.4, 2.6, 1.5 Hz, H-7), 
6.23 (dt, 1H, J = 3.4, 2.6 Hz, H-8) ppm; 13C NMR (100 MHz, DMSO-d6) 𝛿: 154.5, 146.6, 
136.9, 124.0, 123.6, 122.6, 122.0, 120.6, 120.5, 120.4, 120.1, 112.5, 109.83, 109.80, 104.4 
ppm; ES+ MS m/z 250 ([M+H]+ 100%); HRMS m/z calculated for C15H12N3O [M+H]+ 
250.0980, found 250.0977. 
 
5-Bromo-2-methyl-1,3-dinitrobenzene (4.95) 
 
2,6-dinitrotoluene (4.85) (2 g, 11 mmol, 1 equiv.) was suspended in concentrated H2SO4 (8 
mL). DBDMH (1.72 g, 6 mmol, 0.55 equiv.) was added portionwise to the mixture over 10 
min. After a slight exotherm, the mixture went into solution briefly, and then a precipitate 
was formed. The mixture was stirred at rt for 1 h, and the solid was filtered off to afford 
4.95 as bright yellow solid (2.57 g, 90%); 1H NMR (400 MHz, CDCl3) 𝛿: 8.06 (s, 2H, H-2 
and H-3), 2.46 (s, 3H, H-1) ppm. 
The spectroscopic data are consistent with those 137 reported in the literature. 
 
5-Bromo-2-methyl-3-nitroaniline (4.96) 
 
A suspension of 5-bromo-2-methyl-1,3-dinitrobenzene (4.95) (2.47 g, 9.46 mmol, 1 equiv.) 
in EtOH (20 mL) and pyridine (3.82 mL, 47.3 mmol, 5 equiv.) was heated to reflux. A 20% 
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solution of ammonium sulfide (9.67g, 28.4 mmol, 3 equiv.) was further diluted with 20 mL 
of water then added via a pressure equalised addition funnel to the refluxing mixture over 1 
h, then the mixture was further refluxed for 2 h. The reaction mixture was cooled to rt, then 
poured onto cold water. The bright yellow precipitated solid was filtered off and dried in 
vacuo to give 4.96 as a yellow solid (1.88 g, 86%); 1H NMR (400 MHz, CDCl3) 𝛿: 7.23 (d, 
1H, J = 1.9 Hz, H-3), 6.93 (d, 1H, J = 1.8 Hz, H-2), 3.90 (brs, 2H, NHs), 2.12 (s, 3H, H-1) 
ppm. 
The spectroscopic data are consistent with those 137 reported in the literature. 
 
5-Bromo-2-methyl-3-nitrophenol (4.97) 
 
To a suspension of 5-bromo-2-methyl-3-nitroaniline (4.96) (1.78g, 7.69 mmol, 1 equiv.) in 
a mixture of concentrated H2SO4 (3 mL) and water (9 mL) that was cooled to 0 ℃ was 
added a solution of sodium nitrite (584 mg, 8.46 mmol, 1.1 equiv.) in water (10 mL) 
dropwise. The mixture was stirred for 1 h at 0 ℃, then transferred into a mixture of 
concentrated H2SO4 (9 mL) and water (6 mL) heated at 140 ℃ then refluxed for 1 h. The 
mixture was cooled slightly then poured onto cold water, followed by extraction with ether. 
The organic phase was dried over MgSO4, filtered and concentrated in vacuo to afford 4.97 
as an orange solid (1.64 g, 92%); 1H NMR (400 MHz, CDCl3) 𝛿: 7.51 (d, 1H, J = 1.9 Hz, 
H-3), 7.10 (d, 1H, J = 1.9 Hz, H-2), 2.27 (s, 3H, H-1) ppm. 
The spectroscopic data are consistent with those 137 reported in the literature. 
 
5-Bromo-1-methoxy-2-methyl-3-nitrobenzene (4.94) 
 
To a solution of 5-bromo-2-methyl-3-nitrophenol (4.97) (1.62 g, 6.97 mmol, 1 equiv.) in 
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anhydrous DMF (20 mL) that was cooled to 0 ℃ was added sodium hydride (60% in 
mineral oil, 278 mg, 9.06 mmol, 1.3 equiv.), and the resulting slurry was stirred at 0 ℃ for 
1 h before CH3I (0.56 mL, 9.06 mmol, 1.3 equiv.) was added. The mixture was further 
stirred for 3 h while warm to rt. Solvent was removed in vacuo, and the residue was 
purified by column chromatography (1:9 EtOAc/petroleum ether) to afford 4.94 as a yellow 
solid (1.07 g, 63%); 1H NMR (400 MHz, CDCl3) 𝛿: 7.48 (d, 1H, J = 1.9 Hz, H-4), 7.07 (d, 
1H, J = 1.8 Hz, H-3), 3.82 (s, 3H, H-2), 2.23 (s, 3H, H-1) ppm. 
The spectroscopic data are consistent with those 138 reported in the literature. 
 
6-Bromo-4-methoxy-1H-indole (4.93) 
 
To a solution of 5-bromo-1-methoxy-2-methyl-3-nitrobenzene (4.94) (1.64 g, 6.67 mmol, 1 
equiv.) in anhydrous DMF (20 mL) was added DMFDMA (2.66 mL, 20 mmol, 3 equiv.) 
and pyrrolidine (0.66 mL, 8 mmol, 1.2 equiv.). The resulting mixture was stirred at 110 ℃ 
for 4 h. Solvent was removed in vacuo, and the residue was dissolved in diethyl ether (50 
mL) and washed with water and brine (50 mL each). The organic layer was dried over 
MgSO4, filtered, and concentrated in vacuo to give the enamine intermediate as dark red oil 
and used in the next step without further purification. 
To a solution of the enamine intermediate (6.67 mmol, 1 equiv.) in 25 mL of a mixture of 
acetic acid and water (4:1) that was heated at 75 ℃ was added zinc powder (4.8 g, 73.37 
mmol, 11 equiv.) portion wise over 1 h. The mixture was heated to 85 ℃ and stirred for 
further 4 h. The mixture was diluted with water (30 mL) and extracted with diethyl ether 
(50 mL  ×  3). The combined organic layer was dried over MgSO4, filtered, and concentrated 
in vacuo. The residue was purified by column chromatography (1:9 EtOAc/petroleum ether) 
to afford 4.93 as a cream colored solid (818 mg, 54% over two steps); mp: 48-50 °C; IR 
(neat): 3087, 1598, 1523 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 8.07 (brs, 1H, NH), 7.11 (m, 
1H, H-3), 7.00 (dd, 1H, J = 3.2, 2.2 Hz, H-5), 6.57 (d, 1H, J = 1.4 Hz, H-2), 6.54 (ddd, 1H, 
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J = 3.2, 2.2, 0.9 Hz, H-4), 3.865 (s, 3H, H-1) ppm; 13C NMR (100 MHz, DMSO-d6 ) 𝛿: 
153.6, 137.4, 122.9, 117.7, 115.7, 107.5, 103.9, 100.2, 55.6 ppm. 
 
(E)-6-Bromo-4-methoxy-3-(2-nitrovinyl)-1H-indole (4.102) 
 
To a solution of 6-bromo-4-methoxy-1H-indole (4.93) (1.22 g, 5.42 mmol, 1 equiv.) in 
TFA (7 mL) was added DMANE (629 mg, 4.12 mmol, 1 equiv.). The mixture was stirred at 
rt for 0.5 h. Saturated aqueous NaHCO3 (50 mL) was added dropwise to neutralise the 
reaction mixture. The red precipitate was filtered, dissolved in EtOAc (50 mL), dried over 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
(1:4 EtOAc/petroleum ether to neat EtOAc) to afford 4.102 as a bright red solid (1.07 g, 
67%); mp: decomposes at 140 °C; IR (cm-1): 3675, 3415, 3294, 2293, 1680, 1635 cm-1; 1H 
NMR (400 MHz, DMSO-d6) 𝛿: 8.50 (dd, 1H, J = 13.3, 0.5 Hz, H-5), 8.26 (s, 1H, H-4), 
8.08 (d, 1H, J = 13.3 Hz, H-6), 7.30 (d, 1H, J = 1.5 Hz, H-3), 6.88 (d, 1H, J = 1.5 Hz, H-2), 
3.98 (s, 3H, H-1), ppm; 13C NMR (100 MHz, DMSO-d6) 𝛿: 154.5, 139.5, 135.2, 133.4, 
132.9, 116.7, 114.9, 109.2, 108.4, 106.5, 56.4 ppm; ES- MS m/z 295 ([M-H]- 100%); 
HRMS m/z calculated for C11H10BrN2O3 [M+H]+ 296.9875, found 296.9874. 
 
Methyl 5-bromo-1H-pyrrole-2-carboxylate (4.103) 
 
To a solution of methyl pyrrole-2-carboxylate (4.84) (1 g, 8 mmol, 1 equiv.) in CCl4 (60 ml) 
was added iodine (1-2 mg), and the resulting mixture was heated to reflux. A solution of 
bromine (0.41 mL, 10 mmol, 1.25 equiv.) in CCl4 (20 mL) was added dropwise to the 
reaction mixture, and the mixture was refluxed for 0.5 h. The mixture was washed with sat. 
Na2S2O3 aqueous solution (50 mL), then extracted with CH2Cl2 (30 mL   ×  3). The 
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combined organic layer was dried over MgSO4, filtered and concentrated in vacuo. The 
residue was purified with column chromatography (neat petroleum ether to 5% 
EtOAc/petroleum ether) to afford 4.103 as a white solid (455 mg, 28%); 1H NMR (400 
MHz, CDCl3) 𝛿: 9.59 (brs, 1H, NH), 6.76 (dd, 1H, J = 3.8, 2.7 Hz, H-2), 6.14 (dd, 1H, J = 
3.8, 2.6 Hz, H-1), 3.80 (s, 3H, H-3) ppm. 
The spectroscopic data are consistent with those 129 reported in the literature. 
 
6-Bromo-4-methoxy-3-(2-nitroethyl)-1H-indole (4.107) 
 
To a stirred solution of 4.102 (946 mg, 3.19 mmol, 1 equiv.) in 15 mL of a mixture of 
THF/MeOH (5:1) was added NaBH4 (241 mg, 6.38 mmol, 2 equiv.), and the resulting 
mixture was stirred at rt under argon for 1.5 h. The mixture was diluted with H2O (30 mL), 
acidified with 2 N HCl to pH 1-2 then extracted with CH2Cl2 (50 mL  ×  3). The combined 
organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by column chromatography (1:9 to 2:3 EtOAc/petroleum ether) to afford 4.107 as 
a white solid (523 mg, 55%); mp: 98-100 °C; IR (neat): 3407, 1605, 1585, 1543 cm-1; 1H 
NMR (400 MHz, CDCl3) 𝛿: 7.99 (brs, 1H, NH), 7.15 (d, 1H, J = 1.5 Hz, H-3), 6.91 (d, 1H, 
J = 2.5 Hz, H-4), 6.64 (d, 1H, J = 1.3 Hz, H-2), 4.70 (t, 2H, J = 7 Hz, H-6), 3.94 (s, 3H, 
H-1), 3.51 (t, 2H, J = 7.2 Hz, H-5) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 154.4, 138.3, 
122.1, 116.2, 115.8, 110.8, 107.8, 104.0, 76.8, 55.5, 25.3 ppm; ES+ MS m/z 321 ([M+Na]+ 
100%); HRMS m/z calculated for C11H12BrN2O3 [M+H]+ 299.0031, found 299.0032. 
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tert-Butyl (2-(6-bromo-4-methoxy-1H-indol-3-yl)ethyl)carbamate (4.108) 
 
Method 1: 
To a suspension of NaBH4 (201 mg, 5.33 mmol, 6 equiv.) in anhydrous THF (3 mL) was 
added BF3.(OEt)2 (0.66 mL, 5.33 mmol, 6 equiv.), and the mixture was stirred at 0 ℃ for 
0.5 h. A solution of (E)-6-bromo-4-methoxy-3-(2-nitrovinyl)-1H-indole (4.102) (263 mg, 
0.89 mmol, 1 equiv.) in anhydrous THF (4 mL) was added to the mixture dropwise at 0 ℃. 
Ice bath was removed, and the mixture was refluxed for 3 h. 2 N HCl (5 mL) was added 
dropwise to quench the reaction and the mixture was further heated at 85 ℃ for 2 h. The 
mixture was cooled to rt, then THF was removed in vacuo. The residue was diluted with 
water (10 mL), then washed with EtOAc (20 mL  ×  3). The aqueous layer was basified with 
1 N NaOH, then extracted with EtOAc (20 mL  ×  3). The combined organic layer was dried 
over MgSO4, filtered and concentrated in vacuo to afford the tryptamine 4.83 as a yellow 
solid (119 mg) and was used in the next step without further purification. 
To a stirred solution of 4.83 (119 mg, 0.44 mmol, 1 equiv.) in THF (5 mL) was added 
Boc2O (106 mg, 0.49 mmol, 1.1 equiv.) and TEA (0.12 mL, 0.89 mmol, 2 equiv.), and the 
resulting mixture was stirred at rt overnight. Solvent was removed in vacuo, and the residue 
was dissolved in CH2Cl2 (20 mL), then washed with 2 N HCl (20 mL). The organic layer 
was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by 
column chromatography (1:9 to 3:7 EtOAc/petroleum ether) to afford 4.108 as a white 
solid (72 mg, 22% over two steps). 
 
Method 2: 
To a solution of 6-bromo-4-methoxy-3-(2-nitroethyl)-1H-indole (4.107) (523 mg, 1.75 
mmol, 1 equiv.) in 20 mL of a mixture of MeOH and 2 N HCl (1:1) was added Zinc 
powder (2.06 g, 31.5 mmol, 18 equiv.), and the resulting suspension was refluxed at 87 ℃ 
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for 3 h. The excess of Zinc was filtered, and MeOH was removed in vacuo. The mixture 
was basified with 1 N NaOH, then extracted with EtOAc (50 mL  ×  3). The combined 
organic layer was dried over MgSO4, filtered and concentrated in vacuo to afford 
tryptamine 4.83 as a yellow solid (460 mg) and used in the next step without further 
purification. 
To a stirred solution of 4.83 (460 mg, 1.71 mmol, 1 equiv.) in THF (5 mL) was added 
Boc2O (410 mg, 1.88 mmol, 1.1 equiv.) and TEA (0.48 mL, 3.43 mmol, 2 equiv.), and the 
resulting mixture was stirred at rt overnight. Solvent was removed in vacuo, and the residue 
was dissolved in CH2Cl2 (50 mL), then washed with 2 N HCl (50 mL). The organic layer 
was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by 
column chromatography (1:9 to 3:7 EtOAc/petroleum ether) to afford 4.108 as a white 
solid (505 mg, 76% over two steps); mp: 102-104 °C; IR (neat): 3290, 1682, 1651, 1505 
cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 8.46 (brs, 1H, NH), 7.12 (d, 1H, J = 1.5 Hz, H-3), 
6.81 (brs, 1H, H-4), 6.59 (d, 1H, J = 1.3 Hz, H-2), 3.91 (s, 3H, H-1), 3.43 (t, 2H, J = 6.7 
Hz, H-5), 3.00 (t, 1H, J = 6.7 Hz, H-6), 1.42 (s, 9H, tBu) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 156.3, 154.7, 138.4, 121.6, 116.3, 115.6, 113.7, 107.7, 103.6, 79.2, 55.4, 42.1, 28.4 (3C), 
27.0 ppm; ES+ MS m/z 391 ([M+Na]+ 100%); HRMS m/z calculated for C16H22BrN2O3 
[M+H]+ 369.0813, found 369.0812. 
 
tert-Butyl (2-(6-bromo-4-methoxy-1H-indol-3-yl)-2-oxoethyl)carbamate (4.109) 
 
To a stirred solution of tert-butyl (2-(6-bromo-4-methoxy-1H-indol-3-yl)ethyl)carbamate 
(4.108) (595 mg, 1.62 mmol, 1 equiv.) in 15 mL of a mixture of THF/H2O (9:1) was added 
DDQ (808 mg, 3.56 mmol, 2.2 equiv.), and the resulting mixture was stirred overnight at rt. 
THF was removed in vacuo, and the residure was dissolved in EtOAc (50 mL). The 
mixture was washed with saturated NaHCO3 (50 mL), dried over MgSO4, filtered and 
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concentrated in vacuo. The residue was purified by column chromatography (3:7 to 3:2 
EtOAc/petroleum ether) to afford 4.109 as a brown solid (485 mg, 78%); mp 138-140 °C; 
IR (neat): 3390, 3330, 1661, 1518 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 9.86 (brs, 1H, NH), 
7.67 (d, 1H, J = 2.8 Hz, H-4), 7.10 (d, 1H, J = 1.3 Hz, H-3), 6.61 (s, 1H, H-2), 5.52 (brs, 
1H, NH), 4.53 (d, 2H, J = 5.3 Hz, H-5), 3.85 (s, 3H, H-1), 1.42 (s, 9H, tBu) ppm; 13C NMR 
(100 MHz, CDCl3) 𝛿: 190.9, 156.6, 153.5, 138.9, 131.6, 117.2, 116.4, 113.2, 108.3, 106.6, 
79.9, 55.7, 49.8, 28.5 (3C) ppm; ES+ MS m/z 405 ([M+Na]+ 100%); HRMS m/z calculated 
for C16H20BrN2O4 [M+H]+ 383.0606, found 383.0596. 
 
5-Bromo-N-(2-(6-bromo-4-methoxy-1H-indol-3-yl)-2-oxoethyl)-1H-pyrrole-2-carboxa
mide (4.106) 
 
To a solution of methyl 5-bromo-1H-pyrrole-2-carboxylate (4.103) (127 mg, 0.63 mmol, 1 
equiv.) in 10 mL of a mixture of THF/water (3:1) was added KOH (210.4 mg, 3.75 mmol, 
6 equiv.). The mixture was stirred at 60 ℃ for 48 h. The solution was diluted with water 
(10 mL), and acidified to pH 3-4 with 2 N HCl aqueous solution. The aqueous layer was 
extracted with EtOAc (30 mL  ×  3) and the combined organic layer was dried over MgSO4, 
filtered, and concentrated in vacuo (temperature set at rt) to provide corresponding acid 
4.82 and used in the next step without further purification. 
tert-Butyl (2-(6-bromo-4-methoxy-1H-indol-3-yl)-2-oxoethyl)carbamate (4.109) (239 mg, 
0.63 mmol) was dissolved in HCl solution (4.0 M in dioxane, 10 mL), and the solution was 
stirred for 2 h at rt. The mixture was co-evaporated with CH3CN, then CH2Cl2 twice each 
to afford the corresponding amine hydrochloride 4.110 and used in the next step without 
further purification. 
To a solution of 4.82 (0.63 mmol, 1 equiv.) in anhydrous DMF (5 mL) was added LiOH 
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(15 mg, 0.63 mmol, 1 equiv.), and the mixture was vigorously stirred at rt for 1 h. HBTU 
(261 mg, 0.69 mmol, 1.1 equiv.) was added into the mixture and stirred for a further 1 h. In 
another flask, 4.110 (0.63 mmol, 1 equiv.) was dissolved in anhydrous DMF (5 mL). 
DIPEA (0.12 mL, 1.1 equiv.) was added to neutralise the salt, and the mixture was 
transferred to the flask containing the activated acid. The resulting mixture was stirred at rt 
overnight. Solvent was removed in vacuo, the residue was dissolved in EtOAc (30 mL) and 
washed with 2 N HCl and saturated NaHCO3 (30 mL each). The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (1:1 to 4:1 EtOAc/petroleum ether) to afford 4.106 as a white solid (167 
mg, 59% from 4.109); mp: 128-130 °C; IR (neat): 3404, 1682, 1556, 1510 cm-1; 1H NMR 
(400 MHz, CDCl3) 𝛿: 12.27 (brs, 1H, NH), 12.09 (brs, 1H, NH), 8.26 (t, 1H, J = 5.8 Hz, 
NH), 8.18 (d, 1H, J = 3 Hz, H-4), 7.28 (d, 1H, J = 1.5, H-3), 6.84 (m, 2H, H-2 and H-6), 
6.18 (dd, 1H, J = 3.8, 2.5 Hz, H-7), 4.65 (d, 2H, J = 5.8 Hz, H-5), 3.90 (s, 3H, H-1) ppm; 
13C NMR (100 MHz, CDCl3) 𝛿: 190.4, 160.2, 154.4, 139.4, 133.1, 128.5, 116.3, 116.2, 
113.9, 112.4, 111.4, 108.6, 106.3, 102.8, 56.2, 47.9 ppm; ES+ MS m/z 478 ([M+Na]+ 
100%); HRMS m/z calculated for C16H14Br2N3O3 [M+H]+ 453.9401, found 453.9396. 
 
tert-Butyl-6-bromo-3-((5-bromo-1H-pyrrole-2-carbonyl)glycyl)-4-methoxy-1H-indole-
1-carboxylate (4.113) 
 
To a stirred solution of 4.106 (350 mg, 0.77 mmol, 1 equiv.) in anhydrous THF (10 mL) 
was added Boc2O (186 mg, 0.85 mmol, 1.1 equiv.) and DMAP (9.5 mg, 77.4 𝜇mol, 0.1 
equiv.), and the resulting reaction mixture was stirred at rt overnight. Solvent was removed 
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in vacuo, the residue was redissolved in CH2Cl2 (30 mL) and washed with 2 N HCl (30 
mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The 
residue was purified by column chromatography (1:5 to 1:1 EtOAc/petroleum ether) to 
afford 4.113 as a white solid (286 mg, 66%); mp: 170-172 °C; IR (neat): 3407, 3149, 1743, 
1635, 1507 cm-1; 1H NMR (400 MHz, CDCl3) 𝛿: 10.40 (brs, 1H, NH), 8.15 (s, 1H, H-4), 
8.12 (d, 1H, J = 1.5 Hz, H-3), 7.00 (t, 1H, J = 4.4 Hz, NH), 6.93 (d, 1H, J = 1.5 Hz, H-2), 
6.67 (dd, 1H, J = 3.8, 2.7 Hz, H-6), 6.20 (dd, 1H, J = 3.8, 2.7 Hz, H-7), 4.95 (d, 1H, J = 
4.5 Hz, H-5), 3.99 (s, 3H, H-1), 1.69 (s, 9H, tBu) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 
191.4, 160.1, 153.3, 148.3, 137.7, 131.1, 126.9, 119.9, 119.2, 114.9, 112.0, 111.8, 111.2, 
109.1, 103.7, 86.1, 56.0, 49.2, 28.0 (3C) ppm; ES+ MS m/z 578 ([M+Na]+ 100%); HRMS 
m/z calculated for C21H22Br2N3O5 [M+H]+ 553.9926, found 553.9914. 
 
tert-Butyl-6-bromo-3-(2-(5-bromo-1H-pyrrol-2-yl)oxazol-5-yl)-4-methoxy-1H-indole-1
-carboxylate (4.114) 
 
To a stirred solution of 4.113 (280 mg, 0.51 mmol) in anhydrous pyridine (12 mL) was 
added POCl3 (6 mL) dropwise, and the resulting mixture was stirred for 1 h at rt under 
argon. The mixture was diluted with EtOAc (50 mL), then washed with a cold sat. NaHCO3 
solution (50 mL). The organic layer was then washed with 2 N HCl (50 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (1:5 to 3:7 EtOAc/petroleum ether) to afford 4.114 as a white solid (140 
mg, 52%); mp: 174-176 °C; IR (neat): 3083, 1715, 1617, 1574, 1510 cm-1; 1H NMR (400 
MHz, CDCl3) 𝛿: 11.04 (brs, 1H, NH), 8.00 (s, 1H, H-3), 7.74 (s, 1H, H-5), 7.55 (s, 1H, 
H-4), 6.78 (d, 1H, J = 1.5 Hz, H-2), 6.76 (d, 1H, J = 3.7 Hz, H-6), 6.20 (d, 1H, J = 3.7 Hz, 
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H-7), 3.89 (s, 3H, H-1), 1.64 (s, 9H, tBu) ppm; 13C NMR (100 MHz, CDCl3) 𝛿: 154.8, 
153.5, 149.0, 144.8, 137.5, 126.0, 122.2, 121.8, 119.4, 115.4, 112.4, 112.0, 111.8, 109.0, 
108.1, 103.1, 85.1, 55.6, 28.1 (3C) ppm; ES+ MS m/z 538 ([M+Na]+ 100%); HRMS m/z 
calculated for C21H20Br2N3O4 [M+H]+ 535.9820, found 535.9818. 
 
Breitfussin B (4.35) 
 
Breitfussin B precursor 4.114 (119 mg, 0.22 mmol) was dissolved in TFA/Et3SiH (19:1, 4 
mL) and the resulting mixture was stirred at rt for 2 h. Solvents were evaporated under 
reduced pressure, and the residue was suspended in EtOAc (30 mL) and washed with sat. 
aqueous NaHCO3 (30 mL). The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo. The resulting residue was purified by column chromatography (1:4 
to 3:7 EtOAc/petroleum ether) to afford breitfussin B (4.35) as a white solid (90 mg, 93%); 
mp: 204-206 °C; IR: 3445, 3168, 1626, 1601, 1581 cm-1; 1H NMR (400 MHz, DMSO-d6) 𝛿: 12.55 (brs, 1H, NH), 11.73 (d, 1H, J = 2 Hz, NH), 7.78 (d, 1H, J = 2.5 Hz, H-4), 7.36 (s, 
1H, H-5), 7.26 (d, 1H, J = 1.5 Hz, H-3), 6.74 (d, 1H, J = 1.5 Hz, H-2), 6.72 (d, 1H, J = 3.7 
Hz, H-6), 6.27 (d, 1H, J = 3.7 Hz, H-7), 3.96 (s, 3H, H-1) ppm; 13C NMR (100 MHz, 
DMSO-d6) 𝛿: 154.1, 153.5, 146.5, 139.0, 124.1, 123.2, 122.3, 115.8, 113.2, 112.2, 111.2, 
108.5, 104.5, 104.4, 102.4, 56.0 ppm; ES+ MS m/z 438 ([M+H]+ 100%); HRMS m/z 
calculated for C16H12Br2N3O2 [M+H]+ 435.9296, found 435.9292. 
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Appendix: NMR Spectra 
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1H NMR spectrum of 2.34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 2.24 
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13C NMR spectrum of 2.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 2.45 
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1H NMR spectrum of 2.47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 2.48 
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13C NMR spectrum of 2.48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 2.46 
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1H NMR spectrum of 2.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 2.25 
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1H NMR spectrum of 2.26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 2.57 
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13C NMR spectrum of 2.57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.30 
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13C NMR spectrum of 3.30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.19 
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13C NMR spectrum of 3.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.33 
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13C NMR spectrum of 3.33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.25 
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13C NMR spectrum of 3.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.42 
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13C NMR spectrum of 3.42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.43 
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13C NMR spectrum of 3.43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.48 
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13C NMR spectrum of 3.48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.51 
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13C NMR spectrum of 3.51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.67 
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13C NMR spectrum of 3.67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.63 
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13C NMR spectrum of 3.63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.34 
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13C NMR spectrum of 3.34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.58 
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13C NMR spectrum of 3.58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.67 
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13C NMR spectrum of 3.67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 3.61 
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1H NMR spectrum of 3.57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 3.57 
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1H NMR spectrum of 3.59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 3.59 
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1H NMR spectrum of 3.69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 3.69 
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1H NMR spectrum of 4.88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 4.89 
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13C NMR spectrum of 4.89 
 
 
 
 
1H NMR spectrum of 4.86 
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13C NMR spectrum of 4.86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 4.95 
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1H NMR spectrum of 4.96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 4.97 
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1H NMR spectrum of 4.94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 4.93 
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13C NMR spectrum of 4.93 
 
 
 
 
1H NMR spectrum of 4.102 
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13C NMR spectrum of 4.102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum of 4.103 
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1H NMR spectrum of 4.107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 4.107 
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1H NMR spectrum of 4.108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 4.108 
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1H NMR spectrum of 4.109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 4.109 
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1H NMR spectrum of 4.106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 4.106 
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1H NMR spectrum of 4.113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 4.113 
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1H NMR spectrum of 4.114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 4.114 
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1H NMR spectrum of 4.35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR spectrum of 4.35 
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